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Abstract 
 
Background: Diabetes mellitus type 2 (T2DM) and cancer share several common risk 
factors, such as obesity and the adoption of westernized lifestyle, which is characterized by 
the sedentary lifestyle and consumption of unhealthy diet. Several studies showed an 
association between T2DM and the risk for breast cancer (BC). However, the association 
between T2DM and its medication with BC risk had not been studied in Palestine till to 
date.  
Aim: This study aims to investigate the association between T2DM, its medication/s, and 
breast cancer among females in the southern region of the West Bank.  
Study methodology: In this matched case-control study, data were collected for 474 
participants (237 confirmed BC and 237 controls), through the period between June 2016 
to October 2017. Study cases were interviewed at the day care unit of Beit-Jala Hospital, 
while controls were matched by location of residence and age groups. A random sample of 
those registered at Bethlehem and Hebron governorates who underwent a mammography 
and confirmed to be free of BC were included in the study. An interview-based 
questionnaire was used for data collection, structured on the risk factors of BC. 
Statistical analysis: All data were entered and analyzed using SPSS v20 (statistical 
package for social sciences, version 20). Descriptive analysis, Chi-square test, and 
independent sample T-Test were conducted as needed, to examine the difference between 
study cases and control group. In the multivariate analysis, an overall model was 
developed; only factors that showed a significant difference in the previous analysis were 
included in the last model. Forward conditional logistic regression was used to get adjusted 
odds ratios.  
Ethical considerations: The study was proposed by Al Quds University-SPH research 
committee, and IRB (International Review Board). In addition, approval from the Ministry 
of Health as the study was conducted in its setting was assured. A consent form was signed 
by each participant confirming her willingness to participate. 
Results: The mean age of BC diagnosis was 52 years. Among study cases, the most 
common subtype of BC was ductal carcinoma (58%), and (65%) of the study cases were 
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diagnosed at the 2nd or 3rd stage of the disease. Furthermore, only (17%) of study cases 
were found to have BC during a screening program, while 82% were referred after being 
suspected to have BC. About half of the study cases had full mastectomy.  
After conducting multivariate analysis, T2DM itself was not found to increase the risk of 
BC, but its medication, the long acting Insulin Glargine was found to significantly increase 
the risk for BC by 14 folds.  
Several reproductive factors revealed positive association with BC. Having a menarche 
after 13 years of age increased the risk by three folds. Using oral contraceptives doubled 
the risk for BC. Additionally, receiving hormone replacement therapy increased the risk by 
4 folds to have BC too. Breastfeeding for a period of 9 years or more decreased the risk to 
15% compared to those who didn’t breastfeed. Regarding health status history, some 
chronic illnesses showed a significant association with BC risk. Cardiovascular diseases 
(adjusted OR= 3.80, 95%CI: 1.87- 8.07), and joint problems (adjusted OR= 2.64, 95%CI: 
1.45- 4.82) were shown to triplicate the risk for BC too. Moreover, consanguinity parental 
marriage; first degree relative, doubled the risk for BC. Family history of BC significantly 
tripled the risk for BC (adjusted OR= 3.51, 95%CI: 1.47-7.10).  
Furthermore, body mass index (BMI) showed a positive dose-response association with 
BC; i.e. the higher the BMI the greater the risk for BC was found. The use of electric 
blanket significantly tripled the risk too. As for dietary habits, some kinds of food showed 
a significant association with increased risk of BC. Soft drinks and butter either doubled or 
triplicate the risk for BC. In contrast, chicken intake showed a negative “protective” 
significant association with BC risk (adjusted OR= 0.43, 95% CI: 0.22- 0.86).  
Conclusions: This is the first study of its type in Palestine and had consistent results with 
the published research that investigated the association between T2DM, its medication and 
BC risk. Most studies were conducted on datasets that were collected from patients’ 
medical records. Our study used the classical matched case-control, which made it unique 
in its results.  
Our results showed a significant association between BC risk and use of the long acting 
diabetes medication “Insulin Glargine”. Furthermore, we were also able to show that 
consanguinity is a strong risk factor for BC. In addition, reproductive factors, health status 
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factors, family history of BC and lifestyle factors were also confirmed to be important risk 
factors for BC.  
The relationship between T2DM and BC is still a hot field in research which needs further 
investigation in the Northern area of Palestine. Furthermore, T2DM association to other 
cancer types needs to be investigated.  
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ﺩﺭﺍﺳﺔ  :ﺎﻟﺴﻜﺮﻱ ﻓﻲ ﻣﺴﺘﺸﻔﻰ ﺑﻴﺖ ﺟﺎﻻ ﺍﻟﺤﻜﻮﻣﻲﺑ ﺎﺕﻀﻳﻤﺮﺍﻟﺑﻴﻦ  ﻱﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ ﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪ
 ﺍﻟﺤﺎﻻﺕ ﻭﺍﻟﻀﻮﺍﺑﻂ
 ﺍﻟﺨﻄﻴﺐ ﺑﺎﺳﻢ ﺍﻣﺘﺜﺎﻝ ﺗﻮﻓﻴﻖﺇﻋﺪﺍﺩ: 
 
  ﺩ. ﻧﻬﻰ ﺍﻟﺸﺮﻳﻒﺇﺷﺮﺍﻑ: 
 
 ﻤﻠﺨﺺﺍﻟB4
ﻣﻦ ( ﻣﻊ ﺍﻟﺴﺮﻁﺎﻥ ﻓﻲ ﺍﻟﻌﺪﻳﺪ MD2Tﻣﺮﺽ ﺍﻟﺴﻜﺮﻱ ﻣﻦ ﺍﻟﻨﻮﻉ ﺍﻟﺜﺎﻧﻲ ) : ﻳﺸﺘﺮﻙﺧﻠﻔﻴﺔ ﺍﻟﺪﺭﺍﺳﺔ
ﻋﻮﺍﻣﻞ ﺍﻟﺨﻄﺮ، ﻣﺜﻞ ﺍﻟﺴﻤﻨﺔ ﻭﺍﻋﺘﻤﺎﺩ ﺃﺳﻠﻮﺏ ﺍﻟﺤﻴﺎﺓ ﺍﻟﻐﺮﺑﻴﺔ ﺍﻟﺬﻱ ﻳﺘﻤﻴﺰ ﺑﻘﻠﺔ ﺍﻟﻨﺸﺎﻁ ﺍﻟﺒﺪﻧﻲ ﻭﺍﺳﺘﻬﻼﻙ 
ﺑﺄﻣﺮﺍﺽ ﻣﺜﻞ ﺍﻟﺴﻜﺮﻱ ﻭﺍﻟﺴﺮﻁﺎﻥ ﻭﻛﻼﻫﻤﺎ  ﺳﻠﻮﺏ ﺍﻟﺤﻴﺎﺓ ﻫﺬﺍ ﻣﺮﺗﺒﻄﺎً ﺃﺍﻟﺼﺤﻲ. ﻭ ﺍﻟﻨﻈﺎﻡ ﺍﻟﻐﺬﺍﺋﻲ ﻏﻴﺮ
ﻭﺧﻄﺮ  2ﻣﻦ ﺍﻟﻨﻮﻉ ﻟﺴﻜﺮﻱ ﺁﺧﺬ ﻓﻲ ﺍﻻﺭﺗﻔﺎﻉ. ﻫﺬﺍ ﻭ ﻗﺪ ﺃﻅﻬﺮﺕ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﺍﻟﺪﺭﺍﺳﺎﺕ ﻭﺟﻮﺩ ﺍﺭﺗﺒﺎﻁ ﺑﻴﻦ ﺍ
ﺻﺎﺑﺔ ﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ. ﻭﺑﺎﻟﺮﻏﻢ ﻣﻦ ﺫﻟﻚ، ﻟﻢ ﺗﺘﻢ ﺩﺭﺍﺳﺔ ﻣﺮﺽ ﺍﻟﺴﻜﺮﻱ ﻭﺃﺩﻭﻳﺘﻪ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺍﺣﺘﻤﺎﻝ ﺍﻹ
 ﻗﺒﻞ ﺫﻟﻚ ﻓﻲ ﻓﻠﺴﻄﻴﻦ. ﺑﻤﺮﺽ ﺳﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ ﻣﻦ
ﻣﻦ ﻣﺮﺽ ﺍﻟﺴﻜﺮﻱ ﻭﺃﺩﻭﻳﺘﻪ،  2ﺗﻬﺪﻑ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﺇﻟﻰ ﺍﻟﺘﺤﻘﻖ ﻣﻦ ﺍﻟﻌﻼﻗﺔ ﺑﻴﻦ ﺍﻟﻨﻮﻉ  ﻫﺪﻑ ﺍﻟﺪﺭﺍﺳﺔ:
 ﺪ ﺍﻹﻧﺎﺙ ﻓﻲ ﺍﻟﻀﻔﺔ ﺍﻟﻐﺮﺑﻴﺔ.ﻭﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ ﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ ﻋﻨ
ﺍﺳﺘُﺨﺪﻣﺖ ﺩﺭﺍﺳﺔ ﺍﻟﺤﺎﻻﺕ ﻭﺍﻟﻀﻮﺍﺑﻂ ﻟﺪﺭﺍﺳﺔ ﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﻤﺴﺒﺒﺔ ﻟﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ، ﺗﻢ  ﻣﻨﻬﺠﻴﺔ ﺍﻟﺪﺭﺍﺳﺔ:
ﺍﻣﺮﺃﺓ ﻛﻌﻴﻨﺔ  732ﺣﺎﻟﺔ ﻣﺆﻛﺪﺓ ﺍﻟﺘﺸﺨﻴﺺ ﺑﺎﻟﻤﺮﺽ ﻭ  732ﺍﻣﺮﺃﺓ ﻣﺸﺎﺭﻛﺔ ) 474ﺟﻤﻊ ﺍﻟﺒﻴﺎﻧﺎﺕ ﻝ 
، ﺃﻣﺎ ﺍﻟﻨﻬﺎﺭﻳﺔ ﻓﻲ ﻣﺴﺘﺸﻔﻰ ﺑﻴﺖ ﺟﺎﻻﺎﻳﺔ ﺿﺎﺑﻄﺔ(. ﺗﻢ ﺍﺳﺘﻘﻄﺎﺏ ﺍﻟﺤﺎﻻﺕ ﻭﻣﻘﺎﺑﻠﺘﻬﺎ ﻓﻲ ﻭﺣﺪﺓ ﺍﻟﺮﻋ
ﺍﻟﻤﺠﻤﻮﻋﺔ ﺍﻟﻀﺎﺑﻄﺔ ﻓﻘﺪ ﺗﻢ ﻣﻄﺎﺑﻘﺘﻬﺎ ﻣﻦ ﻧﺎﺣﻴﺔ ﻣﻮﻗﻊ ﺍﻹﻗﺎﻣﺔ ﻭﺍﻟﻔﺌﺎﺕ ﺍﻟﻌﻤﺮﻳﺔ ﻣﻊ ﺍﻟﺤﺎﻻﺕ، ﻭﻗﺪ ﺗﻢ 
ﻴﻞ ﻣﻤﻦ ﺗﺄﻛﺪ ﺧﻀﻮﻋﻬﻦ ﻟﺘﺼﻮﻳﺮ ﺍﺧﺘﻴﺎﺭ ﺍﻟﻤﺠﻤﻮﻋﺔ ﺍﻟﻀﺎﺑﻄﺔ ﻋﺸﻮﺍﺋﻴﺎ ﻓﻲ ﻣﺤﺎﻓﻈﺘﻲ ﺑﻴﺖ ﻟﺤﻢ ﻭﺍﻟﺨﻠ
ﻋﻦ ﺪﺍﻡ ﺍﺳﺘﺒﻴﺎﻥ ﺃﺟﺎﺑﺖ ﻣﻦ ﺧﻼﻟﻪ ﺍﻟﻤﺸﺎﺭﻛﺎﺕ ، ﻭﻋﺪﻡ ﺇﺻﺎﺑﺘﻬﻢ ﺑﺎﻟﺴﺮﻁﺎﻥ. ﻭُﺟﻤﻌﺖ ﺍﻟﺒﻴﺎﻧﺎﺕ ﺑﺎﺳﺘﺨﺍﻟﺜﺪﻱ
 ﺃﺳﺌﻠﺔ ﺍﻟﺒﺎﺣﺚ ﻋﻦ ﻁﺮﻳﻖ ﻣﻘﺎﺑﻠﺔ.
)ﺍﻟﺤﺰﻡ ﺍﻹﺣﺼﺎﺋﻴﺔ ﻟﻠﻌﻠﻮﻡ  SSPSﺗﻢ ﺇﺩﺧﺎﻝ ﻭﺗﺤﻠﻴﻞ ﺍﻟﺒﻴﺎﻧﺎﺕ ﺑﺎﺳﺘﺨﺪﺍﻡ ﺑﺮﻧﺎﻣﺞ  ﺍﻟﺘﺤﻠﻴﻞ ﺍﻹﺣﺼﺎﺋﻲ:
، ﻟﻔﺤﺺ ﻣﺪﻯ ﺍﻻﺭﺗﺒﺎﻁ ﺑﻴﻦ )erauqs ihC(ﺍﻻﺟﺘﻤﺎﻋﻴﺔ(. ﺍﺳﺘﺨﺪﻡ ﺍﻟﺘﺤﻠﻴﻞ ﺃﺣﺎﺩﻱ ﺍﻟﻤﺘﻐﻴﺮ، ﺍﺧﺘﺒﺎﺭ 
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ﻋﻨﺪ ﺍﻟﺤﺎﺟﺔ. ﻓﻲ ﺍﻟﺘﺤﻠﻴﻞ ﻣﺘﻌﺪﺩ ﺍﻟﻤﺘﻐﻴﺮﺍﺕ، ﺗﻢ ﺗﻄﻮﻳﺮ  )tset-T(، ﻭﺍﺳﺘﺨﺪﻡ ﺍﺧﺘﺒﺎﺭ ﺍﺑﻂﺍﻟﺤﺎﻻﺕ ﻭﺍﻟﻀﻮ
 ﺔ ﻣﻦ ﺍﻟﺘﺤﻠﻴﻞ ﺃﺣﺎﺩﻱ ﺍﻟﻤﺘﻐﻴﺮ ﻓﻘﻂ.ﺟﻤﻴﻊ ﻋﻮﺍﻣﻞ ﺍﻟﺨﻄﺮ ﺫﺍﺕ ﺍﻟﺪﻻﻟﺔ ﺍﻹﺣﺼﺎﺋﻴﺔ ﺍﻟﻨﺎﺗﺠ ﻧﻤﻮﺫﺝ، ﺗﻀﻤﻦ
. ﺗﻢ ﺗﻢ ﺗﻘﺪﻳﻢ ﻣﻘﺘﺮﺡ ﺍﻟﺪﺭﺍﺳﺔ ﺇﻟﻰ ﻟﺠﻨﺔ ﺃﺑﺤﺎﺙ ﺟﺎﻣﻌﺔ ﺍﻟﻘﺪﺱ ﻟﻠﻌﻠﻮﻡ ﺍﻻﺟﺘﻤﺎﻋﻴﺔ ﺍﻻﻋﺘﺒﺎﺭﺍﺕ ﺍﻷﺧﻼﻗﻴﺔ:
ﺍﻟﺤﺼﻮﻝ ﻋﻠﻰ ﺍﻟﻤﻮﺍﻓﻘﺔ ﺍﻹﺩﺍﺭﻳﺔ ﻣﻦ ﻭﺯﺍﺭﺓ ﺍﻟﺼﺤﺔ ﻷﻥ ﺍﻟﺪﺭﺍﺳﺔ ﺃﺟﺮﻳﺖ ﻓﻲ ﻣﺴﺘﺸﻔﻴﺎﺗﻬﺎ ﻭﻋﻴﺎﺩﺍﺗﻬﺎ. ﺗﻢ 
 ﺗﺴﻠﻴﻢ ﻧﻤﻮﺫﺝ ﻣﻮﺍﻓﻘﺔ ﻟﻜﻞ ﻣﺸﺘﺮﻛﺔ ﻓﻲ ﺍﻟﺪﺭﺍﺳﺔ ﻟﻴﺘﻢ ﺍﻟﻤﻮﺍﻓﻘﺔ ﻋﻠﻴﻪ ﻭﺗﻮﻗﻴﻌﻪ ﻗﺒﻞ ﺍﻟﻤﺸﺎﺭﻛﺔ.
ﻉ ﺍﻟﺴﺮﻁﺎﻥ ﺳﻨﺔ. ﻓﻲ ﺍﻟﻨﺴﺎء ﺍﻟﻤﺼﺎﺑﺎﺕ ﻛﺎﻥ ﻧﻮ 25ﻋﻤﺮ ﺍﻟﺘﺸﺨﻴﺺ ﻟﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ ﻛﺎﻥ ﻣﺘﻮﺳﻂ  ﺍﻟﻨﺘﺎﺋﺞ:
٪ ﻣﻦ ﺍﻟﺤﺎﻻﺕ ﻓﻲ  56٪(، ﻫﺬﺍ ﻭﻗﺪ ُﺷﺨﺼﺖ ﻣﺎ ﻧﺴﺒﺘﻪ  85) ﺍﻷﻛﺜﺮ ﺍﻷﻛﺜﺮ ﺷﻴﻮﻋﺎ ﻫﻮ ﺳﺮﻁﺎﻥ ﺍﻷﻗﻨﻴﺔ
ﺗﻢ ﺗﺸﺨﻴﺼﻬﺎ  ٪ ﻓﻘﻂ ﻣﻦ ﺍﻟﺤﺎﻻﺕ71ﺍﻟﻤﺮﺣﻠﺔ ﺍﻟﺜﺎﻧﻴﺔ ﺃﻭ ﺍﻟﺜﺎﻟﺜﺔ ﻣﻦ ﺍﻟﻤﺮﺽ. ﻋﻼﻭﺓ ﻋﻠﻰ ﺫﻟﻚ ، ﺗﺒﻴﻦ ﺃﻥ 
ﻓﻲ ﺇﺻﺎﺑﺘﻬﺎ. ﻭ ﻗﺪ ﺧﻀﻌﺖ ٪ ﻣﻨﻬﺎ ﺑﻌﺪ ﺍﻻﺷﺘﺒﺎﻩ 28ﻣﻦ ﺧﻼﻝ ﺑﺮﺍﻣﺞ ﺍﻟﻤﺴﺢ ﺍﻟﻮﻗﺎﺋﻲ ، ﺑﻴﻨﻤﺎ ﺗﻢ ﺗﺸﺨﻴﺺ 
 ﺣﻮﺍﻟﻲ ﻧﺼﻒ ﺍﻟﻨﺴﺎء ﺍﻟﻤﺼﺎﺑﺎﺕ ﻻﺳﺘﺌﺼﺎﻝ ﻛﺎﻣﻞ ﻟﻠﺜﺪﻱ.
ﺑﻌﺪ ﺿﺒﻂ ﻋﺪﺓ ﻋﻮﺍﻣﻞ ، ﻟﻢ ﻳﺜﺒﺖ ﺃﻥ ﺍﻟﺴﻜﺮﻱ ﻧﻔﺴﻪ ﻳﺰﻳﺪ ﻣﻦ ﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ ﺑـﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ، ﺇﻻ ﺃﻥ ﺩﻭﺍء 
 ﻣﺮﺓ. 41ﺿﺎﻋﻒ ﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ ﺑـﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ ﺑﻤﻘﺪﺍﺭ  ﻷﻧﺴﻮﻟﻴﻦ ﻁﻮﻳﻞ ﺍﻟﻤﻔﻌﻮﻝ )ﺟﻼﺭﺟﻴﻦ(ﺍﻟﺴﻜﺮﻱ ﺍ
ﻧﺘﺎﺋﺞ ﺍﻟﺪﺭﺍﺳﺔ ﺃﻥ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﺍﻟﻌﻮﺍﻣﻞ ﺍﻹﻧﺠﺎﺑﻴﺔ ﺍﺭﺗﺒﻄﺖ ﺍﺭﺗﺒﺎﻁًﺎ ﺇﻳﺠﺎﺑﻴًﺎ ﻣﻊ ﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ  ﻭﻗﺪ ﻟﻮﺣﻆ ﻣﻦ
ﻣﺮﺍﺕ، ﻭﻛﺬﻟﻚ ﺗﻨﺎﻭﻝ  3ﺻﺎﺑﺔ ﺿﺎﻋﻒ ﺧﻄﺮ ﺍﻹ 31ﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ ؛ ﻓﻘﺪ ﺗﺒﻴﻦ ﺃﻥ ﺍﻟﺒﻠﻮﻍ ﺑﻌﺪ ﺳﻦ 
ﺯﺍﺩﺕ ﺍﻟﺨﻄﺮ  ﻣﻮﻧﺎﺕ ﺍﻟﺒﺪﻳﻠﺔﺮﻳﻀﺎ، ﻭ ﺍﻟﻌﻼﺝ ﺑﺎﻟﻬﺃﻣﺮﺍﺕ  3ﺍﻟﺤﺒﻮﺏ ﺍﻟﻤﺎﻧﻌﺔ ﺍﻟﺤﻤﻞ ﺿﺎﻋﻔﺖ ﺍﻟﺨﻄﺮ 
ﻋﻠﻰ ﺍﻟﻌﻜﺲ ﻣﻦ ﺫﻟﻚ، ﻭﺟﺪ ﺃﻧﻪ ﻣﻊ ﺍﻟﺮﺿﺎﻋﺔ ﺍﻟﻄﺒﻴﻌﻴﺔ ﻭﻓﺘﺮﺓ ﺍﻟﺮﺿﺎﻋﺔ ﺍﻟﻄﺒﻴﻌﻴﺔ ﻓﻮﻕ  ﺿﻌﺎﻑ.ﺃ 4ﺔ ﺑﻨﺴﺒ
ﻌﻠﻖ ﺑﺘﺎﺭﻳﺦ ﺍﻟﺤﺎﻟﺔ ٪ ﺇﺫﺍ ﻣﺎ ﻗﻮﺭﻧﺖ ﺑﻌﺪﻡ ﺍﻟﺮﺿﺎﻋﺔ ﺑﺘﺎﺗﺎ. ﺃﻣﺎ ﻓﻴﻤﺎ ﻳﺘ 51ﺳﻨﻮﺍﺕ ﺍﻧﺨﻔﻀﺖ ﺍﻟﻤﺨﺎﻁﺮ ﺇﻟﻰ  9
ﻟﺜﺪﻱ ﻣﺜﻞ ﺻﺎﺑﺔ ﺑﺴﺮﻁﺎﻥ ﺍﻹ، ﺃﻅﻬﺮﺕ ﺑﻌﺾ ﺍﻷﻣﺮﺍﺽ ﺍﻟﻤﺰﻣﻨﺔ ﺍﺭﺗﺒﺎﻁًﺎ ﻛﺒﻴًﺮﺍ ﺑﺨﻄﺮ ﺍﺍﻟﺼﺤﻴﺔ ﺍﻟﻤﺮﺿﻲ
 (.46.2 ROA( ﻭﻣﺸﺎﻛﻞ ﺍﻟﻤﻔﺎﺻﻞ )88.3 ROAﺃﻣﺮﺍﺽ ﺍﻟﻘﻠﺐ ﻭﺍﻷﻭﻋﻴﺔ ﺍﻟﺪﻣﻮﻳﺔ )
ﻟﻰ ﺫﻟﻚ، ﺿﺎﻋﻒ ﺯﻭﺍﺝ ﺍﻟﻮﺍﻟﺪﻳﻦ ﺍﻷﻗﺎﺭﺏ ﻣﻦ ﺍﻟﺪﺭﺟﺔ ﺍﻷﻭﻟﻰ ﻣﻦ ﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ. ﻭﻛﺬﻟﻚ ﺍﻟﺘﺎﺭﻳﺦ ﺇﺇﺿﺎﻓﺔ 
 (.15.3 ROAﺍﻟﻌﺎﺋﻠﻲ ﻟـﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ ﺯﺍﺩ ﺑﺸﻜﻞ ﻛﺒﻴﺮ ﻣﻦ ﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ ﺑـﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ )
( ﻭﺟﻮﺩ ﻋﻼﻗﺔ ﺇﻳﺠﺎﺑﻴﺔ ﻣﻊ ﺳﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ. ﺑﻤﻌﻨﻰ ﺃﻧﻪ IMBﺃﻅﻬﺮ ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢ ) ﻋﻼﻭﺓ ﻋﻠﻰ ﺫﻟﻚ،
ﻛﻠﻤﺎ ﺯﺍﺩ ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢ ، ﻟﻮﺣﻆ ﻭﺟﻮﺩ ﺧﻄﺮ ﻣﺘﺰﺍﻳﺪ. ﻭﻟﻮﺣﻆ ﺃﻥ ﺍﺳﺘﺨﺪﺍﻡ ﺍﻟﺒﻄﺎﻧﻴﺎﺕ ﺍﻟﻜﻬﺮﺑﺎﺋﻴﺔ ﻗﺪ 
، ﺃﻅﻬﺮﺕ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﺍﻷﻁﻌﻤﺔ ﺙ ﻣﺮﺍﺕ. ﻧﻈﺮﺍ ﻟﻨﻮﻉ ﺍﻟﻐﺬﺍءﺿﺎﻋﻒ ﻣﻦ ﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ ﺑﺎﻟﺴﺮﻁﺎﻥ ﺛﻼ
ﺍﺭﺗﺒﺎﻁًﺎ ﻛﺒﻴًﺮﺍ ﻣﻊ ﺯﻳﺎﺩﺓ ﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ ﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ، ﻓﺎﻻﺳﺘﻬﻼﻙ ﺍﻟﻤﺘﻜﺮﺭ ﻟﻠﻤﺸﺮﻭﺑﺎﺕ ﺍﻟﻐﺎﺯﻳﺔ 
 iiiv
 
ﺻﺎﺑﺔ ﺻﺎﺑﺔ ﻣﺮﺗﻴﻦ ﺃﻭ ﺛﻼﺛﺔ. ﻓﻲ ﺍﻟﻤﻘﺎﺑﻞ، ﻗﻠﻞ ﺗﻨﺎﻭﻝ ﺍﻟﺪﺟﺎﺝ ﻣﻦ ﺧﻄﺮ ﺍﻹﻭﺍﻟﺰﺑﺪﺓ ﺿﺎﻋﻒ ﺍﻟﺨﻄﺮ ﺑﺎﻹ
 (.34.0 ROAﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ )
ﻰ ﻣﻦ ﻧﻮﻋﻬﺎ ﻓﻲ ﻓﻠﺴﻄﻴﻦ، ﻭﻛﺎﻧﺖ ﻧﺘﺎﺋﺠﻬﺎ ﻣﺘﻮﺍﻓﻘﺔ ﻣﻊ ﺍﻷﺑﺤﺎﺙ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﻫﻲ ﺍﻷﻭﻟﺍﻟﺨﻼﺻﺔ: 
ﺻﺎﺑﺔ ﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ. ﺃﺟﺮﻳﺖ ﺍﻟﻤﻨﺸﻮﺭﺓ ﺍﻟﺘﻲ ﺑﺤﺜﺖ ﺍﻟﻌﻼﻗﺔ ﺑﻴﻦ ﻣﺮﺽ ﺍﻟﺴﻜﺮﻱ ﻭﺃﺩﻭﻳﺘﻪ ﻭﺧﻄﺮ ﺍﻹ
ﻣﻌﻈﻢ ﺍﻟﺪﺭﺍﺳﺎﺕ ﻋﻠﻰ ﻣﺠﻤﻮﻋﺎﺕ ﺍﻟﺒﻴﺎﻧﺎﺕ ﺍﻟﺘﻲ ﻳﺘﻢ ﺟﻤﻌﻬﺎ ﻣﻦ ﺍﻟﺴﺠﻼﺕ ﺍﻟﻄﺒﻴﺔ ﻟﻠﻤﺮﺿﻰ. ﺍﺳﺘﺨﺪﻣﺖ 
 ، ﻣﻤﺎ ﺟﻌﻠﻬﺎ ﻓﺮﻳﺪﺓ ﻓﻲ ﻧﺘﺎﺋﺠﻬﺎ.ﺍﻟﻀﺎﺑﻄﺔﺍﺳﺔ ﺍﻟﺤﺎﻻﺕ ﻣﻊ ﺍﻟﻤﺠﻤﻮﻋﺔ ﺩﺭﺍﺳﺘﻨﺎ ﺩﺭ
ﻭﺩﻭﺍء  ﺃﻅﻬﺮﺕ ﺍﻟﻨﺘﺎﺋﺞ ﺍﻟﺘﻲ ﺗﻮﺻﻠﻨﺎ ﺇﻟﻴﻬﺎ ﻭﺟﻮﺩ ﺍﺭﺗﺒﺎﻁ ﻛﺒﻴﺮ ﺑﻴﻦ ﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ ﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ 
ﻫﺬﺍ ﻭﻗﺪ ﺗﻤﻜﻨﺎ ﻣﻦ ﺇﻅﻬﺎﺭ ﺃﻥ ﺯﻭﺍﺝ ﺍﻷﻗﺎﺭﺏ ﻫﻮ ﻋﺎﻣﻞ  ،ﺍﻧﺴﻮﻟﻴﻦ ﺟﻼﺭﺟﻴﻦ )ﻁﻮﻳﻞ ﺍﻟﻤﻔﻌﻮﻝ( ﺍﻟﺴﻜﺮﻱ
، ﻭﺍﻟﺘﺎﺭﻳﺦ ﺍﻟﻌﺎﺋﻠﻲ ﻟﻠﺴﺮﻁﺎﻥ، ﻭ ﺍﻟﺤﺎﻟﺔ ﺍﻟﺼﺤﻴﺔﺍﻣﻞ ﺍﻹﻧﺠﺎﺑﻴﺔ، ﺍﻟﻌﻮ ﻳﻀﺎً ﺃﺧﻄﺮ ﻗﻮﻱ ﻟﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ. ﻭ
 ﺻﺎﺑﺔ. ﺑﺨﻄﺮ ﺍﻹ ﻭﺍﺳﺘﻬﻼﻙ ﺃﻧﻮﺍﻉ ﻣﻌﻴﻨﺔ ﻣﻦ ﺍﻟﻄﻌﺎﻡ ﺃﻅﻬﺮﺕ ﺍﺭﺗﺒﺎﻁﺎً 
، ﻭﺗﺤﺘﺎﺝ ﺇﻟﻰ ﻣﺰﻳﺪ ﻣﻦ ﺍﻟﺘﺤﻘﻖ ﻟﻠﺒﺤﺚ ﻭﻻ ﺗﺰﺍﻝ ﺍﻟﻌﻼﻗﺔ ﺑﻴﻦ ﻣﺮﺽ ﺍﻟﺴﻜﺮﻱ ﻭﺳﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ ﻣﺠﺎﻻ ﻏﻨﻴﺎً 
ﺍﻟﺴﻜﺮﻱ ﺑﺴﺮﻁﺎﻧﺎﺕ ﺃﺧﺮﻯ ﻏﻴﺮ ﻭﺍﻟﺪﺭﺍﺳﺔ ﻓﻲ ﻣﻨﻄﻘﺔ ﺷﻤﺎﻝ ﻓﻠﺴﻄﻴﻦ، ﻭﺩﺭﺍﺳﺔ ﻣﺴﺘﻔﻴﻀﺔ ﻟﻔﻬﻢ ﻋﻼﻗﺔ 
 .ﺳﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ
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Chapter One 
Background and Significance 
 
1.1.  Background 
Diabetes mellitus Type 2 (T2DM) is a major health problem which showed a step 
acceleration in prevalence worldwide in the past two decades (CDC, 2012). The world 
prevalence of diabetes in adults was 6.4% in 2010 and might increase to 7.7% by 2030 (J. 
E. Shaw, Sicree, & Zimmet, 2010). Between 2010 and 2030, there will be a 69% increase 
in number of adults with diabetes in developing countries and a 20% increase in developed 
countries. Arab world will have the second highest increase in percentage of people with 
T2DM in 2030 (J. E. Shaw et al., 2010).  
The association between T2DM and cancer was firstly observed 60 years ago (Rawson, 
1956). Studies found that there is an increased risk among diabetics for specific cancers; 
i.e. liver, pancreas, endometrial, breast among women, non-Hodgkin lymphoma, stomach, 
colon, and kidney cancers. But, prostate cancer incidence was shown to be lower among 
diabetic patients type 2, and no consistent association was found for lung and ovarian 
cancers (Johnson et al., 2012). The relative risk (RR) for developing cancer in diabetic 
patients ranges from RR= 2.0-2.5 for liver, pancreatic and endometrial cancers, and 1.2-1.5 
for breast, colon and bladder cancers (Xu, 2014). It was shown that strength and direction 
of this association depends on the type of diabetes, its duration, type and duration of 
medication, and the type of specific cancer (Tabak et al., 2009). T2DM does not only 
increase the risk of BC, but also increases mortality rate of females, with a crude mortality 
rate of 45.7 per 100,000 person-years (Tseng, Chong, & Tai, 2009). Although this increase 
might be minimal, but the consequence would be significant at the population level 
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(Hardefeldt, Edirimanne, & Eslick, 2012). Among Palestinians, a recent retrospective 
cohort study among Israeli Arabs showed that T2DM rate was lower among cancer cases 
than among cancer-free adult Arabs, but this difference was not statistically significant 
(Idilbi, Barchana, Milman, & Carel, 2013). 
The modifiable risk factors for cancer among diabetic patients were mostly related to 
lifestyle factors; i.e. obesity, poor diet, physical activity and smoking. Also, socioeconomic 
status was shown to affect both the occurrence of T2DM and cancer. Several studies 
support the hypothesis that metabolic syndrome and its components might play an 
important role in the etiology and progression of certain cancer types and a worse 
prognosis for some cancers (Xue F et al, 2007). More specifically, obesity and T2DM have 
been shown to be associated with breast, endometrial, colorectal, pancreatic, hepatic and 
renal cancer (Brauna, Bitton-Worms, & le Roith, 2011). On the other hand, an inverse 
association was found between Mediterranean diet and cancer, (OR=0.4, 95% CI: 0.26-
0.61). It was also concluded that greater adherence to Mediterranean diet is associated with 
lower odds not only for cancer, but for T2DM, as it seems to moderate the prevalence of 
obesity and risks of chronic diseases, in general (Idilbi et al., 2013). 
Menopausal status, along with obesity were found to interfere in the association between 
T2DM and BC; Postmenopasal diabetic women, with estrogen receptor positive BC added, 
had about a 20-27 percent increased risk of BC; (HR=1.22, 95%CI: 1.01-1.47) (Michels et 
al., 2003). This association is explained by the mechanism of the T2DM-cancer link which 
has been hypothesized to be mainly related to hormonal (insulin & insulin-like growth 
factor (IGF)-1), inflammatory or metabolic hyperglycemia characteristics of the T2DM 
(DeCensi et al., 2010; Muti et al., 2002), and even to certain T2DM treatments (Currie et 
al., 2012; Currie, Poole, & Gale, 2009). Moreover, obesity was suggested to be a mediator 
in this mechanism; the associations of glucose, insulin, and IGF-1 pattern were associated 
with BC risk in women with greater BMI (body mass index > 26) (Muti et al., 2002).  
T2DM medications were also shown to affect the risk of BC. Diabetes insulin therapy and 
BC risk is still an active area of investigation. Insulin replacement therapy showed mixed 
results which indicated there is a little effect on BC incidence (Owens, 2012). However, 
the long term (>6 yrs) use of insulin replacement therapies, and incidence of BC is still 
under research. Furthermore, sulfonyureas, like Glipizide, have been used for more than 50 
years; A slightly elevated risk of developing BC has been observed (Currie et al., 2009). 
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However, Metformin (Glucophage) which is the most commonly prescribed oral 
medication for T2DM was found to lower the incidence of BC compared to Sulfonylureas 
(Goodwin, Thompson, & Stambolic, 2012). Whether a non-diabetic BC-diagnosed female 
would benefit from taking Metformin is not known yet. Studies suggest that BC may affect 
how a cell uses glucose and that treating with Metformin may correct this change. Many 
clinical trials are trying to determine if Metformin benefits BC patients independent from 
T2DM (Currie et al., 2009). 
1.2.  Problem Statement  
T2DM and BC risk association remains unclear, particularly because the two diseases 
share several risk factors, including obesity, a sedentary lifestyle, and possibly intake of 
saturated fat and refined carbohydrates, that may confound this association.  
Since the Palestinian population is adopting many of the lifestyle characteristics of more 
affluent societies, this adoption might be associated with diseases such as diabetes and 
cancer. However, the association between T2DM, its medications, and risk of cancer, to 
our knowledge, is not yet studied in Palestine. Our study results will help in developing 
effective intervention programs to deal diabetes and BC in Palestine. 
1.3.  Study Justification 
T2DM is a hot subject in the Palestinian research, and so is cancer, due to their high and 
accelerating prevalence. BC, which is the most prevalent type of cancer among female 
cancer cases in Palestine, is the cancer type that will be studied in our research (MOH, 
2016). 
Among Palestinian population, it was the year 2000 when the first 
baseline data on diabetes mellitus and impaired glucose tolerance was published. Among 
Palestinians aged 25 years or more, the prevalence of diabetes was 9.6% and 10.0% in 
females and males, respectively. The prevalence of impaired glucose tolerance was 8.6%; 
10.3% in females, 6.2% in males. The prevalence of total glucose intolerance (diabetes 
mellitus + impaired glucose tolerance) was 18.4% (Husseini et al., 2009a). During the 
period between 2005 to 2014, T2DM jumped surprisingly in the rank from being the 11th 
cause of death in Palestine to the fourth one (Institue for Health Metrics and Evolution, 
2018), with a percentage of 8.9% of all deaths, following cardiovascular diseases which 
accounted for 29.5% of all deaths, cancer deaths 14.2% then came cerebrovascular 
4 
 
diseases 11.3% (MOH, 2014). In the MoH report of 2015, T2DM was categorized alone, 
due to its increasing prevalence. 
As for cancer in Palestine, the total number of new reported cancer cases in the West Bank 
in the last annual health report was 2,536, with an increase of 5.7% from the 2,400 new 
reported cases in 2015. In 2016, the incidence rate of cancer in West Bank was 86.4 new 
cases per 100,000 people. The number of new reported cases in females was 1,330, which 
resembled 52.4% of new reported cancer cases, and 1,206 among males with 47.6% of new 
reported cancer cases. BC ranked the first type of cancer in the West Bank among all type 
of cancer, with 388 cases, accounting for (15.3%) of total reported cancer cases. In 
addition, BC was the most prevalent type of cancer among females where it accounted for 
28.9% of the total reported cancer cases among Palestinian females. Colorectal cancer 
ranked the second with 262 cases, which accounted for 10.3% of all reported cancer cases. 
The geographical distribution of reported cancer cases showed that Bethlehem governorate 
had the highest incidence rate of cancer cases, it had reached 160.1 per 100,000 population. 
Jericho and Al Aghwar governorate become second with an incidence rate of 123.2 per 
100,000 population, followed by Tulkarm with an incidence rate of 108.5 per 100,000 
populations (MOH, 2016). Among cancer types, BC was the third type of cancer that 
caused death in Palestine with a rate of 11.2%, came after lung (17.5%), and colon cancer 
(12.4%) (MOH, 2017). 
1.4.  22BStudy Aim 
To determine the relationship between T2DM, its medication/s, and breast cancer among 
females in the southern region of the West Bank. 
1.5.  23BStudy Objectives 
1. To determine the prevalence of T2DM among females over 40 years in the southern 
region of Palestine. 
2. To study characteristics of breast cancer cases in the southern region of Palestine. 
3. To determine the association between socio-demographic factors and breast cancer. 
4. To determine the association between reproductive factors and breast cancer. 
5. To determine the association between health status of women, and breast cancer. 
6. To determine the association between diabetes, its medications, and breast cancer. 
7. To determine the association between family history of cancers, and breast cancer. 
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8. To determine the association between lifestyle factors (physical activity, diet intake), 
and breast cancer. 
1.6.  Thesis Structure 
This thesis will be presented in 6 chapters as follows: 
Chapter one: contains the background of the study, problem statement, study 
justification, study aim and objectives. 
Chapter two: includes related data (literature review) of conducted international, regional 
and in country studies and research.  
Chapter three: includes the study conceptual framework. 
Chapter four: includes the study area, study methods, population, sampling method, 
sample size, ethical consideration, data collection, processing and analyzing. 
Chapter five: it presents the results. 
Chapter six: includes discussion, study limitations, conclusions and multi-level 
recommendations. 
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Chapter Two  
Literature Review  
 
2.1.  Diabetes 
According to studies in the late 20th century, it was thought that diabetes prevalence will 
increase to 5.5% of the adult population all around the world (King, Aubert, & Herman, 
1998). Unfortunately, it is the year 2018, and prevalence of diabetes is already 8.8%, and 
thought to be increased to 10% by the year 2045 (Statista, 2018). The number of people 
with diabetes has risen from 108 million in 1980 to 422 million in 2014. In 2015, an 
estimated 1.6 million deaths were directly caused by diabetes. Another 2.2 million deaths 
were attributable to high blood glucose in 2012 (WHO, 2017). Prevalence of T2DM is 
higher in developed than in developing countries currently, but the major part of the 
increase will occur in the developing countries, with a 42% increase in the developed 
countries and a 170% increase in the developing countries. Thus, by the year 2025, more 
that 75% of people with diabetes will be in developing countries. Furthermore, the 
majority of people with diabetes in the developing countries are 10 years younger (45–64 
years) than those in the developed countries, (≥65 years). Regarding gender distribution, 
there are more women than men with diabetes, especially in developed countries (King et 
al., 1998). 
Among Palestinian population, the prevalence of T2DM in adults was 9.7% in 2000, 
increased to 15.3% by 2010. Prevalence in men increased from 9.1% to 16.9% and in 
women from 10.2% to 13.6%. According to an estimation model, the prevalence would be 
20.8% for 2020 and 23.4% for 2030 (Abu-Rmeileh, Husseini, Capewell, & O’Flaherty, 
2013). The number of T2DM new cases in Palestine reported annually, or incidence rate, 
has ranged between 150 to 220 per 100,000 population, but reported cases are considered 
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to represent half of actual cases (Emro, W H O, 2016). In 2016, the new reported T2DM 
cases in MoH primary health care diabetes clinics in West Bank were 5,148 cases, 
distributed to 2,370 cases among males with an incidence rate of 174.6 per 100,000 
population, and 2,778 among females with an incidence rate of 211.5 per 100,000 
population (MOH, 2016). 
2.2.  Cancer 
Cancer constitutes an enormous burden on society in more and less economically 
developed countries alike. The occurrence of cancer is increasing because of the growth 
and aging of the population, as well as an increasing prevalence of established risk 
factors such as smoking, overweight, physical inactivity, and changing reproductive 
patterns associated with urbanization and economic development (Torre et al., 2015).  
The number of new cancer cases is expected to rise by about 70% over the next 2 
decades. Cancer is the second leading cause of death globally, and was responsible for 
8.8 million deaths in 2015. Globally, nearly 1 in 6 deaths is due to cancer, and 
approximately 70% of deaths from cancer occur in low- and middle-income countries 
(WHO, 2018). Based on GLOBOCAN estimates, about 14.1 million new cancer cases 
occurred in 2012 (Globocan, 2012). Over the years, the burden of cancer, like diabetes, 
has shifted to less developed countries, which currently accounts for about 57% of cases 
and 65% of cancer deaths worldwide. Lung cancer is the leading cause of cancer death 
among males in both more and less developed countries, and has surpassed BC as the 
leading cause of cancer death among females in more developed countries; BC remains 
the leading cause of cancer death among females in less developed countries, then come 
liver and stomach cancer among males and cervical cancer among females. Although 
incidence rates for all cancers combined are nearly twice as high in more developed 
than in less developed countries in both males and females, mortality rates are only 8% 
to 15% higher in more developed countries. This disparity reflects regional differences 
in the mix of cancers, which is affected by risk factors and detection practices, and/or 
the availability of treatment. Risk factors associated with the leading causes of cancer 
death include tobacco use (lung, colorectal, stomach, and liver cancer), 
overweight/obesity and physical inactivity (breast and colorectal cancer), and infection 
(liver, stomach, and cervical cancer). A substantial portion of cancer cases and deaths 
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could be prevented by broadly applying effective prevention measures, such as tobacco 
control, vaccination, and the use of early detection tests (Torre et al., 2015). 
Cancer in Palestine, according to Ministry of Health, was the second leading cause of death 
in 2016 accounting for 14% of the total deaths, after cardiovascular diseases which 
accounted for 30.6% of all causes of death. (MOH, 2016).  
2.3.  Breast Cancer 
BC is the most frequently diagnosed cancer and the leading cause of cancer death among 
females worldwide, with an estimated 1.7 million cases and 521,900 deaths in 2012 (Torre 
et al., 2015), while its incidence in 2000 was 1 million worldwide annually (Mcpherson, 
Steel, & Dixon, 2000). BC most recent incidence rate was estimated to be 124 per 100,000 
population (Statista, 2017). It accounts for 25% of all cancer cases and 15% of all cancer 
deaths among females. More developed countries accounted for about one-half of all BC 
cases and 38% of deaths. Highest rates were reported in Britain (Mcpherson et al., 2000), 
then North America, Australia/New Zealand, and Northern and Western Europe. 
Intermediate rates were found in Central and Eastern Europe, Latin America, and the 
Caribbean. Low rates were found in most of Africa and Asia, but rates were on the rise in 
most of developing countries (Berry et al., 2005). In 2017, it was estimated that the 
lifetime probability of a woman to develop BC is 12.4% (Statista, 2017).  
BC as many other cancers, is increasing in less developed countries recently (G. a Colditz, 
Sellers, & Trapido, 2006). Almost 45% of BC incidence cases and more than 55% of 
related deaths, occur in low and middle income countries (Engla, 2010). The most widely 
cited reason for this increase is the “Westernization” of the developing world. 
Westernization accounts for good habits (socioeconomic improvements that increase life 
expectancy and women reproductive control), and on the other hand, the adoption of some 
undesirable habits (dietary changes, decreased exercise, delayed childbearing, having 
fewer children, hormone replacement therapy, reduced breastfeeding), and all increase BC 
risk and are becoming more prevalent in lower income countries (Engla, 2010). 
Unfortunately, westernization in developing countries is not accompanied with effective 
BC screening programs and there is a limited access to treatment  (Torre et al., 2015). 
Another factor accounting for that increase on the other side, is the increase in screening 
activity, which means increase in diagnosis (Althuis, 2005). Mortality rates of BC in 
developing countries are also increasing (Jemal, Center, DeSantis, & Ward, 2010).  
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In Arab countries, like the whole world, BC is the most common cancer among women 
with a young age of around 50 years at presentation. Locally advanced disease is very 
common and total mastectomy is the most commonly performed surgery. Population-based 
screening in those countries with affluent resources and accessible care should be 
implemented (El Saghir et al., 2007). In the Arab middle east countries, it was recorded 
that BC affects younger women than their counterparts in industrialized nations, with 
increasing age-standardized incidence rates from 46.7 per 100,000 in 1998, to 84 per 
100,000 in 2007 (Shamseddine, Tfayli, Temraz, & Abou Mrad, 2010). Information about 
cancer incidence for populations in Cyprus, Egypt, Israel (Jews and Arabs), and Jordan for 
the period 1996–2001 was presented by the Middle East Cancer Consortium (MECC). 
Age-standardized incidence rates per 100,000 females were highest among Israeli Jews 
(93.1), then Cypriot females (57.7), Egyptian females (49.6), Jordanian females (38.0), and 
Israeli Arab females (36.7) (Barchana, 2006).  
The Palestinian community is one of the developing communities, and has the low income 
characteristics pattern. Recently, this community adopted the western lifestyle pattern, and 
is expected to contribute to the increasing number of western diseases (Haidar & Zureik, 
1987). It was revealed that 32% of the cases of BC occurred in Hebron governorate during 
2016, the highest percentage among the other governorates, while the lowest percentage 
was in Jenin governorate at 2% (MOH, 2016). Studies from the Israel Cancer Registry and 
Jerusalem area were reviewed. BC accounted for 30% of all new cases of cancer, and 23% 
of all cancer deaths (Nissan et al., 2004). The incidence of BC is increasing in the Arab 
women, more than the increase in the Jewish females. In a study that was conducted in 
Jerusalem area by Israeli Ministry of Health, it was found that crude incidence for BC in 
Israel in 1995 was 13.6 per 100,000 in Arab women and 102.2 per 100,000 among Jewish 
women. Incidence of BC has increased by 93.7% from 1970 up to 1995 in Arab women, 
while in the Jewish women the increase was only 31.7%. This increase might be real, but it 
might reflect the increase of number by Palestinian women who come to have therapy in 
Jerusalem. It was found that 11% of the Palestinian group were less than 35 years as 
compared to only 5% of the Jewish group. Cases that were diagnosed in screening 
mammography were 39% of Jews, and only 9% in the Palestinian group. Tumors in 
Palestinian women were larger at diagnoses, and generally were detected by physical 
examination and not by screening mammography. Late diagnosis was the major factor 
related to the higher mortality in the Palestinian group (Nissan et al., 2004). During the 
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period 1979–2002, age-adjusted incidence rates among Arab women increased by 202.1% 
(14.1 per 100 000 in 1979–1981 compared with 42.6% in 2000–2002). The age-adjusted 
incidence of BC in the Arab population was doubled from 1980 to 2002. The mortality rate 
ratio between Jewish and Arab women also declined during the years, particularly owing to 
an increase in mortality rates among Arab women with no change in mortality among 
Jewish women (Tarabeia, 2016). 
2.4.  Breast Cancer Risk Factors 
2.4.1.  Age 
The incidence of BC increases with age, doubling about every 10 years until the 
menopause, when the rate of increase slows dramatically (Mcpherson et al., 2000). Table 
2.1 is derived from breast cancer risk factors summary magazine, 
Table  0.1: Incidence of breast cancer by age among females. 
Female age Chances of developing breast cancer in the next 10 
years  
20 1 in 1674 
30 1 in 225 
40 1 in 69 
50 1 in 44 
60 1 in 29 
70 1 in 26 
Lifetime risk (0-85) 1 in 8 
 www.komen.org 2016 Susan G. Komen Item No. KO0092 4/16 
According to international data, in the Middle East, BC diagnosis age is younger than the 
world in the age group 25-34 years; Highest rates were reported in Egypt and the lowest 
were reported in Jordanian and Israeli Arab populations. While between 57% and 68% of 
all BC in the Arab populations of Egypt, Jordan, and Israel were diagnosed before the age 
of 55 years, only 44% of BC cases in Cypriots and 37% among Israeli Jews were 
diagnosed in the same age group (Barchana, 2006). Among Palestinians, the mean age of 
BC diagnosis was 51.5 years, which was 4 years younger than Jews in the same region 
(Nissan et al., 2004).  
2.4.2.  Marital status 
Being single not only increases the risk of BC (OR=1.18, 95%CI: 1.15-1.20), but also 
single women are diagnosed in a later stage of cancer (Hinyard L et al, 2017). 
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2.4.3.  Consanguinity 
In the Arab world, marriage among relatives is so often. Marrying a relative is practiced in 
many parts of the world and only recently the rate has declined in Western countries to 
below 1% of all marriages (Denic & Bener, 2001). Therefore, very few studies took this 
issue into account. In a study that was done in 2001 in the United Arab Emirates, 
consanguinity, which is marriage from relative, had increased the risk of breast cancer 
among daughters. Of 1445 analyzed subjects, 40% (579) had unrelated and 60% (866) had 
related parents. Among the subjects’ in-laws, 41% (594) were consanguineous with 
RR=0.66, with no difference at the age at diagnosis (P = 0.29) (Denic & Bener, 2001). 
2.4.4.  Socio-demographic factors 
High socio-demographic and economic factors are thought to be a risk all over the world, 
by 20% increase in the risk in higher socioeconomic groups, and among higher income  
(Hvidtfeldt et al., 2013; S. A. Robert et al, 2004)  
In Palestine, female employment, higher educational level, which can be characteristics of 
high socio-economic status, among north Palestinian women, increased the risk for BC 
(Darweesh, 2009). 
2.4.5.  Reproductive factors 
Absolute age is not always the issue, age at menarche and menopause also affect the risk. 
The longer the time spent in menstruation phase, the higher the risk. Females who start 
menstruating earlier in life or who have a late menopause have an increased risk of 
developing breast cancer. Women who have their menopause before the age of 45 have 
half the risk than those who have it after 55 of age. Women who had done bilateral 
oophorectomy before the age of 35 years, had 40% of the risk of BC of women who had a 
natural menopause. In addition, late age at first pregnancy or first birth, increase the 
lifetime incidence of BC. The risk of BC in women who have their first child after the age 
of 30 is twice the risk among women who have their first child before the age of 20. The 
highest risk group are those who have a first child after the age of 35, these women have 
even higher risk than nulliparous women (Mcpherson et al., 2000). 
Many studies showed that late age at marriage and pregnancy increases the risk (American 
Cancer Society, 2018). Approximately an 18% increase in the risk was reported among 
12 
 
women married at older age (Hirose et al, 1995). The risk was doubled when 1st pregnancy 
occurred after 30 (Engla, 2010), and increased by 3 folds after age of 40 (Mcpherson et al., 
2000). In Gazan women, an increased risk was observed in women who had their first 
pregnancy after 35,  (OR=11.56, 95%CI: 1.64-81.35) (Kariri et al., 2017). Among 
Palestinian women in the North, there was a 10% increase in the risk for females with first 
marriage occurred after the age of 20 years (Darweesh, 2009). 
A positive dose response relationship was reported between 1st pregnancy age and BC risk. 
Having the 1st pregnancy after 30 had increased the risk among French women, (RR=1.17, 
95%CI: 0.97-1.41) (Gauthier et al., 2004), among Chinese women (RR=2.67, 95%CI: 
1.28-3.45) (H. B. Nichols et al., 2005; Yuan, Vu, Ross, Gao, & Henderson, 1988), and 
among American women (RR=2.18, 95%CI: 1.36, 3.49) (Ma et al., 2010). The highest risk 
was found among women in Spain ,(OR= 3.5 95%CI: 1.41-9.83) (Ramon et al, 1996). In 
addition, early age at first pregnancy in the Arab world (less than 30) (OR=0.23, 95%CI: 
0.16-0.32), was negatively associated with BC (Laamiri, Bouayad, Hasswane, & Ahid, 
2015). 
The same applied for 1st age at delivery which increases the risk of getting BC, comparing 
1st delivery after 30 to less than 20. The increase in the risk ranged from 20% to 27% 
(Albrektsen, Heuch, Hansen, & Kvåle, 2005; Ma, Bernstein, Pike, & Ursin, 2006).  When 
having the first baby after the age of 40 years,  RR was 1.16, (95%CI: 1.02-1.32) (Warner 
et al., 2014). 
Age at menarche and menopause also affected the risk of BC. It was reported that an 
additional year for age at menarche decreased the risk by 5%. Menopause itself was not 
associated with an increased risk of developing cancer. However, the rate of BC increases with 
age. In addition, some of the drugs used to manage menopausal symptoms might increase or 
decrease the risk (Laura J. Martin, 2017). However, late age at menopause (more than 55) 
was found to increase the risk of BC (OR=2.36, 95%CI: 1.91-2.91) (Warner et al., 2014). It 
was suggested that early menarche and late menopause increase the risk of BC by 
prolonged ovarian hormone production (Andrea Z LaCroix, 1997), due to more cumulative 
menstrual cycles and more ovulation (Clavel chapelon et al, 2002; K. L. Terry, Willett, 
Rich-edwards, David, & Michels, 2008). It was reported that for every year older a 
woman’s age at menopause, BC risk increased by about 3 percent (Lancet Oncology, 
2012). On the contrary, a study held in north Palestine showed an opposite result, with 
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OR=0.30 when menopause occurs at 50 or more (Darweesh, 2009). The inconsistency 
between Palestinian results and the previous results may be due to the cutoff point, which 
was 55 years in European studies. 
Number of full term pregnancies was negatively associated with BC risk. This result was 
consistent not only for one type, but all subtypes of BC, for pre and post-menopausal 
women (Li et al., 2013). Three or more full term pregnancies decreased the risk of BC 
(OR=0.76, 95%CI: 0.54-1.05) (Hirose et al, 1995). Females who had 5 full term 
pregnancies had half or third the risk of BC, with (RR=0.65) (Blamey et al., 2004), and 
(RR=0.39, 95%CI 0.19-0.80) (Yuan et al., 1988) respectively. Multiparity in Morocan 
women decreased BC risk (OR=0.64, 95%CI: 0.53-0.77) (Laamiri et al., 2015). Among 
Palestinian women in the Northern region, a 50% decrease in the risk was reported among 
females with 4 full term pregnancies or more (Darweesh, 2009).  
Nulliparity, on the other hand, was reported as a risk factor for BC (Weir & Ali, 2007). It 
was estimated that the cumulative incidence of BC in developed countries would be 
reduced by more than half, if women had the average number of births and lifetime 
duration of breastfeeding that had been prevalent in developing countries until recently 
(Valerie Beral, 2002). Relative risk declined by approximately 9.0% for each additional 
parity (Weir & Ali, 2007), in addition to a decrease of 7.0% for each birth (Valerie Beral, 
2002). 
Abortion was suspected to be a risk factor for BC. Most studies differentiated between 
induced and spontaneous abortions, many studies found no connection between any type of 
abortions and BC incidence (American Cancer Society, 2014). On the other hand, a 
comprehensive review reported an increase in the risk (OR= 1.3, 95%CI: 1.2-1.4), for only 
induced abortion (Brind, Chinchilli, Severs, & Summy-long, 1996). An estimated 11% 
increase risk in BC was confirmed with each induced abortion (Blamey et al., 2004). BC 
risk was found to be doubled in induced abortion (OR=1.9), and increased by 50% 
(OR=1.5) for spontaneous abortion (Holly Howe et al, 1989). This disagreement in 
findings may be due to intentional recall bias by women, who wouldn’t accurately tell their 
history of abortion, because it was illegal in many countries. Among Palestinian women in 
the north, history of abortion either induced or spontaneous increased the risk significantly 
(OR=6.69) (Darweesh, 2009).  
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Breastfeeding is known to be protective for breast cancer. It is clearly known that long-
term breastfeeding can be linked with up to a 30% reduction in breast cancer risk (Weir & 
Ali, 2007). A clear dose response relationship, was noted with risk of breast cancer; BC 
relative risk decreased by 4·3% for every 12 months of breastfeeding. In addition, 
breastfeeding could account for almost two-thirds of estimated reduction in breast cancer 
incidence. Furthermore, it was reported that fewer parous women with cancer had ever 
breastfed than parous controls (71% vs 79%), and their average lifetime duration of 
breastfeeding was shorter (9.8 vs 15.6 months) (Valerie Beral, 2002). It was found that the 
protective effect depends on whether the cancer is hormone receptor-negative or positive.  
(Li et al., 2013; Ma et al., 2010; H. B. Nichols et al., 2005; Warner et al., 2014). Analysis 
showed a protective effect of ever breastfeeding against hormone receptor-negative BC, 
and this effect seemed to be several times stronger than what had been suggested by 
studies of all BC without stratification by receptor status. Women with the highest risk of 
receptor negative BC, can potentially benefit more from breastfeeding  (Islami et al., 
2015).  
Having an irregular menstrual cycle was found to increase the risk in a Jordanian study 
(Wasileh P Nustas et al, 2002). Other studies showed the opposite results, it was reported 
that longer menstrual cycles (more than 28 days) at ages 18 to 22 years were associated 
with a lower incidence of premenopausal BC before age 40 (Terry et al 2008), especially 
after adjustment for reproductive factors and family history, (OR=0.44, 95%CI: 0.22-0.86) 
(Den Tonkelaar et al, 1996). It is worth noting that these results were limited to longer 
cycles, not shorter ones. 
Long-term use of hormone replacement therapy, but apparently not long-term use of oral 
contraceptives, was also related to increased risk of BC (Beral, Banks, Bull, & Reeves, 
2003). Despite the use of mega-doses of hormones in fertility treatments, there was no 
evidence that these treatments are hazardous to the breast (Gauthier et al., 2004). It was 
reported that a history of oral contraceptive use slightly and significantly increases BC 
incidence (OR=1.08, 95%CI: 1.00-1.17), but the duration of use was not associated with 
the risk. Furthermore, it was noticed that time since last oral contraceptive use, was 
associated with higher risk more than recent use (Gierisch et al., 2013). The associations 
also depended on the receptor subtype. Association of ever use of oral contraceptives and 
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BC among women who are BRCA1 or BRCA2 mutation carriers were similar to those 
reported for the general population (OR=1.21; CI 0.93-1.58). Findings were similar when 
examining BRCA1 and BRCA2 mutation carriers separately (Moorman et al., 2013). On 
the other hand, among Moroccan females, it was revealed that oral contraceptives beyond 
6 months, increased the risk of BC (OR=1.25, 95%CI: 1.01-1.55). Moroccan data reported 
that extensive use of contraceptives at a late age of reproductive life leaded to a significant 
increase of developing BC (Laamiri et al., 2015). 
Hysterectomy and oophorectomy result in less number in ovarian cycles, therefore, they 
were found to decrease the risk of BC. Hysterectomy either with ovarian conservation or 
removal, was found to reduce the risk of BC (Press et al., 2011). It was reported that the 
risk of BC was reduced in women who underwent bilateral oophorectomy with 
hysterectomy (OR=0.8, 59%CI: 0.7- 0.9), or hysterectomy alone (OR=0.7, 95%CI: 0.6-
0.8) (Parazzini F et al, 1997). In addition, bilateral oophorectomy was associated with 
more reduction of BC risk (OR=0.59, 95%CI: 0.50-0.69). It should be mentioned that 
hormone replacement therapy cannot be separated from these surgeries, which might 
suppress that effect. Medical strategies in our region start hormonal therapy just after 
hysterectomy or oophorectomy. Estrogen alone is usually given, which increases the risk 
more than any other hormone therapy  (Toine Lagro-Janssen, Walter W Rosser, 2003). 
2.4.6.  Health status 
Body mass index, history of diseases, and some chronic medication were taken into 
account in this section. Obesity was associated with a two fold increase in the risk of BC in 
postmenopausal women (RR=2) (Mcpherson et al., 2000). Furthermore, another study 
reported that higher body mass index (BMI) was associated with higher risk of BC, with a 
clear dose response relationship regardless of menopausal status, the RRs of BC in 
ascending order of BMI categories were 1.10 for the category (22.5-24.9) BMI, RR=1.45 
for the category (25-27.4) BMI, RR=1.62 for the category (27.5-29.9) BMI, and 1.36 for 
the category of BMI 30 or more, when compared to BMI < 22.5 (Hormones, Cancer, & 
Group, 2003). A 5-unit increase in BMI was associated with a 12% increase in risk, and 
obese women had a 20% to 40% increase in the risk (American Institute for Cancer 
Research, 2017). On the other hand, obesity among premenopausal women was protective, 
(RR=0.7) (Mcpherson et al., 2000). The positive association between obesity and 
postmenopausal BC is thought to be due estrogen, which a risk factor for BC. Estrogen is 
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synthesized in adipose tissue. Obesity is also associated with high levels of insulin, a 
known mitogen. It is suggested that insulinemia is an independent risk factor for BC and 
may have a substantial role in explaining the obesity – BC relationship (Gunter et al., 
2009). 
Cardiovascular diseases, osteoporosis, auto-immune diseases, joint problems ,and many 
other chronic conditions are considered to be risk factors for BC (Cancer research UK, 
2014a). Among chronic drugs that were taken for more than 6 months, Aspirin in almost 
all studies confirmed the protective role, with about 30% decrease in the risk, for all breast 
cancer subtypes (D. Schreinemachers et al, 1994), or for only hormone positive receptor 
tumors in other studies, (OR=0.74 95%CI: 0.60-0.93) (M. B. Terry, Gammon, Teitelbaum, 
Britton, & Neugut, 2004). Not only Aspirin, but all NSAID's (non-steroidal anti-
inflammatory drugs) showed same protective role in BC (OR=0.60, 95%CI: 0.40-0.91) 
(Randall E Harris et al, 1996).  
Digoxin, an anti-arrhythmic drug, was associated with 39% increase in the risk of BC 
(RR=1.39, 95%CI: 1.32-1.46) (Biggar, Wohlfahrt, Oudin, Hjuler, & Melbye, 2011). It was 
reported recently that the increase in the risk was higher only for hormone receptor positive 
tumors (Osman et al., 2017), as Digoxin chemically resembles estrogen and may have 
estrogenic effect (Rifka SM et al, 1976), and can cause gynecomastia (Dicky RP et al, 
1975). 
2.4.7.   Family history 
Up to 10% of BC in Western countries is due to genetics. Many families affected by breast 
cancer show an excess of ovarian, colon, prostatic, and other cancers attributable to the 
same inherited mutation (Mcpherson et al., 2000). Approximately 17% to 19% of breast 
cancer in the population could be attributed to family history. Women with family history 
of BC, even if the nearest relative with BC is a third-degree relative, are at increased risk 
of the disease. It was found that a threefold increase in risk of BC was reported among 
those with the highest family history score. Furthermore, the risk was increased for women 
with a first-degree relative with breast cancer (OR=2.45 95%CI: 1.84 -3.06). A greater risk 
was observed if the first-degree relative was a woman's mother (OR=2.44, 95%CI: 1.77-
3.42) rather than a sister (OR=2.01, 95%CI: 1.66-2.43). The risk was clearer when the 
subject is diagnosed before the age of 50 years (Slattery & Martha, 1993). 
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The following categories identify women who have three or more times the population risk 
of developing breast cancer according to (Mcpherson et al., 2000): a woman who has one 
first degree relative with bilateral breast cancer or breast and ovarian cancer, Or one first 
degree relative with breast cancer diagnosed under the age of 40 years or one first degree 
male relative with breast cancer diagnosed at any age, Or two first or second degree 
relatives with breast cancer diagnosed under the age of 60 years or ovarian cancer at any 
age on the same side of the family, or three first or second relatives with breast and ovarian 
cancer on the same side of the family, or families with four or more relatives affected with 
either breast or ovarian cancer in three generations and one alive affected relative 
(Mcpherson et al., 2000). 
2.4.8.   Lifestyle 
This group of risk factors includes physical activity, history of smoking, some daily habits, 
and nutrition. 
Physically active women are at a lower risk of having breast cancer than inactive women; 
The average breast cancer risk reduction associated with physical activity was 12% (Wu Y 
et al, 2013). The reduction in the risk was reported for both premenopausal and 
postmenopausal women; However, the evidence for an association is stronger for 
postmenopausal BC (Eliassen AH et al, 2010; Fournier A et al, 2014).  
Considering active and passive smoking, an increased risk was reported among only active 
smokers, with highest risk found for those who smoked for more than 50 years, and start 
smoking at teenage, but the analysis didn’t show an association with passive smoking (Luo 
et al., 2011). On the other hand, passive smoking, as well as active smoking was a 
significant risk in a more recent cohort study, (HR=1.16 95%CI: 1.05-1.28) for active 
smokers, and (HR=1.14 95%CI: 1.04-1.25) for passive smokers (Dossus et al., 2014).  
2.4.9.  Nutritional factors, alcohol 
The fact that diet can be a risk for breast cancer has been studied for years. Dietary fat has 
been the most investigated kind of food. It is believed that a high-fat diet is not directly 
related to the risk of breast cancer (Eunyoung Cho et al., 2003). The true relation between 
fat intake and breast cancer does not appear to be particularly strong or consistent 
(Mcpherson et al., 2000). On the contrary, it was reported that overall caloric intake, and 
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obesity in particular with certain weight-gain patterns, are related to increased breast 
cancer risk, with different effects between pre- and postmenopausal women (Endogenous 
Hormones Breast Cancer Collaborative Group, 2003; Harvie et al., 2005). This agrees with 
a proven role of regular physical activity in reducing breast cancer risk (Bardia et al., 
2006). High fruit and vegetable consumption is related to decreased BC risk in most 
studies (S. Zhang et al., 1999). Especially, the consumption of cruciferous vegetables, 
which was shown in vitro and in vivo to be related to such protection. Of all food items 
studied, regular alcohol consumption, even at moderate levels, has consistently been found 
to be related to a mild increase in breast cancer risk in women (Mcdonald et al., 2004). 
Furthermore, it was found that consumption of a dietary pattern characterized by 
vegetables, fruit, fish, and soy and its derivatives, as well as patterns designated as 
traditional and Mediterranean, reduced the risk of breast cancer, while consumption of the 
alcoholic pattern was associated with increased risk of breast cancer. A positive association 
was observed relative to the western dietary pattern; however, most of these results were not 
statistically significant (Albuquerque, Baltar, & Marchioni, 2014). A significant 
association was found between meat consumption and risk of breast cancer (RR=1.17, 
(95%CI: 1.06-1.43). On the other hand, many systematic reviews identified no statistically 
significant findings by red meat, white meat, dairy fluid, dairy solid and egg consumption 
(Missmer et al, 2002). It was also reported that saturated fat intake increased the risk 
(RR=1.19, 95%CI: 1.06-1.35) (Boyd et al., 2003). On the contrary, saturated fat in case 
control studies decreased the risk (RR 0.91, 95%CI: 0.66-1.28) (Weir & Ali, 2007). 
Since decades, alcohol is thought to be a risk factor for many cancers, and specifically for 
BC. Consumption of the “alcoholic” pattern increased BC risk by 27%. among older 
women (>50 years) (P. Terry, Suzuki, & Hu, 2001). Two cohort studies (Cottet et al., 2009; 
P. Terry et al., 2001), and four case-control studies (Bessaoud, Tretarre, Daurès, & Gerber, 
2012; Nkondjock & Ghadirian, 2005; Ronco et al., 2006; Stefani et al., 2009) had 
identified a pattern of alcoholic beverage consumption;  Findings indicated that 
consumption of alcoholic beverages is a significant risk factor for breast cancer in pre- and 
postmenopausal women (World Cancer Research Fund & American Institute for Cancer 
Research, 2007). However, no association between BC and alcohol consumption was 
identified in case control studies. An explanation might be the relative stability and 
homogeneity of the population’s lifestyle and dietary habits (Nkondjock & Ghadirian, 
2005). Similarly, Ronco et al. did not find an association between the “alcoholic” dietary 
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pattern and breast cancer, even when the analysis was stratified by menopausal status. 
These authors suggested the absence of an effect was due to the low prevalence of alcohol 
consumption among women ( approximately 20%) (Albuquerque et al., 2014).  
As seen above, evidence of all of the previous risk factors of breast cancer are not 
consistent in all literature, table 2.5 reviews a summary of these risk factors and their 
evidence differences. 
Furthermore, T2DM and breast cancer share some common risk factors. A review of 
modifiable and non-modifiable risk factors for both T2DM and breast cancer are 
summarized in table 2.2 and 2.3 respectively.  
2.5.  Diabetes and breast cancer 
T2DM is associated with an increased risk of breast cancer. Three mechanisms are thought 
to contribute to the association between T2DM and BC: activation of the insulin pathway, 
activation of the insulin-like-growth-factor pathway, and impaired regulation of 
endogenous sex hormones. But the exact mechanism of T2DM association with cancer 
remains uncovered and needs to be examined in further studies (Dankner, Shanik, Keinan-
Boker, Cohen, & Chetrit, 2012). A statistically significant 20% increased risk of breast 
cancer was reported among women with T2DM (RR=1.20, 95%CI: 1.12-1.28). The 
increase in the risk has ranged from 1.2 to 2.5 folds. Insulin blood levels are high among 
T2DM patients, and were positively associated with the risk of breast cancer, (HR=1.46, 
95%CI: 1.00-2.13). High insulin level was associated with BC among nonusers of 
hormone therapy (HR=2.40, 95%CI: 1.30-4.41), and among obese women (HR for BMI ≥ 
30 kg/m² =2.12, 95%CI: 1.26-3.58); However, this association was attenuated by 
adjustment for insulin. This tells that hyper-insulinemia is an independent risk factor for 
breast cancer and may have a substantial role in explaining the obesity – breast cancer 
relationship (Gunter et al., 2009). When insulin is taken as a treatment, the risk of BC is 
increased dramatically (OR=2.98, 95%CI: 1.26-7.01) (García-Esquinas et al., 2015). Pre-
diabetes also was found to increase the risk of BC in postmenopausal women (adjusted 
OR=2.08, 95%CI: 1.10-3.96) as does diabetes (adjusted OR=2.85, (CI 1.55-5.26). A 
history of diabetes preceding BC by ≥7 years and <7 years were both associated with an 
increased risk for BC (adjusted OR=2.80, 95%CI: 1.40-5.60) and (OR=3.00, 95%CI: 1.50–
5.90), respectively (Salinas-Martínez et al., 2014). 
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On the other hand, no significant association was found between T2DM and breast cancer 
in other studies (OR=1.09, 95%CI: 0.82-1.45). T2DM was only linked to the risk of 
developing TN tumors (OR=2.25, 95%CI: 1.22–4.15) (García-Esquinas et al., 2015). 
2.5.  Metformin and breast cancer 
Many studies have suggested that Metformin decreases the incidence of several common 
cancers. The mechanism is not clearly understood, but the most probable mechanism is 
that Metformin acts as a growth inhibitor for human BC cells (Zakikhani, Dowling, Fantus, 
Sonenberg, & Pollak, 2006). In a clinical experiment it was found that Metformin inhibits 
breast cancer cell growth, colony formation and induces cell cycle arrest in vitro, 
Metformin reduces levels of cell cycle promoters and inhibits signaling in breast cancer 
cell lines (Alimova et al., 2009). A dose response relationship is noted with the use of 
Metformin as protective factor, a study showed that among diabetics, the risk of 
developing HR/HER2- tumors decreased with longer Metformin use (OR per year of use= 
0.89, 95% CI: 0.81-0.99) (García-Esquinas et al., 2015).  Compared with other antidiabetic 
drugs, a 30% decrease in the risk was found among Metformin users (RR=0.69, 95%CI: 
0.61-0.79) (DeCensi et al., 2010).  
When taken as an independent variable, Metformin users were less likely with a diagnosis 
of breast cancer OR=0.77; (CI; 0.61-0.99) than non-Metformin users (Bosco, Antonsen, 
Sørensen, Pedersen, & Lash, 2011). Long-term use of more than five years of Metformin 
was also associated with decreased risk of breast cancer (adjusted OR= 0.44, 95%CI: 0.24-
0.82) (Bodmer, Meier, Krahenbuhl, Jick, & Meier, 2010). Furthermore, postmenopausal 
women with diabetes receiving medications other than Metformin, had a slightly higher 
incidence of BC (HR=1.16, 95%CI: 0.93-1.45) (Chlebowski et al., 2012). 
Metformin not only reduces the risk of BC, but also might reduce the development of 
multidrug resistance in vitro in breast cancer cells and may reverse resistance once it has 
occurred. People with T2DM and cancer who take Metformin have been reported to have a 
31% reduction in the occurrence of new cancers. Also, Metformin has been suggested to 
benefit all-cause survival in those with breast cancer (H. Nichols, 2017). 
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2.6.  Insulin replacement therapy, other oral hypoglycemic drugs 
and breast cancer 
Long acting Insulin Glargine was associated with increased BC risk in many cohort studies 
(Jennifer W Wu, 2017), and the risk was higher when it was taken after other kinds of 
insulin (Peeters, Bazelier, Leufkens, Auvinen, & Staa, 2016). On the other hand, it was 
found that Glragine non-significantly decreased the risk of BC (HR=0.59 95%CI: 0.28-
1.25). And adjusted HRs for death or cancer associated with insulin Glargine compared 
with human insulin was  (HR=0.58, 95%CI: 0.32-1.06) (Blin et al., 2012). 
The odds ratio of BC increasing evidence shows that insulin sensitizers such as 
Thiazolidinediones (TZDs) are associated with prostate cancer and HER2-positive BC 
among diabetic patients (Dankner, Balicer, et al., 2012). The diabetic patients who are 
treated with insulin or insulin secretogogues are more likely to develop cancer than those 
with Metformin (Blin et al., 2012).  
Sulfonyureas are usually prescribed with Metformin in a combination therapy, so the 
slightly elevated risk for breast cancer associated with Sulfonyureas is not seen (Currie et 
al., 2009). Glucose lowering agents were shown to have an effect on cancer risk, as 
indicated by the higher rates seen in patients using Sulfonylurease relative to those using 
Metformin (Bowker, Majumdar, Veugelers, & Johnson, 2006). 
An overall review of sugar lowering drugs, their mechanism of action, and a comparison of 
their advantages and disadvantages is summarized in table 2.4.   
Finally, and according to this review, the study conceptual framework will be presented. 
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Table 2.2: Non Modifiable Risk Factors of Type 2 Diabetes and Breast Cancer  
Compared Risk Factors Type 2 Diabetes Mellitus  Breast Cancer 
Age  26.9 % of adults age ≥65 yrs or older have been 
diagnosed or have undiagnosed diabetes compared to 
3.7% in adults aged 20-44.* 
The older an individual is, the more likely she or he 
will develop BC. 
Rate of BC increases after age 40 and are highest 
over age 70. 
Gender 11.8 % of all men ≥ 20 yrs of age have diabetes vs. 
10.8 % of all women.* 
Men are more likely to have undiagnosed diabetes 
Being female is the most common risk factor for BC. 
BC is 100 times more common in women than in 
men. 
Having a family history of 
the disease 
If your siblings or parents have diabetes, you have a 
higher risk.* 
A family history of certain types of cancer can 
increase your risk of BC. This increased risk may be 
due to genetic factors (known and unknown) and 
lifestyle. 
Race  Compared to non-Hispanic whites, the risk of 
diagnosed diabetes was 18% higher in Asian 
Americans, 66 % higher among Hispanics and 77% 
higher among non-Hispanic blacks. * 
Non-Hispanic white women have the highest BC 
incidence overall. African American women have 
the highest BC mortality overall. 
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Table 2.3: Modifiable Risk Factors of Type 2 Diabetes and Breast Cancer 
Risk factors: Type 2 Diabetes Mellitus Breast Cancer 
High blood pressure 2 out of 3 people with diabetes report having high blood pressure (140-
90 or higher).* 
No association  
Physical inactivity Being active helps maintain normal levels of blood sugar and keeps 
your body sensitive to insulin.( D. E. R. Warburton, C. W. Nicol, and 
S. S. D. Bredin, “Health benefits of physical activity: the 
evidence.,” CMAJ, vol. 174, no. 6, pp. 801–9, Mar. 2006.)  
Regular exercise appears to lower BC risk by 
about 10-20 %. This benefit is most clearly 
seen in postmenopausal women. 
Overweight or 
obesity 
Being overweight raises the risk. * 
For most people, losing weight can reverse T2DM. 
Before menopause, being overweight or obese 
modestly decreases risk. 
After menopause, being overweight or obese 
increases risk. 
Unhealthy diet Diets low in red and processed meats and high in vegetable, fruit, 
whole grains cereals and dietary fiber may protect against T2DM by 
improving insulin sensitivity.  
  
Note: While low carbohydrate, high protein and fat diets have been 
shown to reduce weight and lower insulin levels, large randomized 
clinical trials have only been performed on low fat, low calorie diets to 
date. 
Studies now show that eating vegetables may 
slightly lower the risk of some breast cancers. 
(“Fruit and vegetable intake and risk of breast 
cancer by hormone receptor status,” J. Natl. 
Cancer Inst., vol. 105, no. 3, pp. 219–36, Feb. 
2013.)  
Eating a high fat diet during adolescence may 
be associated with increased risk of 
premenopausal BC. 
Smoking May be an independent risk factor for developing T2DM. 
Smoking increases risk for complications from diabetes, such as – 
cardiovascular disease, damage to the retina of the eye and other 
diabetes-related health outcomes. (“Diet, Lifestyle, and the Risk of 
Type 2 Diabetes Mellitus in Women - NEJM.” 
http://www.nejm.org/doi/full/10.1056/NEJMoa010492.) 
Smoking’s effect on breast cancer is still under 
study. Although there is growing evidence that 
smoking may slightly increase the risk of 
breast cancer, overall, study findings remain 
mixed. 
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Risk factors: Type 2 Diabetes Mellitus Breast Cancer 
Alcohol Excessive alcohol consumption has been associated with increased 
risk for T2DM. However, moderate alcohol (about 2 drinks per day) 
consumption appears to lower risk slightly. (“Moderate Alcohol 
Consumption Lowers the Risk of Type 2 Diabetes: A meta-analysis 
of prospective observational studies,” Diabetes Care, vol. 28, no. 3, 
pp. 719–725, Mar. 2005.) 
Studies show that women who had more than 
two alcoholic drinks per day had a 20 % 
higher risk of BC. 
However, drinking low to moderate amounts 
of alcohol may lower the risks of heart 
disease, high blood pressure and mortality. 
Pre-diabetes If pre-diabetes is left untreated, it often progresses to T2DM.* Increases the risk of BC in postmenopausal 
women (AOR=2.08, 95%CI: 1.10-3.96)  
(Salinas-Martínez et al., 2014). 
Gestational Diabetes 
 
If you had gestational diabetes, your risk for developing T2DM later 
on increases by about 35-65%. * 
No association 
Metabolic 
Syndrome or insulin 
resistance syndrome 
A diagnosis of metabolic syndrome can result in up to a 5 fold 
increase risk for developing T2DM. (E. S. Ford, C. Li, and N. Sattar, 
“Metabolic syndrome and incident diabetes: current state of the 
evidence.,” Diabetes Care, vol. 31, no. 9, pp. 1898–904, Sep. 2008.) 
Associated with a moderately increased risk 
for postmenopausal BC. (“Metabolic 
syndrome and postmenopausal BC: 
systematic review and meta-
analysis.,” Menopause, vol. 20, no. 12, pp. 
1301–9, Dec. 2013.). Still an area of 
investigation. 
* (Centers for Disease Control, 2011) 
- Note:  of course there are other known risk factors for breast cancer, such as age at first pregnancy and age at 
menopause, which will be discussed in our objectives and conceptual framework 
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Table 2.4: Comparison of Anti-diabetic Medications 
Agent** Mechanism*** Advantages* Disadvantages** 
Sulfonylurea (Glyburide, 
Glimepiride, glipizide) 
Stimulating insulin 
release by pancreatic beta 
cells by inhibiting 
the KATP channel 
• Inexpensive 
• Fast onset of action 
• No effect on blood pressure 
• No effect on low-density 
lipoprotein 
• Lower risk of 
gastrointestinal problems than 
with Metformin 
• More convenient dosing 
• Causes an average of 5–10 pounds weight gain 
• Increased risk of hypoglycemia 
• Glyburide has increases risk 
of hypoglycemia slightly more as compared with 
Glimepiride and Glipizide 
• Higher risk of death compared with 
metformin(http://news.yahoo.com/metformin-
outperforms-common-class-diabetes-drugs-
study-160405357.html) 
Metformin Acts on the liver to 
reduce gluconeogenesis 
and causes a decrease 
in insulin resistance via 
increasing AMP Kinase  
signaling 
• Not associated with weight gain 
• Low risk of hypoglycemia as 
compared to alternatives 
• Good effect on LDL cholesterol 
• Decreases triglycerides 
• No effect on blood pressure 
• Inexpensive 
• Increased risk of gastrointestinal problems 
• Contraindicated for people with moderate or 
severe kidney disease or heart failure because of 
risk of lactic acidosis due to Alcoholism 
• Increased risk of Vitamin B12 deficiency 
• less convenient dosing Metallic taste 
Alpha-glucosidase 
inhibitor (Acarbose, 
Miglitol, Voglibose) 
Reduces glucose 
absorbance by acting 
on small intestine to 
cause decrease in 
production of enzymes 
needed to digest 
carbohydrates 
• Slightly decreased risk of 
hypoglycemia as compared to 
sulfonylurea 
• Not associated with weight gain 
• Decreases triglycerides 
• No effect on cholesterol 
• Less effective than most other diabetes pills in 
decreasing glycated hemoglobin 
• Increased risk of GI problems than other 
diabetes pills except Metformin 
• Inconvenient dosing 
• Expensive 
Thiazolidinediones 
(Pioglitazone, 
Rosiglitazone) 
Reduce insulin resistance 
by activating PPAR-γ in 
fat and muscle 
• Lower risk of hypoglycemia 
• Slight increase in high-density 
lipoprotein 
• Actos linked to decreased 
triglycerides 
• Increased risk of heart failure 
• Causes an average of 5–10 pounds weight gain 
• Higher risk of edema 
• Higher risk of anemia 
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• Convenientdosing • Increases low-density lipoprotein 
• Avandia (Rosiglitazone)  linked to increased 
triglycerides and risk of heart attack 
• Actos linked to increased risk of bladder cancer 
• Slower onset of action 
• Requires monitoring for hepatotoxicity   
• Increased risk of limb fractures 
• Expensive 
Agent** Mechanism*** Advantages* Disadvantages** 
*Cambon-Thomsen, A.; Rial-Sebbag, E.; Knoppers, B. M. (2007). "Trends in ethical and legal frameworks for the use of 
human biobanks". European Respiratory Journal 30 (2): 373–382. doi:10.1183/09031936.00165006. PMID 17666560.  
** (Drugs, 2012) ( "The Oral Diabetes Drugs: Treating Type 2 Diabetes" (PDF). Best Buy Drugs (Consumer Reports): 
20. Retrieved September 18, 2012.,) 
*** Table entries taken from page 185 in: Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up 
Series). Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 0-7817-7153-6. 
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Table  2.5: Breast Cancer Risk Factors 
Increases risk ('sufficient' or 'convincing' 
evidence) 
May increase risk 
('limited' or 'probable' 
evidence) 
Decreases risk 
('sufficient' or 
'convincing' evidence) 
May decrease risk 
('limited' or 'probable' 
evidence) 
• Alcoholic beverages 
• Diethylstilbestrol 
• Estrogen-progestogen contraceptives 
• Estrogen-progestogen menopausal 
therapy 
• X radiation and Gamma radiation 
• Body fatness* 
• Adult attained height* 
• Digoxin 
• Hormone replacement 
therapy 
• Ethylene oxide 
• Shift work involving 
circadian disruption 
• Tobacco smoking 
• Adult attained 
height** 
• Greater birth weight** 
• Abdominal fatness* 
• Adult weight gain* 
• Total dietary fat* 
• Breastfeeding • Body fatness** 
• Physical activity 
* Post-menopausal breast cancer only. ** Pre-menopausal breast cancer only. 
International Agency for Research on Cancer (IARC) and The World Cancer Research Fund/American Institute for Cancer 
Research (WCRF/AICR) classifications. Find out more about IARC and WCRF/AICR classifications.  
(Parkin, Boyd, & Walker, 2011) 
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Chapter 3 
Conceptual Framework 
 
3.1. Introduction 
In this chapter, the mechanism that describes the association between diabetes and BC is 
presented. The study model will be shown and explained too.  
3.2. Association between diabetes and breast cancer 
The association between T2DM and breast cancer was firstly investigated about 50 years 
ago. The exact mechanism behind this correlation is not clearly understood yet, but three 
main mechanisms were suggested to explain this association (Wolf, Sadetzki, Catane, 
Karasik, & Kaufman, 2005).  
3.2.1. Activation of the insulin pathway: 
The insulin pathway: The first step in activation of the insulin pathway is the binding of 
insulin to the insulin receptor, which is a tyrosine kinase composed of two α subunits and 
two β subunits. Healthy breast tissue and breast-cancer cells express insulin receptors as 
many well as other tissues in the body like liver, adipose tissue and skeletal muscles. The 
binding of insulin to insulin receptor (IR), leads to auto-phosphorylation of tyrosine 
residues in the intracellular subunits and activation of the tyrosine kinase. Once activated, 
several intracellular proteins are phosphorylated, including members of the insulin receptor 
family and this activates phosphatydylinositol 3-kinase, which in turn activates the 
pathway, leading to activation of extracellular-signal-regulated-kinase cascade, one of the 
mitogen-activated protein kinase pathways (Wolf et al., 2005). Insulin signaling has a 
metabolic role, but enzymes in the pathway also have important roles in tumorigenesis 
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(Frenso Vara JA et al, 2004). Also, insulin was found to stimulate cell-cycle progression in 
a kind of breast-cancer cells by itself or synergistically with estradiol (Lai, Sarcevic, Prall, 
& Sutherland, 2001). Furthermore, overexpression of insulin receptor can induce 
malignant transformation in breast epithelial cell lines (Lucia Frittitta et al, 1995). 
Stimulation by progestins, or the activity of oncogenes can lead to overexpression of IR in 
breast cancer, by contrast with adipose tissue, breast-cancer tissue showed diminished 
down regulation of insulin receptors in response to insulin (Papa et al., 1990). 
The binding of insulin to insulin receptors in breast cancer cells was higher than any tissue, 
in 22 of 23 samples of breast cancer (Humanmammarycarcinoma, Benson, & Holdaway, 
1982). The binding of insulin in breast cancer was not reduced, even in the presence of 
high serum concentrations of insulin, furthermore, the concentration of insulin receptor 
was six-fold higher in 159 samples of breast cancer than in 33 samples of healthy breast 
tissue; concentrations of insulin receptor were also higher in breast -cancer tissue than in 
other healthy tissue, including the liver. And it was correlated with tumor size, grade, and 
estrogen-receptor concentration (Papa et al., 1990). Not only cancer incidence was related 
to high insulin concentrations, but also with cancer recurrence and death (Giudice et al., 
1998).  
3.2.2. Activation of Insulin like growth factor pathway: 
This pathway consists of a network of ligands (IGF1 and IGF2), insulin-like growth factor 
binding proteins (IGFBP), and the IGF1 receptor (IGF1R). IGF1 and IGF2 are highly 
homologous to insulin and IGF1R shares 55% homology with IR. IGF1R and IR can form 
hybrid receptors, which have high affinity with IGF1 and low affinity with insulin. 
Activation of IGF1R by IGF1 activates the same proteins and pathways that are activated 
by insulin and insulin receptors. Therefore, the specificity of the IGF pathway depends 
mainly on the ligand and its receptor and not on the downstream parts of the cascade. The 
insulin-like-growth-factor system is thought to be a key regulatory pathway in breast 
cancer (Siddle K et al, 2001). High circulating concentrations of IGF1 and IGF-BP3 are 
associated with increased risk of premenopausal breast cancer and increased IGF1 is 
thought to be an important link between obesity and increased risk of breast cancer (Wolf 
et al., 2005). 
However, T2DM usually affects postmenopausal women and, controlled for obesity, blood 
concentrations of IGF1, IGF2, and their binding proteins are usually not raised in patients 
with diabetes, suggesting that these growth factors might not have a direct role in the 
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association between diabetes and breast cancer. A high concentration of insulin could 
stimulate the IGF pathway in T2DM through the non-specific activation of the IGF1R and 
the IGF1R/IR hybrid receptor. However, the importance of this mechanism in the 
pathogenesis of breast cancer remains to be defined (Wolf et al., 2005). 
3.2.3. Impaired sex-hormone regulation: 
High endogenous plasma concentrations of estrogens and androgens, as well as low plasma 
concentrations of sex hormone binding globulin (SHBG) are strongly associated with 
breast-cancer risk in postmenopausal women (Key T et al, 2002). Deregulation of plasma 
concentrations of sex hormones, caused by increased production of estradiol and androgens 
combined with decreased liver production of SHBG, has been suggested as the main 
mechanism that connects postmenopausal obesity and breast-cancer risk. Similar changes 
in concentrations of sex hormones and SHBG are found in women with diabetes, and these 
changes remain significant even after adjustment for obesity (Nyholm H et al, 1989). 
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Figure  0.1: Activated signal transduction pathways in T2DM also involved in breast 
cancer (Wolf et al., 2005). 
 
Insulin resistance leads to high plasma insulin concentrations, which activate the 
extracellular-related-kinase cascade and the AKT pathway through activation of the insulin 
receptor or the insulin-like-growth-factor (IGF) receptor. High expression of the insulin 
receptor in breast cancer augments activation of these pathways. Diabetes mellitus 
increases production of sex hormones and deceases sex hormone binding globulin (SHBG) 
production, leading to high plasma-free estrogen concentrations, which in turn activate the 
estrogen receptor (ER). Activation of these pathways can lead to cell-cycle progression and 
decreased apoptosis (Wolf et al., 2005). 
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3.3. Metabolic syndrome and Breast cancer 
Metabolic syndrome is defined as a cluster of conditions- increased blood pressure, high 
blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride 
levels - that occur together, which is linked to obesity, less physical inactivity, and insulin 
resistance. Altogether increase the risk of heart disease, stroke and diabetes. Any of these 
conditions alone can increase the risk of serious disease (Mayo Clinic, 2018). 
Many theories have explained it by using the concept of metabolic syndrome, and studied 
its association with breast cancer risk. According to these theories, obesity is the mediator 
for this association. Metabolic syndrome, variously called as insulin resistance syndrome 
or syndrome X or Reaven syndrome, consists of a group of metabolic abnormalities which 
include central obesity, hyperglycemia, hyperinsulinemia, hypertension, hyper-
triglyceridemia, low high-density lipoprotein (HDL) cholesterol, hyperuricemia, and 
increased levels of fibrinogen that confer increased risk of cardiovascular disease and 
diabetes mellitus (WHO, 1999). Metabloic syndrome has recently been proposed to play a 
part in breast carcinogenesis (Burhan Wani et al, 2017). The metabolic syndrome could 
impact the risk of breast cancer through alterations in a number of interrelated hormonal 
pathways, including those involving insulin, estrogen, cytokines, and growth factors (Xue 
F et al, 2007). 
Metabolic syndrome is also associated with increasing levels of inflammatory cytokines 
and Leptin, which can stimulate cell proliferation through various mechanisms, and is 
inversely associated with adiponectin, which down-regulates tumor cell proliferation and 
up-regulates apoptosis (Xue F et al, 2007). Insulin itself is an inflammatory agent, which 
may induce carcinogenic reactions on a chronic basis (Tiberian J, 2017), so as previously 
seen, it is about insulin itself and not high sugar in the blood.  
3.4. Diabetes medications and breast cancer 
3.4.1. Metformin and breast cancer 
Metformin (1,1-dimethylbiguanide hydrochloride) is a biguanide commonly used in the 
treatment of T2DM mellitus. It is frequently referred to as an ‘‘insulin sensitizer’’ because 
in settings of insulin resistance and hyperinsulinemia, it lowers circulating insulin levels 
(Witters, 2001). There is some evidence that suggests that the mechanism of action of 
Metformin involves enhancement of signaling through the insulin receptor, leading to 
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improvement of insulin resistance, followed by reduction in insulin levels (Stith, 2014). 
However, recent work provides evidence that the key action of Metformin is the inhibition 
of hepatic glucose output by inhibition of gluconeogenesis, with a secondary decline in 
insulin levels, in the absence of a major effect on insulin signaling (R. J. Shaw et al., 
2005). There is strong evidence that in the liver, this mechanism involves the activation of 
AMP kinase (Zakikhani et al., 2006). Metformin is an AMP kinase- dependent growth 
inhibitor for breast cancer cells (Zakikhani et al., 2006). In vitro, Metformin showed 
biological activity against all estrogen receptor (ER) positive and negative, normal and 
abnormal breast cancer cell lines tested. It inhibited cellular proliferation, reduced colony 
formation and caused partial cell cycle arrest, so it inhibits breast cancer cell growth, 
colony formation, and induces cancer cells arrest (Alimova et al., 2009). 
3.4.2. Synthetic insulin, insulin analogues and breast cancer 
As explained above, long and short acting synthetic insulin, are associated with increased 
risk of breast cancer for the same reason that insulin levels are increased in the body, so the 
same effect of hyperinsulenemia, which consists a great part of metabolic syndrome. Long 
acting insulin has a stronger association, because it is in contact with insulin receptors 
either in the normal tissue or cancer cells for a longer time (Suissa et al., 2011). 
3.5. Study conceptual model 
Risk factors of BC other than T2DM were investigated in our study, due to their 
overlapping effects; for example, socio demographic factors, is related to health status, 
family history, and reproductive factors, which all together are associated with BC risk. 
The same applies to T2DM, which is strongly associated with health status and lifestyle. 
The following figure (figure 3.2), major groups of variables are presented. Our study is a 
case-control study in which BC is the dependent factor, and other groups of variables are 
the independent variables. The study model was built on the Mayo Clinic (Mayoclinic 
staff, 2015), and British cancer research organization (Cancer research UK, 2014b). Risk 
factors of BC are categorized in this model into major 6 groups; Socio-demographic 
factors which include age, family size, type of living place, educational level, employment 
information, consanguinity, and marital status; Reproductive factors, which include 
pregnancy, delivery, breastfeeding, hormonal use, oral contraceptives, and reproductive 
organ surgeries; Health status, which includes chronic diseases, chronic  medication and 
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BMI; T2DM factors, which include period, age at diagnosis, T2DM medication and their 
regimen; Family history, which includes relatives with breast cancer or other cancers; 
Lifestyle factors, which includes physical activity, daily habits, and food intake.   
 
Figure 3.2: Study conceptual framework, breast cancer is the dependent variable and all 
other group of variables in the figure are the independent variables in our study. 
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Chapter Four 
Methodology 
 
In this chapter, study setting, sample frame, sampling methods and sample size are 
presented. Also, study tools, and statistical analysis.  
4.1. Study Design 
This study is a case control study with a ratio 1:1, matched by age groups and residency 
location of the study subjects.  
4.2. Operational Definitions 
• Breast cancer case: is a female who has a malignant mass in the breast confirmed 
by ICD10 code 'C50' (National Cancer Registry, 2018), derived from the oncology 
department records. 
• Breast cancer control: is a female who had undergone mammography test and 
confirmed as cancer-free female by the code BIRADS1, i.e 0.00% likelihood of 
cancer, and so only routine screening is recommended. 
• Type 2 Diabetes mellitus patient: is any female with fasting blood sugar (FBS) 
equals to or more than 110 mg/dL accessed from the females' records, which is also 
the criterion followed in the hospital. 
• 1st degree relative: includes mother, father, sister, brother, sun, and daughter. 
• 2nd degree relative: includes grandfather, grandmother, uncle, aunt, niece, nephew, 
and cousin (from both sides; father and mother). 
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4.3. Study Setting 
There are three oncology departments in the West Bank; i.e. Al Watani Hospital at Nablus 
governorate, Augusta Victoria Hospital in Jerusalem, and Beit-Jala Governmental Hospital 
at Beit-Jala. 
Since our study was all conducted in the Ministry of Health settings, approvals were 
confirmed before the field research get started, signed and delivered to all branches that 
would be included in our study (Annex 3).  
The study was conducted at 2 main settings; The first was Beit-Jala Governmental 
Hospital, in which the daycare oncology department offers medical services for cancer 
patients in the middle and southern region of the West Bank, including Ramallah, 
Jerusalem, Bethlehem, Beit-Jala, Beit-Sahour and Hebron.  The second was the primary 
health care mammography units which belong to Palestinian Ministry of Health, and are 
distributed throughout the West Bank providing diagnostic and screening services. Routine 
screening programs are available for any female aged 40 years or over; Regardless to her 
age, any female with a suspected mass is referred to these units. Mammogram and 
ultrasound tests are available. In our study, the major mammography units of Bethlehem 
and Hebron were included, due to difficulty to access all units in the southern region of the 
West Bank.  
4.4. Sample Frame 
Study cases were chosen from the daycare unit of the oncology department at Beit-Jala 
hospital, as reported in their records.  
Controls were chosen from cancer-free females who had mammography testing at the 
primary health care units in Bethlehem and Hebron, chosen only among females who were 
available for screening and not for diagnostic purposes. 
4.5. Study Sample Size 
Sample size was calculated by the online calculation software called “Epitool” (Australian 
biosecurity CRC, n.d.); For a case control study sample size determination, the following 
calculations parameters were used: an 80% power, an estimated odds ratio of 2.0 for the 
association between diabetes and BC with 95% confidence (Boyle, 2012; Salinas-Martínez 
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et al., 2014). Therefore our target sample was about 500 (250 study cases and 250 control 
group).  
Table  0.1: Sample Size Calculation Results 
 P= 0.005 P= 0.01 P= 0.02 P=0.03 P= 0.04 P= 0.05 P=0.1 
OR=2 4749 2395 1218 826 630 513* 280 
OR=3 1586 801 409 279 213 174 97 
OR=4 882 446 228 156 120 98 56 
OR=5 596 302 155 106 82 67 38 
OR=10 217 110 57 39 30 25 15 
*the least needed sample size for our study 
4.6. Selection of Study Sample 
Selection of study cases: 237 BC patients that were chosen while attending the day care 
clinic or receiving chemotherapy.  
Control group: 237 female controls were chosen from the mammography units in 
Bethlehem and Hebron primary health care clinics.  
Study cases inclusion-exclusion criteria: 
1. Cases should be females confirmed with BC using the code "C 50".  
2. BC should be the primary cancer diagnosed, and not secondary to other 
malignancy. 
3. The participant was considered diabetic, if two conditions were satisfied, when 
FBS was ≥110 mg/dL, and when T2DM was diagnosed at least one year before 
cancer. Those who were diagnosed with T2DM after BC were excluded. 
4. Only those who were 40 years or older were included, as controls, who had done 
mammography screening test in the governmental sector program, were at least 
40 years old.  
5. Only alive patients were included (no proxies). 
Control group inclusion-exclusion criteria: 
1.  Controls should be cancer-free females according to the BI-RADS1, confirming 
they had never been diagnosed with any malignancy. 
2.  Only females who came for screening purposes were chosen, those who were 
referred by a physician were excluded, because they have suspected tissue 
abnormality. 
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3.  Women who had their mammography screening test done before January 2016 
were excluded, to have a time start line. 
4.  The participant was considered diabetic if FBS was ≥110 mg/dL, 
 
4.7. Study Tools 
− Patients’ medical records: Cases' records were accessed through oncology registry 
system at Beit-Jala Hospital, and also through registry department or the central data 
system of the hospital. Controls' records were accessed through the data system of the 
mammography unit itself.  
− Questionnaires: The questionnaire was built on previous validated questionnaire: 
i.e. the Cancer Research UK (Cancer research UK, 2014a). Questions which were unique 
for our community were taken from previous master thesis (Qasem,2013); (Barham, 2013; 
Rabadi, 2012). The questionnaire was administered through a face to face interview with 
the study participants.  
Questionnaire parts: The questionnaire consisted of 105 questions, categorized into 7 
main parts (Appendix 1). Each part of the questionnaire contained a group of the main risk 
factors of BC including the following: 
Part 1: Socio-demographic factors, (Question1 to Question 16)  
Part 2: Reproductive health factors, (Question 17 to Question 43) 
Part 3: Health Status, (Question 44 to Question 52) 
Part 4: Family History, (Question 53 to Question 57) 
Part 5: Type 2 Diabetes Mellitus (T2DM), (Question 58 to Question 61) 
Part 6: Lifestyle factors: physical activity, food intake, (Question 62 to Question 98) 
Part 7: Breast Cancer characteristics -only for study cases-, (Question 99 to question 105)  
4.8. Questionnaire Validation 
The questionnaire was validated by an oncologist, a medical doctor "radiologist" who reads 
the mammography tests, a radiology technician with expertise in cancer scanning and 
epidemiology, and an endocrinologist. They evaluated the content of the questionnaire and 
the survey methodology. The questionnaire was modified according to their suggestions 
and edition, especially in cancer treatment methods and diabetes medication.  
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4.9. Data Collection 
1- Data collected form patients’ medical records: Data were collected from cancer patients’ 
medical records included: date of diagnosis, stage at diagnosis, type of cancer, and therapy 
strategy. We also could retrieve information regarding, patients’ diseases and medication 
history, and family history of cancer, but these data were not available in all patients’ 
records. 
2- Interview questionnaire: The questionnaires were administered face to face or by phone 
call interview. Phone calls were done through the hospital staff, who explained the study 
and its objectives to the participants, and asked for their permission to fill the 
questionnaire. After getting the acceptance, the study researcher continued the survey at 
the phone. 
Cases were recruited by being available at the daycare unit of Beit-Jala Hospital. An 
interview was conducted by the researcher to have the questionnaires filled, after signing 
the consent form by the patient.  
Controls were accessed through records of mammography units of Ministry of Health 
either in Bethlehem or Hebron. Controls were chosen as confirmed cancer-free females 
who had their mammography test done not before January 2016. Hard copy files were 
manually checked in order to only select the normal mammography results, which are 
(BIRADS 1), and their contact information were derived from these files, due to their 
unavailability at the mammography unit. Controls were chosen to be frequency- matched 
to the cases in terms of age group and region. 
During the interview, emphasis was made in recalling BC risk factors before the disease 
and not after, to ensure the reliability of the answers. For Diabetes Mellitus status of the 
participants were determined by the last fasting blood sugar (FBS) result derived from their 
records.  
4.10          Ethical Considerations 
The project was ethically approved by the institutional review board (IRB) committee of 
Al-Quds University. In addition, Ministry of Health approvals were confirmed as the study 
was conducted in their settings (Appendix 3). Furthermore, participants signed a consent 
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form (Appendix 2) that confirmed their willingness to be included, after they were 
informed about the aim of the study. 
4.11 Statistical Analysis 
Data were coded, then entered and analyzed using the Statistical Package for the Social 
Sciences version 20 (SPSS). Descriptive statistics were represented to show frequencies, 
percentages for categorical variables, and means and standard deviation for continuous 
variables. Chi-square test and T-test were used as needed to calculate the difference 
between cases and controls regarding all variables in the study. A P-value <0.05 was 
considered statistically significant. Variables that showed a significant difference between 
cases and controls were included in our multivariate model for risk estimation. Conditional 
forward logistic regression was used to get odds ratios. Our principal measure of 
association was the Adjusted Odds Ratios (AORs) with 95% confidence intervals (95% 
CI).  
. 
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Chapter Five 
 Results 
 
5.1. Introduction 
In this chapter results are presented in three parts: description of study cases, the univariate 
analysis and finally the multivariate analysis.  
5.2. Descriptive Analysis 
Our study consisted of 474 participants, 237 women were confirmed BC cases, and 237 
females were cancer free females confirmed by mammography test results done during the 
last year before the interview date.  
Table 5.1 shows the characteristics of the study cases. The mean age of the study cases at 
recruitment was 55 (±SD 10.9), while the mean age at diagnosis was 52 (±SD 10.90). 
About 88% of the study cases attending Beit-Jala Hospital were from the southern region 
of the West Bank. Most of the study cases were diagnosed at stage 2 and 3 of cancer with a 
percentage of (35%), and (30%), respectively. The vast majority of the cases (82%) were 
diagnosed with BC after having an obvious lump, while only 17% were diagnosed by 
screening. More than the half of study cases had ductal carcinoma (58%). It should be 
mentioned that 30% of the study cases were diagnosed before the year 2014, i.e before 
electronic cancer registry system was implanted in the hospital, therefore, did not have any 
reporting for their BC type. Almost all cases had chemotherapy treatment (98%). 
Regarding surgery treatment, about 83% of cases had undergone partial mastectomy, while 
about half of them had undergone full mastectomy. Furthermore, 75% of cases had surgery 
as the first line treatment, and didn’t receive neo-adjuvant therapy. Cases were classified 
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into 7 age groups, with a 5 year- interval for each group, but the oldest age group, 
consisted of any female aged 70 years or more. 
Table  0.1: Description of study cases' characteristics, disease status and treatment 
Variable Description Frequency  N (%) 
Age at diagnosis  Mean (SD)  
Min-Max 
51.62 (10.90) 
31-99 
Cancer type  Missed   71 (30) 
Ductal  138 (58.2) 
Lobular  19 (8) 
Follicular  5 (2.1) 
Mixed (ductal, lobular) 4 (1.7) 
Cancer stage at diagnosis  Missed  16 (6.7) 
1st  29 (12.3) 
2nd  84 (35.4) 
3rd  71 (30) 
4th (metastasis)  37 (15.6) 
Breast Cancer detection  Obvious lump  195 (82.3) 
Screening  40 (16.9) 
By chance  2 (0.8) 
Therapy  Radiotherapy  92 (38.8) 
Hormonal therapy  76 (32) 
Surgery  203 (58.7) 
Chemotherapy  233 (98) 
Neo – adjuvant therapy  Yes  60 (25.3) 
No  177 (74.7) 
Place of living  Southern region*  208 (87.8) 
Northern region** 29 (12.2) 
Weight before diagnosis (kg) Mean (SD) 
Min- Max 
79.19 (14.32) 
41-120 
Weight change after treatment 
(kg) 
Mean (SD) 
Min- Max 
1.35 (10.86)  
-39 - 43 
Breast surgeries done  Biopsy  237 (100) 
Partial mastectomy 126 (53.1) 
Full mastectomy  111 (46.8) 
Age at recruitment (years) Mean (SD) 
Min- Max 
54.62 (10.91) 
39-100 
Age groups at recruitment 
(years)  
40-44 50 (21.1) 
45-49 40 (16.9) 
50-54 37 (15.6) 
55-59 40 (16.9) 
60-64 19 (8.0) 
65-69 27 (11.4) 
≥ 70 24 (10.1) 
  *Southern region: Hebron, Bethlehem, Beit-Jala, Beit-Sahour 
  **Northern region: Jerusalem, Ramallah, Jericho  
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5.3. Univariate Analysis 
5.3.1. Socio-demographic factors and breast cancer 
The vast majority of the control group (98.7%), and the study cases (87.8%) were from the 
Southern region. Study cases were significantly more educated than the control group 
(p<0.05), and a higher percentage of the study cases were living in private houses 
(p<0.05). Study cases’ current family size was significantly smaller than that of the control 
group (p<0.05). Moreover, approximately 58% of the study cases, and 46% of the control 
group had parents who are 1st degree relatives (p<0.05) (table 5.2).  
Table  0.2: Socio-demographic characteristics of the study subjects 
Variable Description Control Group Study Cases 
Chi-
square 
N=237 (%) N=237 (%) P-value 
Region  Southern region * 234 (98.7) 208 (87.8) <0.01 Northern region ** 3 (1.3) 29 (12.2) 
Educational 
level 
1-6 years 117 (49.3) 81 (34.2) 
<0.01 7-9 years 62 (26.2) 59 (24.9) 10-12 years 44 (18.6) 49 (20.7) 
>12 years 14 (5.9) 48 (20.2) 
Type of living 
place 
Separate house 147 (62) 198 (83.5) <0.01 Apartment 90 (38) 39 (16.5) 
Monthly 
income 
Less than 1000 55 (23.2) 78 (32.9) 
0.09 1000 to 2000 121 (51.1) 103 (43.5) 
2001 or more 61 (25.7) 56 (23.6) 
Work Yes (now or then) 23 (9.7) 35 (14.8) 0.09 No 214 (90.3) 202 (85.2) 
Period of work 
(years) 
Less than 15 15 (65.3) 16 (45.7) 
0.31 15-30 7 (30.4) 15 (42.9) 
More than 30 1 (4.3) 4 (11.4) 
Marital status  Single 10 (4.2) 19 (8.0) 
0.20 Married 189 (79.7) 185 (78.1) 
Divorced or widowed 38 (16.1) 33 (13.9) 
Parental 
consanguinity 
No Relation 123 (51.9) 100 (42.2) 
<0.01 1st Degree Relation 52 (21.9) 102 (43.0) 
2nd Degree Relation 62 (26.2) 35 (14.8) 
*Southern region: Hebron, Bethlehem, Beit-Jala, Beit-Sahour  
**Northern region: Jerusalem, Ramallah, Jericho  
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5.3.2.  Reproductive health and breast cancer 
In table 5.3, the reproductive health characteristics of married women are presented. 
Women in the control group were shown to be significantly married earlier, they got 
pregnant and had their first child at an age more before 18 years. However, and since study 
cases got married at an older age, they had more full term pregnancies than controls 
(p<0.05).  In addition, about 2/3 of married women in both groups had 5 or more children. 
Moreover, there was a significant difference among breastfeeding mothers; control group 
seemed to breastfeed their children for a longer period.  
Table  0.3: Reproductive health characteristics of married study subjects 
Variable Description 
Control Group 
N= 228 
N (%) 
Study Cases 
N= 218 
N (%) 
Chi 
square 
P-value 
Age at first 
marriage (years) 
≤18  124 (54.4) 95 (43.6) 0.02 >18  104 (45.6) 123 (56.4) 
Age at first 
pregnancy (years) 
≤18  105 (46.5) 63 (30.9) <0.01 >18  121 (53.5) 141 (69.1) 
Age at first 
Delivery (years) 
≤18 81 (36) 54 (26.9) 0.04 >18 144 (64) 147 (73.1) 
Current 
pregnancy  
Yes 2 (0.9) 3 (1.4) 0.62 No 226 (99.1) 215 (98.6) 
Number of full 
term pregnancies 
No pregnancies 3 (1.3) 17 (7.8) 
<0.01 1-4  47 (20.7) 61 (28.0) 
≥5  177 (78.0) 140 (64.2) 
Abortion 
  
Yes 125 (55.8) 119 (58.6) 0.56 No 99 (44.2) 84 (41.4) 
Number of 
abortions 
 
No abortion 99 (44.2) 84 (41.3) 
0.24 1  61 (27.2) 46 (22.7) 
>1  64 (28.6) 73 (36) 
Breastfeeding  Yes 217 (96.4) 187 (93) 0.11 No 8 (3.6) 14 (7) 
Age at 1st 
breastfeeding* 
(years) 
≤18  77 (35.5) 48 (25.7) 
0.03 >18 140 (64.5) 139 (74.3) 
Overall 
breastfeeding 
duration (all 
children) (years) 
Didn’t breastfeed 4 (1.8) 8 (3.7) 
<0.01 
≤ 3   19 (8.4) 51 (23.4) 
4-6  32 (14.1) 58 (26.6) 
7-9  59 (26.0) 48 (22.0) 
>9 113 (49.8) 53 (24.3) 
 
In table 5.4, it is shown that age of menarche was significantly higher among study cases 
than control group (p=0.002). Also, study cases tended to use oral contraceptive pills and 
hormone replacement therapy significantly more than control group (p<0.05). More than 
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the half of both cases and controls were postmenopausal females with no significant 
difference between the two groups.  
Table  0.4: Reproductive health characteristics of study subjects 
Variable Description  
Control Group 
N= 237 
N (%) 
Study Cases 
N= 237 
N (%) 
Chi 
square 
P-value 
Age at menarche 
(years) 
<13  58 (24.5) 32 (13.5) 0.002 
 ≥13 179 (75.5) 205 (86.5) 
Rhythm of 
menstrual cycle 
Regular 103 (43.5) 91 (38.4) 0.21 
 
 
Irregular 7 (3) 14 (5.9) 
Stopped 127 (53.6) 132 (55.7) 
Age at menopause 
(years) 
≤44  12 (9.4) 20 (15.2) 0.26 
 
 
45-49  41 (32.3) 34 (25.8) 
≥50 74 (58.3) 78 (59.1) 
Hysterectomy  Yes 5 (2.1) 7 (3.0) 0.56 
 No 232 (97.9) 230 (90.0) 
Oophorectomy (one 
ovary or both) 
No oophorectomy 233 (98.3) 231 (97.5) 0.82 
 
 
Unilateral removal 2 (0.8) 3 (1.3) 
Bilateral removal 2 (0.8) 3 (1.3) 
Use of hormone 
replacement therapy 
Yes 8 (3.4) 36 (15.2) <0.05 No 229 (96.6) 201 (84.8) 
Past oral contraceptive 
use for ≥ 2 months  
Yes 25 (10.5) 47 (19.8) 0.005 
 No 212 (89.5) 190 (80.2) 
Recent use of Oral 
contraceptives**  
Yes 3 (1.3) 00 (0.0) 0.08 
 No 234 (98.7) 237 (100) 
Age at 1st use of Oral 
contraceptives** 
<30 13 (52) 27 (57.4) 0.66 
 ≥30 12 (48) 20 (42.6) 
Total period of oral 
contraceptive use 
(years)** 
<2  13 (52) 14 (29.8) 0.07 
 ≥2  12 (48) 33 (70.2) 
**Among those using oral contraceptive pills only  
5.3.3. Health status and breast cancers 
Table 5.5 shows the history of breast examination patterns done for study subjects. Study 
cases tended to have their first breast examination at a younger age, and had done the 
examination more frequently than controls. 
Table  0.5: Breast examination pattern among study subjects 
Variable Description Control Group N=237 (%) 
Study Cases 
N=237 (%) 
Chi 
square 
P-value 
1st Breast examination 
Age (years) Mean (SD) 52.04 (11.2) 49.36 (12.4) 0.01 
Number of breast tests in 
the last 5 years Mean (SD) 1.42 (0.7) 1.8 (1.4) <0.01 
Last Breast Test Age Mean (SD) 53.47 (10.5) 52.77 (11.3) 0.48 
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Results in table 5.6 indicate that cases were significantly having a greater BMI than 
controls (p<0.05). Regarding history of diseases, study cases suffered from osteoporosis, 
cardiovascular diseases, joints problems, and auto-immune diseases more than the control 
group. Almost 40% of both cases and controls were on aspirin as a prophylactic drug, as 
they were all over 40 years old. 
Table  0.6: Medical history of the study subjects 
Variable Description Control Group N=237 (%) 
Study Cases 
N=237 (%) 
Chi 
Square 
P-value 
Body Mass Index Normal  29 (12.3) 44 (18.8) <0.01 
  Overweight  112 (47.2%) 56 (23.1)  
  Obese 56 (23.4) 70 (29.5)  
  Morbid obesity 40 (17) 67 (28.6)  
Medication ≥6 
months 
Aspirin 103 (43.5) 97 (40.9) 0.58 
Digoxin 2 (0.8) 6 (2.5) 0.15 
Chronic diseases No diseases 93 (39.2) 87 (36.7) 0.59 
  Hypertension  109 (46) 98 (41.4) 0.35 
  Cardiovascular diseases 22 (9.3) 60 (25.3) <0.01 
  Allergy 16 (6.8) 27 (11.4) 0.08 
  Glandular diseases 10 (4.2) 18 (7.6) 0.12 
  Osteoporosis 25 (10.5) 42 (17.7) 0.02 
  Joint problems 57 (24.1) 81 (34.2) 0.01 
  Hyperlipidemia 54 (22.8) 69 (29.1) 0.11 
  /Hypercholesterolemia    
  Auto-immune disease* 0.00 12 (5.1) -- 
*Auto immune disease: includes Celiac disease, dermatomyositis, Hashimoto disease, 
Myasthenia Gravis, Systemic Lupus Erythematous, type 1 diabetes, Multiple Sclerosis, 
pernicious anemia.  
5.3.4. Family history and breast cancer 
There was a significant difference between study cases and control group for having a 
relative with a BC or any other cancer. Almost one third (n=73) of females in the study 
cases, and only 10 percent (n=23) of females in the control group had at least one relative 
with BC (p <0.05). In addition, almost 41% of the study cases (n=84) had at least one 
relative with other type of cancer than BC, compared to only 20% in the control group 
(n=50) (p <0.05) (Table 5.7). 
 Table  0.7: Family history of cancer of the study subjects 
Variable Relative Degree 
Control Group 
N= 23 (%) 
Study Cases 
N= 73 (%) 
Chi-Square 
P value 
Relative with breast cancer 1st degree 8 (35) 27 (37) 0.44 2nd degree 15 (65) 46 (63) 
Relative with other cancer 1st degree 12 (5.1) 29 (12.2) 0.19 2nd degree 45 (19) 102 (43) 
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5.3.5. Type 2 diabetes mellitus (T2DM) and breast cancer 
As shown in table 5.8, prevalence of T2DM among controls was significantly lower 
(14.8%, n=35) when compared to study cases (24%, n=57) (p<0.05). No significant 
difference was found between study cases and controls in diabetes age of diagnosis (mean 
age 49.6 (±SD 9.4) in study cases, 50.8 (±SD 10.3) in control group, p=0.52), nor in 
duration of T2DM (p= 0.93).  Table 5.9 shows the T2DM medication among diabetics in 
study subjects. Among blood sugar lowering agents, Metformin and Lantus (Insulin 
Glargine) use were significantly different between study cases and control group.  
Table  0.8: T2DM characteristics of study subjects 
Variable Category Control Group N= 237 (%) 
Study Cases 
N= 237 (%) P-value 
T2DM 
  
Yes 35 (14.8) 57 (24) 0.01 
 No 202 (85.2) 180 (76) 
T2DM diagnosis  age 
(years) 
<50  16 (45.7) 22 (38.6) 0.52 
 ≥50 19 (54.3) 35 (61.4) 
Duration of T2DM* Mean (SD) 7.91 (8.30) 8.07 (4.41) 0.93 
*For BC cases, the duration was calculated prior to BC diagnosis 
 
Table  0.9: T2DM medication use among study subjects 
Medication  
Category  Control Group 
N= 35(%) 
Study Cases 
N= 57(%) 
Chi-
Square 
P-value 
Metformin Yes  32 (91) 56 (98.2) .02 No  3 (9) 1 (1.8) 
Glibenclamide Yes 15 (42.8) 25 (43.9) 0.92 No 20 (57.2) 32 (56.1) 
Repaglinide Yes 1 (2.8%) 00 -- No 34 (79.2) 56 (100) 
Vildagliptin + 
Metformin 
Yes 3 (9) 5 (8.8) 0.97 No 32 (91) 52 (91.2) 
Pioglitazone Yes 1 (2.8) 3 (5.3) 0.58 No  34 (79.2) 54 (94.7) 
Vildagliptin Yes  00 4 (7.0) 0.11 No  35 (100) 53 (93) 
Glipizide Yes 00 3 (5.3) 0.17 No 35 (100) 54 (94.7) 
Insulin Glargine (lantus) Yes 2 (5.7) 24 (42.1) <0.01 No 33 (94.3) 33 (57.9) 
Insulin aspart novorapid) Yes 2 (5.7) 2 (3.5) 0.62 No 33 (94.3) 55 (96.5) 
Insulin human Yes 5 (14.3) 12 (21.5) 0.86 No 30 (85.7) 45 (78.5) 
Insulin novomix Yes 00 1 (1.8) 0.43 No 35 (100) 56 (98.2) 
Liraglutide Yes 1 (2.8%) 00 0.19 No 34 (97.2) 57 (100) 
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Although Metformin use among study cases was significantly higher (98%) compared to 
control group (91%) (table 5.9), but the dosage was higher in the control group (mean=2.1 
±SD 0.57) compared to study cases (mean=1.6 ±SD 0.68), p <0.05). In addition, a 
significant difference was shown between cases and controls regarding Lantus (Insulin 
Glargin) use (table 5.9), but the dosage didn’t show a significant difference between the 
two groups (table 5.10). 
Table  0.10: T2DM medication dosage among study subjects  
Variable 
Control 
Group 
n=35 
n (%) 
Study Cases 
n=57 
n (%) 
P-value 
Metformin daily dose 
 
 
Once daily 3 (8.5) 28 (50) <0.01 
2 times/ day 21 (60.0) 22 (38.5) 
3 times/ day 8 (22.8) 6 (10.5) 
Metformin total period Mean (SD) 7.39 (7.33) 7.46 (5.72) 0.96 
Metformin start age Mean (SD) 50.75 (9.25) 54.55 (10.28) 0.09 
Metformin stopping age Mean (SD) 58.15 (8.55) 62.01 (10.16) 0.07 
Insulin Glargine total 
period 
Mean (SD) 3 (1.41) 9.83 (6.72) 0.17 
Insulin Glargin start age Mean (SD) 51 (12.72) 54 (5.98) 0.42 
Insulin Glargine stopping 
age 
Mean (SD) 54 (14.14) 64 (6.83) 0.06 
5.3.6. Lifestyle and breast cancer  
As shown in table 5.11, there was a significant difference between the cases and controls 
regarding total weekly physical activity; Control group seemed to be more physically 
active (p<0.05). On the contrary, no difference was seen regarding the hours of rest per day 
among both groups (p=0.17). Electric blanket was used more among study cases than 
control group (p<0.05). 
Table  0.11: Daily activity characteristics of study subjects 
Variable Category  Control Group N=237 (%) 
Study Cases 
N=237 (%) P-value 
Total score of physical 
activity per week* (METs) 
Mean 
(SD) 
1755.05 
(1677.3) 
1367.63 
(1331.8) <0.01 
Number of rest hours per 
day 
Mean 
(SD) 
3.24  
(1.94) 
3.51  
(2.25) 0.17 
Using electric blanket  Yes 14 (5.9) 39 (16.5) <0.01 
No  223 (94.1) 198 (83.5) 
* An equivalent combination of moderate- and vigorous-intensity physical activity achieving at 
least 600 MET-minutes. - derived from WHO (World Health Organization, 2010). 
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Regarding smoking profile represented in table 5.12, there were significant differences 
between cases and controls; Past cigarette smoking was higher among cases (p<0.05), in 
contrast, controls had smoked Nirgela more than cases (p<0.05). Having a smoker parent 
was significantly higher among study cases (p<0.05).  
Table  0.12: Smoking history among study subjects 
Variable  Category  Control group 
N= 237 (%)  
Study cases 
N= 237 (%) 
Chi square 
P-value  
Current Smoking  Yes/ no 3 (1.3) 9 (3.8) 0.07 
Past smoking Yes/ no 00 10 (4.2) <0.01 
Nirgela smoking Yes/ no 5 (2.1) 3 (1.3) <0.01 
Smoker parent Yes/ no 99 (41.8) 131 (55.3) <0.01 
Food intake was different between cases and controls as seen in table 5.13; most kinds of 
food showed significant differences between cases and controls, including milk (p <0.05), 
chips and popcorn (p =0.02), nuts (p =0.01), diet soft drinks (p =0.01), regular soft drinks 
(p =0.02), red meat (p <0.05), fish and tuna (p <0.05), chicken (p <0.05), salad (p <0.05), 
eggs (p =0.01), cheese (p =0.003), white bread (p =0.01), wheat bread (p <0.05), and butter 
(p =0.001). More than 70% of our sample in both groups had low intake of milk, cake, 
chips, nuts, low sugar soft drinks, and butter (once weekly or less). On the other hand, 
chicken, salads, eggs, cheese, white bread, and soft drinks were taken more than once 
weekly by about 2 thirds of both groups.  
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Table 5.13a: Food intake among study subjects  
Variable Category Control Group N=237 (%) 
Study Cases 
N= 237 (%) 
Chi-Square 
P value 
Milk 
  
  
≤ once/week 124 (52.3) 159 (67.1) <0.01 
2-6 times/week 95 (40.1) 43 (18.1) 
≥ once daily 18 (7.6) 35 (14.8) 
Cake pastry 
  
  
≤ once/week 170 (71.7) 167 (70.5) 0.31 
2-6 times/week 64 (27) 62 (26.2) 
≥ once daily 3 (1.3) 8 (3.4) 
Biscuits 
  
  
≤ once/week 157 (66.2) 143 (60.3) 0.05 
2-6 times/week 74 (31.2) 77 (32.5) 
≥ once daily 6 (2.5) 17 (7.2) 
Chips & Pop-corn 
  
  
≤ once/week 166 (70.0) 181 76.4) 0.02 
2-6 times/week 68 (28.7) 47 (19.8) 
≥ once daily 3 (1.3) 9 (3.8) 
Nuts 
  
≤ 3 times/month 204 (86.1) 180 (75.9) 0.01 
≥ once/week 33(13.9) 57 (24.1) 
Diet soft drinks 
  
  
Never 213 (89.9) 191 (80.6) 0.01 
1-3 times/month 16 (6.8) 25 (10.5) 
≥ once/week 8 (3.4) 21 (8.9) 
Soft drinks 
  
  
  
Never 70 (29.5) 73 (30.8) 0.02 
1-3 times/month 26 (11) 26 (11) 
1-6 times/week 137 (57.8) 120 (50.6) 
≥ once/day 4 (1.7) 18 (7.6) 
Red meat 
  
  
Never 24 (10.1) 32 (13.5) <0.01 
1-3 times/month 107 (45.1) 65 (27.4) 
≥ once/week 106 (44.7) 140 (59.1) 
Fish & tuna 
  
  
never 49 (20.7) 33 (13.9) <0.01 
1-3 times/month 113 (47.7) 76 (32.1) 
≥ once/week 75 (31.6) 128 (54) 
Chicken 
  
≤ once/week  27 (11.4) 58 (24.5) <0.01 
>once/week  210 (88.6) 179 (75.5) 
Peanuts 
  
  
Never 56 (23.6) 55 (23.2) 0.26 
1-3 times/month 40 (16.9) 54 (22.8) 
≥ once/week 141 (59.5) 128 (54) 
Potato Never 19 (8) 29 (12.2) 0.24 
  1-3 times/month 35 (14.8) 39 (16.5)  
  ≥ once/week 183 (77.2) 169 (71.3)  
Salad < 3 times/month 3 (1.3) 31 (13.1) <0.01 
  1-6 times/week 185 (78.1) 162 (68.3) 
  ≥ once/day 49 (20.6) 44 (18.6) 
Eggs < 3 times/month 55 (23.2) 59 (24.9) 0.01 
  1-6 times/week 170 (71.7) 149 (62.9)  
  ≥ once/day 12 (5.1) 29 (12.2)  
Cheese < 3 times/month 41 (17.3) 61 (25.7) <0.01 
  1-6 times/week 184 (77.6) 151 (63.7)  
  ≥ once/day 12 (5.1) 25 (10.5)  
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Table 5.13b: Food intake among study subjects  
Variable Category Control Group 
N=237 (%) 
Study Cases 
N= 237 (%) 
Chi-Square 
P value 
White bread 
  
  
  
< 3 times/month 30 (12.7%) 27 (11.4%) 0.01 
1-6 times/week 16 (6.8%) 33 (13.9%) 
Once/day 81 (34.2%) 96 (40.5%) 
≥2 times/day 110 (46.4%) 81 (34.2%) 
Wheat bread 
  
  
  
< 3 times/month 130 (54.9%) 140 (59.1%) <0.01 
1-6 times/week 14 (5.9%) 38 (16%) 
Once/day 64 (27%) 35 (14.8%) 
≥2 times/day 29 (12.2%) 24 (10.1%) 
Butter 
  
< 3 times/month 213 (89.9%) 188 (79.3%) <0.01 
≥ once/week 24 (10.1%) 49 (20.7%) 
 
5.4. Multivariate Analysis 
In this section of analysis, one model was developed, in which all significant risk factors 
revealed in Chi-Square and T-Test results were included. As seen in the table, higher 
educational level, living in a separate home, 1st degree parental consanguinity, older age at 
menarche, oral contraceptive and hormone replacement therapy, family history of breast 
cancer, being underweight, cardiovascular diseases, joints' problems, insulin Glargine, 
electric blanket use, and some kinds of food all increased the risk, while longer period of 
breastfeeding and chicken intake were associated with lower risk of breast cancer (table 
5.14). 
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Table  0.14: Multivariate model for breast cancer risk  
Variable Category 
Sig. 
Of 
AOR 
AOR 
95%C.I. for 
AOR 
Lower 
limit 
Upper 
limit 
Educational Level 
  
  
  
1-6 years .000 Ref. - - 
7-9 years .063 1.89 .97 3.70 
10-12 years .067 1.94 .95 3.93 
More than 12 years .000 8.43 3.44 20.64 
Type of living place  Separate home .000 Ref - - 
Apartment .001 .37 .20 .68 
Parental Consanguinity  
  
  
No Relation .001 Ref. - - 
1st Degree Relation .003 2.48 1.35 4.55 
2nd Degree Relation .205 .64 .33 1.27 
Total period of 
breastfeeding 
  
  
  
Didn’t breastfeed .000 Ref. - - 
1-3 years  .276 .55 .19 1.61 
4-6 years .520 .72 .26 1.98 
7-9 years .066 .39 .14 1.06 
> 9 .000 .16 .06 .41 
Age at menarche  <13 years .000 Ref. - - 
≥13 years  .000 3.57 1.77 7.20 
Oral contraceptive use  No .000 Ref - - 
Yes .031 2.23 1.08 4.61 
Hormone replacement 
therapy  
No .000 Ref. - - 
Yes .005 3.97 1.51 10.42 
Have a relative with 
breast cancer?  
No .000 Ref - - 
Yes .000 3.51 1.74 7.10 
Body Mass Index  
  
  
  
Less than 25 (Normal weight) .000 Ref. - - 
25-29.99 (Overweight) .000 .19 .08 .41 
30-34.99 (Obese) .473 .74 .33 1.67 
35 or more (Morbid obesity) .236 .59 .25 1.40 
Cardiovascular disease No  .000 Ref. - - 
Yes .000 3.89 1.87 8.07 
Joints problems  No .000 Ref. - - 
Yes .001 2.65 1.45 4.82 
Insulin Glargine  No .000 Ref. - - 
Yes .001 15.51 2.95 81.59 
Electric blanket use  No .000 Ref. - - 
Yes .007 3.23 1.38 7.58 
Soft drinks intake  
  
  
  
Never .036 Ref - - 
1-3 times/month .304 .63 .27 1.51 
1-6 times/week .068 .58 .32 1.04 
≥ 1/day .090 3.54 .82 15.25 
Butter intake  <1 / day .000 Ref. - - 
≥ once/day .008 2.61 1.28 5.32 
Chicken intake  < once weekly .000 Ref. - - 
≥ once weekly  .017 .43 .22 .86 
Conditional forward logistic regression model includes: diabetes status, educational level, type of living 
place, parental consanguinity, number of full-term pregnancies, age at first marriage, pregnancy, delivery and 
breastfeeding, total period of breastfeeding, age at menarche, oral contraceptive use, hormone replacement 
therapy, relative with breast cancer, relative with other cancer, body mass index, cardiovascular diseases, 
osteoporosis, joints' problems, Metformin use, Metformin daily dose, insulin Glargine use, smoker parent, 
electric blanket use, MET score, soft drinks, red meat, nuts, and butter intake.  
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Chapter Six 
Discussion, Conclusions, Limitations and Recommendations 
 
6.1 Discussion 
Our study was a case control study conducted mainly in Beit-Jala Hospital and 
mammography units of the southern region of Palestine. A total of 237 study cases and 237 
controls were included to study risk factors of breast cancer, including mainly its 
association to T2DM. 
Study participants were recruited between June 2016 and October 2017. Study cases were 
easier to allocate than the control group; Chemotherapy daycare unit at Beit-Jala Hospital 
offers its medical service for cancer patients on regular and ordered basis, so it was easy to 
recruit patients during their chemotherapy session. As for controls, they couldn’t be 
recruited at mammography units on that regular basis, so it was necessary to get their 
contact information, after official permissions were obtained, in order to access these 
participants by phone calls. Electronic files of study cases were accessed at the daycare 
unit. Some information were missed, especially for those cases diagnosed with BC before 
2014, as the HIS (health information system) get in practice in 2013.  
6.1.1 Characteristics of study cases  
Mean age at diagnosis in our sample was 52, similar to that in other Arab countries like 
Jordan (Arkoob, 2010), Saudi Arabia, Egypt, Tunisia, Syria, and older Palestinian studies 
(El Saghir et al., 2007), and among both Jewish and Arab women in our region (Nissan et 
al., 2004). The age at diagnosis reported in the Arab world ranged from 43 to 52, with a 
mean of 48 years (Najjar & Easson, 2010), which was a decade younger than that of 
industrialized countries (El Saghir et al., 2007). It is worth noting that our cases were 
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breast cancer patients over the age of 40 years, so the real mean age at diagnosis in our 
region might be a younger age. Regarding age groups of the study cases, it was found that 
the most frequent group was that between 40 to 44 years old, same result was found among 
Lebanese women (Elsaghir NS et al, 2002), and Iraqi women (30% of cases were between 
40 to 49 years) (Alwan, 2010), whereas global data showed different results, most studies 
showed an increased risk of BC with age (Weir & Ali, 2007). This may be due to the fact 
that Palestinian population is considered young, with elderly (over 60) accounting for only 
4.8% of the population (PCBS, 2017). 
Upon examining cancer subtypes, it was clearly noticeable that about two thirds (58%) of 
our cases were diagnosed with ductal carcinoma. Similar results were found among 
Egyptian and Iraqi women (Alwan, 2010; S. Omar et al, 2003). But almost 77% of 
Jordanian cases had ductal carcinoma (Arkoob, 2010). The results might reflect the actual 
number, but it also could be falsely increased due to the fact that lobular carcinoma is more 
difficult to detect by both physical examination or mammography (Li, Anderson, Daling, 
& Moe, 2003). 
Most of cases were diagnosed in the 2nd and 3rd stage of the disease (65%), which indicated 
the detection of the mass by the patient or the physician, and not by screening examination. 
This finding was confirmed by the result that only 17% were diagnosed by screening, 
while 83% detected their own mass. The same exact percent was reported among 
Palestinian women in the northern region, with 84% noticed their mass by themselves (A. 
Z. Haj Qasem, 2000). Similar disease characteristics regarding cancer subtypes and stage 
at diagnosis were freported among Egyptian, Jordanian, and Iraqi females (Alwan, 2010; 
Arkoob, 2010; S. Omar et al, 2003) 
The vast majority (88%) of the study cases were from the southern region of Palestine, as 
Beit-Jala Hospital is the only hospital providing service for cancer patients in the south 
(Bethlehem governorate, Hebron governorate); Patients in the north and in the middle seek 
medical intervention in other nearer hospitals. In addition, during data collection, it was 
noticed that there were certain places with large number of patients, like Dura and Yatta in 
Hebron, which might be explained by environmental hazards, genetic factors, and 
consanguinity, and it is worth investigation. 
Several treatments have been implicated for BC. Only 25% of study cases were given neo-
adjuvant therapy, which indicated surgery as the first option in our medical strategies. In 
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the Arab world, approximately 80% of BC cases had undergone mastectomy (El Saghir et 
al., 2007), compared to 68% in our study, which might indicate a better treatment strategy. 
Thirty percent of the study cases in our study received hormonal therapy, at least once in 
their treatment schedule, which is restricted for hormone responsive tumor; This finding 
was similar to the findings among Palestinian women in the northern region (Darweesh, 
2009), and among Iraqi women (Alwan, 2010). 
6.1.2 Socio-demographic risk factors and breast cancer 
Several studies reported that high socio-demographic and economic status is a risk for BC 
(Akinyemiju, Pisu, Waterbor, & Altekruse, 2015), with an overall estimation of 20% 
increase in the risk for higher socio-economic factors (95%CI: 1.05–1.37) (S. A. Robert et 
al, 2004). This positive association was clearer among Hispanic and Asian women (Ysot K 
et al, 2001), and not only for BC, but for colon, ovary and melanoma cancers (Faggiano et 
al, 1997). Our analysis reported similar results, where high educational level and living in a 
separate house increased the risk for BC. Regarding educational level in our study, it 
showed a positive association with the risk of BC, with a well-established dose response 
relationship. Those who studied for more than 12 years have 8 fold increased risk than 
those who studied for 6 years or less. In north Palestine, the increase was by 4 folds for 
high educated women compared to low educated ones (Darweesh, 2009). Same result was 
reported among Egyptian women (El Saghir et al., 2007). In Europe, a direct dose response 
association was reported between education level and postmenopausal BC incidence 
(Hvidtfeldt et al., 2013). Considering type of living place in our results, it was found that 
living in an apartment significantly decreased the risk of getting BC to the third when 
compared to living in a separate home (OR=0.37). The same association was observed in a 
study of 47,586 females held in 2015 (Akinyemiju et al., 2015). It is worth mentioning that 
living in a separate house in our community doesn’t necessarily mean a better 
socioeconomic status, as most of Palestinian families living in rural areas have their own 
separate houses, and not apartments.  
A suggested explanation for the association between socio economic level and BC can be 
better diagnosis; Higher knowledge increases the awareness and so increases the screening 
strategies, and medical access. Alternatively, a real higher incidence might be responsible 
for this association, where hormonal factors, due to late marriage age, late pregnancy age, 
decreased breastfeeding, and lower parity which are characteristics of higher socio-
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economic factors, might mediate this association (Blamey et al., 2004; Hvidtfeldt et al., 
2013; Li et al., 2013; Ma et al., 2010). 
On the other hand, the opposite relation was found in other studies, where lower 
socioeconomic status increased the risk of BC, as females had less awareness toward 
screening techniques and diagnosis (Malley et al 2000). In our study, monthly income was 
lower among study cases. However, it is worth noting that mammography is available to 
almost all females above 40 in our community, as a free service provided by the Ministry 
of Health. 
Discussing consanguinity is an issue only in the developing countries; In our study, 
daughters of unrelated parents showed a decreased BC risk, whereas those with 1st degree 
relative parents had increased risk by 2.5 folds. Similar finding was reported in UAE in 
which unrelated parents of the subjects decreased the risk to the half  (RR=0.5, 95%CI: 
0.27- 0.93) (Denic & Bener, 2001). This genetic issue was investigated in a very recent 
study conducted in Palestine, which showed a real genetic mutation among BC females 
who had related parents, but the study revealed that although the consanguinity rate is high 
in the Palestinian population, no significant difference exists between consanguinity in BC 
and control groups, but the sample size was very low (N. Herbawi, 2016).  
     6.1.3 Reproductive health factors and risk of breast cancer 
Most of the reproductive health characteristics in our study went with the general 
reproductive characteristics of the Palestinian society, such as young marital age, 
multiparity, and high breastfeeding practice.  According to PSBC 2016, the mean age for 
the 1st marriage was 19.8 years in the southern region of Palestine; Consequently, they 
were at a young age at 1st pregnancy, 1st delivery and breastfeeding. In our analysis, the 
age of 18 years was considered as a cutoff point. Our multivariate results showed no 
significant risk regarding age at first marriage or pregnancy. On the contrary, among 
Palestinian women in the North, there was a 10% increase in the risk when the 1st marriage 
was at the age of 20 or more (Darweesh, 2009). And the OR among Gazan women who 
had their first pregnancy after the age of 35 years was 11.56 (95%CI: 1.64-81.35) (Kariri et 
al., 2017). Our results were different due to the inconsistency in the cutoff point. 
 To study the effect of number of full term pregnancies in our study, five full term 
pregnancies was considered as a cutoff point, as it was the mean of live births in Palestine 
57 
 
(PCBS 2016). Our results revealed no significant association between full term 
pregnancies and the risk of BC. However, number of full term pregnancies was negatively 
associated with BC risk in almost all studies, even in the western world. This  result was 
consistent not only for one type, but all subtypes of BC, for pre and post-menopausal 
women (Li et al., 2013). The reduction in the risk ranged from 18% to 60% (Blamey et al., 
2004; Hirose et al, 1995; Ma et al., 2010; Yuan et al., 1988).  Even in the Northern region  
Palestine, a 50% decrease in the risk was reported among women with 4 full term 
pregnancies or more (Darweesh, 2009). In addition, multi-parity was shown to be 
protective among Moroccan women (Laamiri et al., 2015).  
One of the well established protective factors against BC is breastfeeding (Islami et al., 
2015). In our results, almost all women who had children had practiced breastfeeding, but 
the protective effect in our analysis wasn’t in breastfeeding itself, but in its period. 
Previous studies found that breastfeeding itself was protective; A Saudi study reported that 
never having breastfed had doubled the risk (OR=1.89, 95%CI: 1.19-2.94) (Nasser Elkom 
et al, 2014). Furthermore, breastfeeding decreased the risk of having BC by almost 60% in 
an Israeli study in our region, (OR=0.39, 95%CI: 0.26-0.59) (Shema L et al, 2007). Similar 
result was reported in Morocco with a 35% risk reduction (OR=0.65, 95%CI: 0.55-0.78) 
(Laamiri et al., 2015). Other results even in USA confirmed this association with 14% 
increased risk among women who had never breastfed, (RR=1.14, 95%CI: 0.17-1.38) 
(Warner et al., 2014). Breastfeeding has been proposed to protect against BC through 
hormonal mechanisms that include postponing the resumption of ovulatory menstrual 
cycles after a pregnancy (Russo, 1994), reducing estrogen levels in the breast (Petrakis et 
al, 1987), and having fully differentiated breast tissue which is less susceptible to the 
hormones (Russo et al, 2000). In addition, it has been proposed that breastfeeding also has 
a direct mechanical effect by which carcinogenic agents are excreted from the breast ductal 
tissue (Ma et al., 2010).  
Upon examining period of breastfeeding, results of studies were inconsistent. A study that 
summarized findings from developed countries showed that for every year a woman 
breastfed, her risk of developing BC was reduced by 4.3% (Collaborative Group on 
Hormonal Factors in Breast Cancer, 2002). Similar results were reported in an American 
study for different age and ethnic groups (Furberg H et al, 1999). In China, the risk was 
reduced to the half in those who breastfed more than 3 children compared to those who 
never lactated (OR=0.53, 95%CI: 0.27-1.04)  (T. Zheng et al., 2001). An article review 
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showed that OR was 1.37 for never breastfed compared to 16 months or more of 
breastfeeding (Engla, 2010). In our study, a very clear inverse dose response relationship 
was found, with AOR=0.39 for the group of 9 years or more of breastfeeding, compared to 
never breastfed, with a decrease the risk by 25% to 30% for additional  3 years of 
breastfeeding. Among Palestinian women in the north, the risk for those who never 
breastfed was doubled compared to those who had lactated for 4 years or more (Darweesh, 
2009). It was found that the reduced risk was only for hormone negative disease (Li et al., 
2013). On the contrary, no association was found between breastfeeding period and the 
risk of BC (Ramon et al, 1996), either in developed or developing countries (Collaborative 
Group on Hormonal Factors in Breast Cancer, 2002). It was found that 1 year of 
breastfeeding increased the risk (OR=1.27, 95%CI: 0.78-2.06) compared to no 
breastfeeding (Hirose et al, 1995).  
Older age at menarche in our results was associated with increased risk of BC. The risk 
was increased by three folds by menarche at the age of 13 or more (AOR=3.56). On the 
contrary, older age at menarche was inversely associated with BC risk in many studies, 
even in the Arab world. The high risk group were females with menarche before age of 12 
years (OR =1.5) (Engla, 2010), or 11 years (Mcpherson et al., 2000), whilr the protection 
was in females who had menarche after 14(OR=0.84, 95%CI: 0.65-1.09) (Hirose et al, 
1995). Furthermore, it was found among 117 studies that BC risk was increased by a factor 
of 1.050 for every year younger at menarche (Lancet Oncology, 2012), and  a delay of 2 
years at menarche had led to a 10% reduction in BC all around the world (Hsieh CC et al, 
1990). This protection applied for all cancer subtypes (OR=0.72) (Ma et al., 2006). Similar 
results were found among Moroccan women; Age at menarche less than 13 were 
significantly associated with BC, in Morocco (P=0.002), and north Palestine (OR=6.50)  
(Darweesh, 2009; Laamiri et al., 2015). The protective result of older age at menarche, was 
explained by decreasing the cumulative  number of  ovulatory cycles, which is negatively 
associated with the risk, so with younger age at menarche, and with older age at 
menopause, a female would have more cycles, and so increased risk (Clavel chapelon et al, 
2002; K. L. Terry et al., 2008). Consistent to our findings , was a Chinese-Vietnamese 
study which showed a slight increase in the risk of BC with older age at menarche 
(OR=1.11, 95%CI: 0.8-1.35) (H. B. Nichols et al., 2005). 
Oral contraceptive pills (OCP) use for 2 months or more have significantly doubled the 
risk in our results (AOR=2.22). Similar result were revealed among Jordanian females 
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(Wasileh P Nustas et al, 2002), and among Palestinian females in the northern region with 
OR=2.54 (Darweesh, 2009). Some studies reported that the increase in the risk was for oral 
contraceptive use only before full term pregnancy, (OR=2.2) (Pike, Rosario, & Gray, 
1981). However, almost all studies found a slight increase in the risk (Moorman et al., 
2013). Other studies reported that the increased risk was only for the next 10 years just 
after the last OCP use (Gierisch et al., 2013; Jr, 1996). Some studies on the other hand, 
found a decreased risk among women but at least after 10 years of the last use of OCPs 
(England, 2002).  
Hormone replacement therapy (HRT) was very strongly associated with risk of BC in our 
results (AOR=3.97). Similar results were reported among Saudi and jordanian women, 
(OR=2.25, 95%CI: 1.65-3.08) (Nasser Elkom et al, 2014; Wasileh P Nustas et al, 2002). 
The increase in the risk could be attributed to  the influence of HRT on reducing the 
effectiveness of mammography by creating denser breast tissue (WIH JAMA, 2002). Our 
results were similar to almost all previous studies, even Europen; The increase risk among 
HRT users ranged from 30% in past users, to 60% in current users, revealing a dose 
response relationship with duration of use (Andrea Z LaCroix, 1997; Toine Lagro-Janssen, 
Walter W Rosser, 2003). Furthermore, it was reported that estrogen alone in HRT had 
reduced BC risk in young women, and increased the risk in older women (Howel A et al, 
2011).  
6.1.4 Health status and risk of breast cancer 
In this group of factors, Body Mass Index (BMI), chronic diseases history, and chronic 
medication were included in our study. 
BMI and the risk of BC depended on menopausal status and hormone receptor nature. In 
our analysis, surprisingly, being underweight was associated with increased risk. Different 
results were found among women  in the middle east; where obesity (BMI ≥ 30) was 
associated with increased risk for BC in Gaza Strip (OR=4.70, 95%CI: 1.62-13.69), in 
Egypt, in Saudi Arabia (OR=2.29 95%CI: 1.68-3.13), and in Iran (OR=3.21 95%CI: 1.15-
8.47) (Amin, 2016; Kariri et al., 2017; Montazeri et al., 2008; Nasser Elkom et al, 2014). 
However, being obese was a risk only among postmenopausal women in Tunisia (OR=2.1 
95%CI: 1.1-3.9) (Msolly Awatef et al, 2011). Same results were reported in a study 
included more than 13000 women with BC, where obesity in premenopausal women was 
protective (adjusted hazard ratio=0.82), but in postmenopausal women led to a 
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statistically significant increase in the risk, (adjusted hazard ratio=1.65) (Chen et al., 
2016). Postmenopausal obesity was associated with 20% to 40% increase in risk of 
developing BC, but in premenopausal women, overweight and obesity were associated 
with a 20% decreased risk in hormone positive tumors (Mark Munsell et al, 2014).  
BMI and T2DM together with their relation to cancer in general were recently studied all 
over the world, it was reported that 4.5 % of cancer cases around the world were attributed 
to being overweight (BMI >25 kg/m2) and having T2DM together. Overweight alone was 
responsible for twice as many cancer cases as T2DM alone (Pearson-Stuttard et al., 2017). 
It is suggested that obesity creates multiple pathways of chronic inflammation in the body 
and the breasts, as it enlarges fat cells, spurring inflammation. Obesity also creates insulin 
resistance, causing the body to produce more insulin in order to control blood sugar levels. 
It is well known that insulin is an inflammatory agent which creates a snowball effect of 
inflammation and enlarged fat cells; Since fat cells produce estrogen, obesity and insulin 
resistance can result in an overproduction of estrogen, raising not only the risk of BC, but 
also increases metastasis and recurrence of the disease (Tiberian J, 2017). 
History of chronic diseases was strongly associated with BC risk in our study. The 
association was most obvious in cardiovascular diseases (AOR =3.88). In addition, joint 
problems doubled the risk of having BC. The percentage of females who had auto immune 
diseases was higher among study cases, but didn’t show a significant risk due to their low 
frequency in the control group in our study. Joint problems and osteoporosis were found to 
be associated with postmenopausal hormonal changes. Our result regarding higher risk 
among females with joint problems were confirmed by the inverse association found 
between bone mineral density and the risk of BC, in which the mean bone mineral density 
Z-score was significantly lower among BC cases among south population in an Israeli 
study (Fraenkel et al., 2013). On the other hand, the opposite result was reported in a 
different study, but it was due to Bisphoshponate treatment for osteoporosis, like Raloxifen 
or Tamoxifen (Martino et al., 2004), which both were responsible for a reduction in BC 
risk among women (Powles T J et al, 2012). 
Considering cardiovascular diseases (CVDs), which were a significant risk in our results, 
most studies analyzed them as a side effect of BC treatment, but not as a risk predisposing 
BC. An overlap between BC and CVDs risk factors was reported in many studies; 
Inflammation was a shared risk factor for both BC and CVDs as a mediator of both disease 
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processes, (Coussens LM et al, 2002; Libby P, 2006). Chronic inflammation was 
associated with oxidative stress, and this too is associated with both diseases processes 
(Koene RJ et al, 2016). Chronic inflammation not only increased the risk, but the prognosis 
to metastatic tumors (North Carloina Univ, 2012). 
In our findings, Aspirin had no association with BC, as our sample included only women 
aged 40 years or over, and since Aspirin is prescribed as a prophylactic medication for 
women at this age, most women included in our sample were on Aspirin with no difference 
among cases and controls. The (no protective role) for Aspirin was confirmed only in few 
studies  (S. M. Zhang, Cook, Manson, Lee, & Buring, 2008). 
6.1.5 Family history and risk of breast cancer  
Confirming previous international findings, family history of BC was significantly 
associated with BC risk in our results; A female who had a relative with BC of any degree 
was 3.5 folds more likely to have BC than those who didn’t have any relative with BC. It 
was believed that up to 10% of BC cases in Western countries were due to genetic 
predisposition (Mcpherson et al., 2000), with a threefold increase in the risk of BC among 
those with family history of BC  (Slattery & Martha, 1993). The consistent increase in the 
risk was when the relative is a mother or a sister (G. A. Colditz et al., 1996). The relative 
risk of BC ranged from 1.5 to 3.6 in a pooled analysis depending on the relative degree, 
with the highest risk was reported among women who had a mother or a sister with BC 
(Pharoah, Day, Duffy, Easton, & Ponder, 1997). Furthermore, positive family history of 
BC among Gazan women, increased the risk for BC (OR=2.7, 95%CI: 1.04-7.20), similar 
results were reported among Moroccan women (OR=11.15, 95%CI: 2.54-49)  (Kariri et al., 
2017; Laamiri et al., 2015) 
6.1.6 Diabetes and risk of breast cancer  
Results of our study revealed a significant difference between study cases and the control 
group regarding prevalence of T2DM. T2DM prevalence in the control group was 14.8%, 
the mean age of diabetics in the control group was 54 years (±SD 9.88). The prevalence of 
T2DM reported in PCBS in the same age group was 19.1% (PCBS, 2016), which is about 
5% higher than our finding. Overall prevalence of T2DM among women aged 25 or more 
in southern region was 9.6% (Husseini et al., 2009b).  
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The main aim of our study was to investigate the association between T2DM and BC. 
After adjustment for covariates, the association disappeared. On the contrary, several 
studies reported an increased risk of BC among diabetic women, including Palestine; In a 
recent case control study conducted in Gaza, T2DM increased the risk of BC (OR=6.84, 
95%CI: 1.77-26.36) (Kariri et al., 2017). The reported increase in the risk all over the 
world had ranged from 23% (Liao et al., 2011) to 27% (Boyle, 2012). This increase in the 
risk was limited to estrogen receptor negative BC (Palmer, 2017). However, subtypes of 
receptors were not available in our study, due to limited information in the registry system.  
Regarding T2DM treatment in our results, it was found that almost all diabetic patients 
were treated with tablets, and almost 24% were treated with insulin. Previous Palestinian 
data reported that 21.2% of diabetes clinics' attendees were treated with insulin, while 
63.0% were treated with tablets, 14.8% were treated with both tablets and insulin, only 
1.0% of diabetic patients were treated by diet only (MOH, 2016). Considering T2DM 
treatent and BC risk in our study, Insulin Glargine was significantly associated with 
increased risk of BC (AOR=15.5), our findings for insulin Glargine were consistent with 
several studies, but the risk was higher in our findings. Glargine was associated with an 
increased risk of BC in several studies (HR=1.44, 95%CI: 1.11-1.85), with the risk being 
doubled when receiving Glargine for more than 30 months (HR=2.29, 95%CI: 1.26-4.16) 
(Jennifer W Wu, 2017). On the other hand, no association was found between BC and 
Insulin Glargine in a preclinical study (HR=1.04, 95%CI: 0.91-1.17). Furthermore, it was 
reported that insulin analogues (Aspart, Determir, Glulisine or Lispro), and human insulin, 
might induce the progression of BC by up regulating mitogenic signaling pathways, but 
didn’t increase the incidence (Bronsveld et al., 2015). Findings in other studies found that 
the risk was only elevated among insulin analogues switchers after Glargine (Peeters et al., 
2016). It was suggested to switch to shorter acting insulins, especially with females having 
predisposing risk factors and family history (Ahmed, 2010). Other insulin analogues in our 
study didn’t show a significant association with BC, like Novorapid, and human insulin, 
since the frequency of users was limited. 
The most prescribed diabetes medication, Metformin, didn’t show an association with BC 
in our findings. Many studies on the other hand, showed that Metformin was protective. 
Some studies investigated T2DM as an independent risk factor from receiving Metformin, 
and reported that T2DM itself is a significant risk factor, but Metformin alone was 
protective (Armstron, George, & Halabi, 2013). In our study, Metformin couldn’t be 
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studied alone, as almost all diabetic females were on Metformin as a general 1st line 
strategy to treat T2DM in our country (98% of diabetic cases, and 91% of diabetic control 
group were on Metformin therapy). Reduction in the risk among Metformin users had 
ranged from 25% to 50% (Chlebowski et al., 2012; Nananda F Col et al, 2012). Decreased 
risk was reported either for long term use (>5 years) of Metformin (OR=0.44, 95%CI: 
0.24-0.82) (Bodmer et al., 2010), or short term use (OR=0.63, 95%CI: 0.53–0.75) (Libby 
G, Donnelly LA, Donnan PT, 2009). Furthermore, Metformin was protective in 
physiological preclinical studies (Zakikhani et al., 2006), (Alimova et al., 2009), by 
inhibiting BC stem cells (Hirsch, Iliopoulos, Tsichlis, & Struhl, 2009). 
On the other hand, fewer studies found that Metformin had no significant reduction in the 
risk for BC (Franciosi, Lucisano, Lapice, Strippoli, & Nicolucci, 2013), nor with BC 
incidence (Noto, Goto, Tsujimoto, & Noda, 2015). Metformin, according to those studies, 
was found to be associated with decreased mortality and recurrence only in BC patients, 
but not with the risk (Heckman-stoddard, Decensi, Sahasrabuddhe, & Ford, 2017).  
 
6.1.7 Lifestyle and risk of breast cancer  
In general, physical activity in our results was not significantly different between control 
group and study cases. The only factors that were found to be significantly different 
between cases and controls in univariate analysis, were metabolic equivalent score (MET 
score), having a smoker parent, and the use of electric blanket.  
Women who practiced regular recreational or occupational activities were few compared to 
our sample size. The same applied for smoking, with suspected under-reporting, due to the 
fear from stigma reasons.  
According to many previous studies, high recreational physical activity was inversely 
associated with BC risk, with a significant 20% to 25% decrease in the risk. It was reported 
that body mass index (BMI) might play a confounding role (Bardia et al., 2006). The 
associations were the strongest for recreational activity, lifetime activity, activity done 
after menopause, and for activity that is of moderate to vigorous intensity performed 
regularly, confirming that BMI was a confounder for the association (Lynch BM et al, 
2011). In some studies, the decreased risk was reported not only for one subtype of BC, but 
for all subtypes (Lope V et al, 2017).  
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Electric blanket use, was found to be a significant risk for BC in our analysis; According to 
scientific hypothesis, electric blanket use increased the risk of BC by increasing the 
exposure to electric magnetic field (Feychting M et al, 2006). On the contrary, no 
difference in exposure to magnetic fields was found between cases and controls among the 
users of electric blankets (Kabat & Leske, 2004). In addition, in a larger epidemiological 
study, the relative risk for electric blanket use was not elevated (RR=1.08, 95%CI: 0.95, 
1.24) after controlling for other breast cancer risk factors (Ladn F et al, 2000). Same results 
applied for pre and post-menopausal women, with no difference for increased period of the 
electric blanket use (Gammon et al., 1998). 
6.1.8 Food intake and risk of breast cancer  
Our results regarding food intake showed a significant difference between cases and 
controls, regarding some kinds of food when comparing the highest intake category to the 
lowest one. Soft drinks and butter were found to increase BC risk, while chicken 
significantly decreased the risk. 
Results of many previous studies representing food intake were inconsistent, due to the 
lack of homogeneity of assessment method, or to type of food processing in each country. 
Most studies had classified food into 3 major patterns, Healthy Mediterranean (high oil, 
vegetables, and fish), which is the nearest to our food pattern, Western- High fat (Canned 
fish, meat products, pizza/pies, eggs, alcoholic beverages, cakes, and butter), and Drinker 
(high alcohol) pattern. The Mediterranean diet was confirmed to be protective, (HR=0.85 
95%CI: 0.75-95) (Cottet et al., 2009), especially with high vegetable consumption, 
(RR=0.75, 95%CI: 0.66-0.85) (S. Gandini et al, 2000). On the other hand, it was reported 
that the protection was only in fresh fish (OR=0.77, 95%CI: 0.58–1.01), whereas an excess 
of raw vegetables and olive oil increased the risk significantly (OR=1.22, 95%CI: 1.06-
1.32)  (Bessaoud et al., 2012). A positive association with BC was observed regarding 
Western dietary pattern; However, most of these results were not statistically significant 
(Albuquerque et al., 2014). Drinker diet, which is not familiar in our country, was the only 
significant pattern which increased the risk of BC according to other studies (P. Terry et 
al., 2001). 
In our study, fish and canned Tuna were categorized together, with their consumption was 
higher among study cases. An explanation might be heterocyclic amines, which are by-
products of meat and fish cooking, which are mutagens and can cause cancer according to 
65 
 
clinical studies on animals (David W Layton et al, 1995). Furthermore, butter, which is a 
fat rich item, was a risk factor for BC in our study. High fat intake was found to elevate the 
risk, and even doubling it in some studies, (OR=2.72, 95%CI: 1.16-6.37)  (Boyd et al., 
2003; Ronco et al., 2006). In addition, cheese, eggs, and chips intake was higher among 
cases, which all contain a kind of fat. 
Red meat intake was reported to increase the risk of BC (RR=1.17, 95%CI: 1.06-1.29) 
(Boyd et al., 2003), confirming a dose response relationship (E Cho et al., 2006). The 
increased risk was highest for well-done bacon, beef, and hamburger (W. Zheng et al., 
1998), which are not the kind of meat consumed in our country. Red meat consumption in 
our findings was not associated with BC; Meat processing in our country is different than 
that in western countries. In addition, high meat intake in our community might be an 
indicator for better living standards, and higher health awareness.  
Chicken intake was associated with a decreased risk in our results. Chicken is an excellent 
dietary source of niacin, vitamin B6, choline, selenium and tryptophan, and also contains 
vitamin B-12, vitamin D, iron, and zinc. Chicken is far lower in saturated fat and 
cholesterol than red meat. Chicken consumption has been found in numerous studies to be 
associated with lower risk of BC. Consumption of white meat was associated with 
lower breast density, a strong BC risk factor. Another explanation might be food 
substitution, i.e. eating chicken rather than red meat which reduces the proportion of red 
meat in the diet (Warren et al., 2017).  
In this study, we were able to show higher prevalence of T2DM among BC cases than 
controls. Several risk factors associated with BC risk were found, including medication of 
Diabetes, oral contraceptive pills, hormone replacement therapy. In addition, we identified 
several health factors associated with BC risk, like cardiovascular diseases, joint problems, 
and BMI. Food intake, physical activity, and some daily habits affected the risk of BC 
significantly. Furthermore, consanguinity, positive family history, and higher educational 
level increased BC risk.  
6.2 Conclusions  
This is the first study of its type in Palestine. The study had some consistency with the 
published research that investigated the association between T2DM, its medication and BC 
risk. Most studies were performed on datasets that were collected from patients’ medical 
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records. Our study used the classical matched case-control, which made it unique in its 
results.  
After controlling for several factors, T2DM itself was not found to increase the risk for 
BC, whereas its medication the long acting Insulin Glargine was shown to significantly 
increase the risk for BC by 14 folds.  
Other non-modifiable risk factors were associated with BC in our study, which were family 
history, consanguinity, reproductive health factors, and other chronic diseases such as 
cardiovascular diseases and joints’ problems. Modifiable risk factors for BC revealed in 
our study were breastfeeding, oral contraceptive pills, hormone replacement therapy, 
female weight, electric blanket use and intake of some kinds of food.  
6.3 Study limitations 
Our study, although included a large sample size, but only represented the Southern region 
of Palestine. To a large extent, our results were consistent with previous studies conducted 
in the Northern region of Palestine.  
Data collection in our study included interviews as the main source, and to a lesser extent, 
access to patients' medical records at the Ministry of Health. These records were 
electronically registered through the “Avicenna program” for all study cases. However, 
due to some program limitations, there was a gap in some information and search options.  
Controls couldn’t be recruited from the same hospital, as they should be confirmed as BC 
free females. Therefore, it was decided to match study cases by residence location; 
Controls were chosen from the two main mammography units in Hebron and Bethlehem, 
which might cause a selection bias.  
Regarding study cases' characteristics, some information were missing in the registry 
system, like cancer subtypes or receptor status of the tumor cells. The same applied to 
T2DM history and treatment. Therefore, we depended on the participants recall and 
answers, which exposed our data to recall bias.  
Women included in our sample were at the age of 40 years or older. Cases couldn’t be 
included from other age groups since women who had done mammography were only 40 
years or over. Therefore, our results can only be generalized for this age group.  
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6.4 Recommendations 
For Patients and general population 
T2DM is, to an extent, a modifiable disease. It can be controlled by having healthy diet, 
being physically active, and by being adherent to the proper medication/s. Regarding breast 
cancer, screening and prevention are the best ways to avoid the disease. It is recommend 
for all women to respond to the advice of doing self-breast examination and 
mammography as scheduled by the health case staff, as the earlier the diagnosis is, the 
better management strategies and treatment success.  
 For research field 
- Further investigation for the association between T2DM, its medication, and breast 
cancer should be taken into account in other regions of Palestine. In addition, the 
association of T2DM with other cancer types must be investigated.  
- Other new hypothesis for cancer occurrence of cancer must be done in Palestine 
too. For example, adiposity is nowadays is suspected to affect the success of cancer 
therapy. Therefore, we recommend conducting a study on nutrition and obesity on 
cancer control.  
- In general, cancer research in Palestine is still poor and any new hypothesis must be 
encouraged to be investigated.  
For Ministry of Health and policy makers 
- To improve the hospital information system, and the registration system that is 
currently used at the Ministry of Health.  
- Breast cancer screening is not yet mature in Palestine and women must be 
encouraged to perform it. More mammography units must be established to 
increase the access of women. Mobile mammography units are suggested as a 
solution for accessibility which will affect BC prognosis.  
- Diabetes screening program must be initiated  
- Awareness campaigns on diabetes self-care and prevention must be supported. 
- Advocacy campaigns to support women with breast cancer must be initiated to help 
them in having better quality of life.  
- Consanguinity marriage is still very common in Palestine. Advocacy programs 
should be conducted in Palestine to educate people on the health risks of this issue. 
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 ﻛﻠﻴﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻣﺔ  
 ﺭﻗﻢ ﺍﻻﺳﺘﻤﺎﺭﺓ : ___________                    ﻣﻜﺎﻥ ﺍﻟﻤﻘﺎﺑﻠﺔ : __________ 
  oN               seY  A ﻫﻞ ﺃﻧﺖ ﻣﺼﺎﺑﺔ ﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ؟
 oN               seY  B ﻫﻞ ﻣﻀﻰ ﺳﻨﺔ ﻋﻠﻰ ﺗﺸﺨﻴﺺ ﺳﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ؟
 oN               seY  C  ﻫﻞ ﺃﻧﺖ ﻣﺼﺎﺑﺔ ﺑﺎﻟﺴﻜﺮﻱ؟
 oN               seY  D ﻫﻞ ﺗﻢ ﺗﺸﺨﻴﺺ ﺍﻟﺴﻜﺮﻱ ﻗﺒﻞ ﺳﻨﺔ ﻋﻠﻰ ﺍﻻﻗﻞ ﻣﻦ ﺳﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ؟
 oN               seY  E ﻫﻞ ﺗﻢ ﺗﺸﺨﻴﺼﻚ ﺑﺄﻱ ﺳﺮﻁﺎﻥ ﺁﺧﺮ ﻗﺒﻞ ﺳﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ؟
 
 ﺭﻗﻢ ﺍﻟﻤﻠﻒ DS .1 __________
 ﺍﺳﻤﻚ ﺍﻟﺮﺑﺎﻋﻲ  DS .2 __________
 ﺭﻗﻢ ﺍﻟﺘﻠﻔﻮﻥ ﺃﻭ ﺍﻟﺠﻮﺍﻝ  DS .3 __________
 ﺭﻗﻢ ﺍﻟﻬﻮﻳﺔ  DS .4 __________
 ﺗﺎﺭﻳﺦ ﻣﻴﻼﺩﻙ؟ DS .5 __/__/____
 ﻣﺎ ﻫﻮ ﺗﺤﺼﻴﻠﻚ ﺍﻟﻌﻠﻤﻲ ﺍﻷﻋﻠﻰ؟  DS .6 |___|
 (         21-11ﺛﺎﻧﻮﻱ ) -3(         01-7ﺃﻋﺪﺍﺩﻱ )  -2(        6 -0ﺍﺳﺎﺳﻲ ) -1
 ﺟﺎﻣﻌﻲ -5ﻛﻠﻴﺔ            -4
 ﺃﻳﻦ ﺗﻘﻴﻤﻴﻦ ﺣﺎﻟﻴﺎ؟   DS .7 ____ ﻣﺤﺎﻓﻈﺔ
 ﻣﺎ ﻧﻮﻉ ﺍﻟﺴﻜﻦ؟  DS .8 
 ﺑﻴﺖ ﺻﻔﻴﺢ  -4ﺑﻴﺖ ﺷﻌﺮ         -3ﺷﻘﺔ ﻓﻲ ﻋﻤﺎﺭﺓ         -2ﺑﻴﺖ ﻣﺴﺘﻘﻞ            -1
 ﻣﺎ ﻋﺪﺩ ﺃﻓﺮﺍﺩ ﺍﻷﺳﺮﺓ ﺍﻟﻤﻘﻴﻤﺔ ﻓﻲ ﻣﻨﺰﻟﻚ ﺍﻟﺤﺎﻟﻲ؟ )ﺑﻤﺎ ﻓﻴﻬﻢ ﺍﻧﺖ( DS .9 |___|___|
 ﻣﺎ ﺩﺧﻞ ﺍﻷﺳﺮﺓ ﺍﻟﺸﻬﺮﻱ ؟  )ﺑﺎﻟﺸﻴﻜﻞ( DS .01 |__|
 (   0003 – 1002) -3   (           0002 – 0001) -2               0001ﺃﻗﻞ ﻣﻦ  -1
    0005ﺃﻛﺜﺮ ﻣﻦ  -5(          0005 – 1003) -4
ﻧﻌﻢ       
 ﻻ
 ﻫﻞ ﻋﻤﻠﺖ ﺃﻭ ﺗﻌﻤﻠﻴﻦ ﺧﺎﺭﺝ ﺍﻟﺒﻴﺖ  ؟  DS .11
 ﻣﺎ ﻫﻮ ﺍﻟﻌﻤﻞ ﻭ ﻣﺎ ﻣﺪﻧﻪ؟ DS .21 
 3ﺍﻟﻤﻬﻨﺔ  2ﺍﻟﻤﻬﻨﺔ  1ﺍﻟﻤﻬﻨﺔ  
    ﺃ. ﻧﻮﻉ ﺍﻟﻤﻬﻨﺔ 
    ﺪﺓ ﺍﻟﻌﻤﻞ ﻣﺏ. 
 
ﻧﻌﻢ       
 ﻻ
 ﻫﻞ ﻋﻤﻠﺖ ﺑﺪﻭﺍﻡ ﻟﻴﻠﻲ ؟  DS .31
 ﻣﺎ ﻣﺪﺓ ﺩﻭﺍﻣﻚ ﺍﻟﻠﻴﻠﻲ ﺑﺎﻟﺴﻨﻮﺍﺕ؟ DS .41 |__|
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 ﺻﻠﺔ ﺍﻟﻘﺮﺍﺑﺔ ﺑﻴﻦ ﻭﺍﻟﺪﻙ ﻭﻭﺍﻟﺪﺗﻚ؟ DS .51 |__|
 ﺃﻗﺮﺑﺎء ﺩﺭﺟﺔ ﺃﻭﻟﻰ )ﺍﺑﻨﺎء ﻋﻢ، ﺍﺑﻨﺎء ﻋﻤﺔ، ﺃﺑﻨﺎء ﺧﺎﻟﺔ(    -1     ﻻ ﻗﺮﺍﺑﺔ                     -0
 ﻣﻦ ﻧﻔﺲ ﻋﺎﺋﻠﺔ ﺍﻷﻡ ﺃﻭ ﻋﺎﺋﻠﺔ ﺍﻷﺏ -2 
 ﻣﺎ ﻫﻲ ﺣﺎﻟﺘﻚ ﺍﻻﺟﺘﻤﺎﻋﻴﺔ؟  DS .61 |___|
 ﺃﺭﻣﻠﺔ -4ﻣﻄﻠﻘﺔ         -3ﻣﺘﺰﻭﺟﺔ              -2         82 ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝ --ﻋﺰﺑﺎء   -1
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺗﺰﻭﺟﺖ ﺃﻭﻝ ﻣﺮﺓ؟ HR .71 |__|
ﻧﻌﻢ       
 ﻻ
 ﻫﻞ ﺃﻧﺖ ﺣﺎﻣﻞ ﺣﺎﻟﻴﺎ ؟  HR .81
ﻛﻢ ﻋﺪﺩ ﺍﻟﻤﺮﺍﺕ ﺍﻟﺘﻲ ﺣﻤﻠﺖ ﺑﻬﺎ؟ )ﺷﺎﻣﻞ ﺍﻟﺤﻤﻞ ﺍﻟﻌﺎﺩﻱ ﻭﺍﻟﺨﺪﺍﺝ ﺍﻹﺟﻬﺎﺽ ﻭ ﻓﻘﺪﺍﻥ  HR .91 |___|___|
.      ﻣﻼﺣﻈﺔ : ﻋﺪﺩ )ﺻﻔﺮ( ، ﺍﻟﺠﻨﻴﻦ ﻭ ﺍﻟﺤﻤﻞ ﻓﻲ ﺍﻟﻘﻨﻮﺍﺕ ﻭ ﺍﻟﺤﻤﻞ ﺍﻟﺤﺎﻟﻲ ﺇﻥ ﻭﺟﺪ( 
   82ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝ
 ﻛﻢ ﻋﺪﺩ ﺍﻷﺣﻤﺎﻝ ﺍﻟﺘﻲ ﺃﺩﺕ ﺇﻟﻰ ﺇﻧﺠﺎﺏ ﺃﻁﻔﺎﻝ ﺃﺣﻴﺎء؟  HR .02 |___|___|
 ﺃﻧﺠﺒﺖ ﻣﻦ ﺫﻛﻮﺭ؟ﻛﻢ ﻋﺪﺩ ﻣﺎ  HR .12 |___|___|
 ﻛﻢ ﻋﺪﺩ ﻣﺎ ﺃﻧﺠﺒﺖ ﻣﻦ ﺇﻧﺎﺙ؟ HR .22 |___|___|
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻓﻲ ﺃﻭﻝ ﺣﻤﻞ ؟ )ﻣﻬﻤﺎ ﻛﺎﻧﺖ ﻧﺘﻴﺠﺘﻪ، ﺇﺟﻬﺎﺽ ﺃﻭ ﺣﻤﻞ ﻛﺎﻣﻞ ﺃﻭ ﺧﺪﺍﺝ( HR .32 |___|___|
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻓﻲ ﺃﻭﻝ ﻭﻻﺩﺓ ؟  )ﺳﻮﺍء ﺣﻤﻞ ﻛﺎﻣﻞ ﺃﻭ ﺧﺪﺍﺝ( HR .42 |___|___|
ﻧﻌﻢ       
 ﻻ
 82؟   ﺍﻟﺠﻮﺍﺏ )ﻻ( ، ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝ ﻫﻞ ﺃﺭﺿﻌﺖ ﺍﻷﻁﻔﺎﻝ ﺭﺿﺎﻋﺔ ﻁﺒﻴﻌﻴﺔ HR .52
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺃﺭﺿﻌﺖ ﺃﻭﻝ ﻁﻔﻞ؟  HR .62 |___|___|
ﻟﻮ ﺟﻤﻌﻨﺎ ﻛﻞ ﻓﺘﺮﺍﺕ ﺍﻟﺮﺿﺎﻋﺔ ﻟﺠﻤﻴﻊ ﺍﻷﻁﻔﺎﻝ ، ﻛﻢ ﻓﺘﺮﺓ ﺇﺭﺿﺎﻋﻬﻢ ﻣﺠﻤﻮﻋﺔ ؟   HR .72 ﺳﻨﺔ |__|
 )ﺑﺎﻟﺴﻨﻮﺍﺕ(
ﻧﻌﻢ       
 ﻻ
ﻫﻞ ﺍﺳﺘﺨﺪﻣﺖ ﺣﺒﻮﺏ ﻣﺎﻧﻌﺔ ﻟﻠﺤﻤﻞ ﻟﻤﺪﺓ ﺷﻬﺮﻳﻦ ﺃﻭ ﺃﻛﺜﺮ ﻷﻱ ﺳﺒﺐ )ﺗﻨﻈﻴﻢ ﺩﻭﺭﺓ ، ﺣﺐ  HR .82
  33 ﺍﻟﺠﻮﺍﺏ )ﻻ( ، ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝﺷﺒﺎﺏ ، ﻣﻨﻊ ﺣﻤﻞ( ؟    
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻓﻲ ﺃﻭﻝ ﺍﺳﺘﺨﺪﺍﻡ ﻟﺤﺒﻮﺏ ﻣﻨﻊ ﺍﻟﺤﻤﻞ؟  HR .92 |___|___|
ﻧﻌﻢ       
 ﻻ
 23 ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝﺍﻹﺟﺎﺑﺔ )ﻧﻌﻢ( ، ﻫﻞ ﺗﺴﺘﺨﺪﻣﻴﻦ ﺣﺒﻮﺏ ﻣﻨﻊ ﺍﻟﺤﻤﻞ ﺣﺎﻟﻴﺎ؟      HR .03
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺗﻮﻗﻔﺖ ﻋﻦ ﺍﺳﺘﺨﺪﺍﻡ ﺣﺒﻮﺏ ﻣﻮﺍﻧﻊ ﺍﻟﺤﻤﻞ؟ HR .13 |__|__|
  ﺑﺎﻟﺴﻨﻮﺍﺕﻟﻮ ﺟﻤﻌﻨﺎ ﺍﻟﻔﺘﺮﺓ ﺍﻟﺘﻲ ﺍﺳﺘﺨﺪﻣﺖ ﻓﻴﻬﺎ ﺣﺒﻮﺏ ﻣﻨﻊ ﺍﻟﺤﻤﻞ ، ﻣﺎ ﻁﻮﻝ ﺍﻟﻔﺘﺮﺓ؟  HR .23 |__|__|
 ﻓﻲ ﺃﻱ ﻋﻤﺮ ﺑﺪﺃﺕ ﻋﻨﺪﻙ ﺍﻟﺪﻭﺭﺓ ﺍﻟﺸﻬﺮﻳﺔ؟ ﺳﻦ ﺍﻟﺒﻠﻮﻍ HR .33 |__|__|
 |___|
 
 
 
 
 ﺍﻟﺸﻬﺮﻳﺔ :ﻁﺒﻴﻌﺔ ﺩﻭﺭﺗﻚ  HR .43
 ﻣﻨﺘﻈﻤﺔ   -1
 ﻟﻴﺴﺖ ﻣﻨﺘﻈﻤﺔ  -2
 ﺃﺳﺘﻌﻤﻞ ﻫﺮﻣﻮﻧﺎﺕ ﺑﺪﻳﻠﺔ   -3
 53ﺃﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝ  --ﺗﻮﻗﻔﺖ ﺍﻟﺪﻭﺭﺓ ﺍﻟﺸﻬﺮﻳﺔ  ﻧﻬﺎﺋﻴﺎ   -4
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺗﻮﻗﻔﺖ ﺩﻭﺭﺗﻚ ﺍﻟﺸﻬﺮﻳﺔ؟ HR .53 |___|
ﻧﻌﻢ       
 ﻻ
 04 ﺍﻹﺟﺎﺑﺔ )ﻻ( ، ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝﻫﻞ ﺗﻌﺮﺿﺖ ﻟﻌﻤﻠﻴﺔ ﺇﺳﺘﺌﺼﺎﻝ ﺭﺣﻢ؟   HR .63
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺗﻢ ﺍﺳﺘﺌﺼﺎﻝ ﺍﻟﺮﺣﻢ؟  HR .73 |___|___|
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 ﻫﻞ ﺗﻌﺮﺿﺖ ﻟﻌﻤﻠﻴﺔ ﺍﺳﺘﺌﺼﺎﻝ  ﺃﺣﺪ ﺍﻟﻤﺒﺎﻳﺾ ﺃﻭ ﻛﻠﻴﻬﻤﺎ؟  HR .83 |___|
 04ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝ   --ﻟﻢ ﺃﺗﻌﺮﺽ   -0
 ﻧﻌﻢ، ﺃﺣﺪ ﺍﻟﻤﺒﺎﻳﺾ ﺗﻢ ﺍﺳﺘﺌﺼﺎﻟﻪ      -1
 ﻧﻌﻢ، ﻛﻼﻫﻤﺎ   -2
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺍﺳﺘﺌﺼﺎﻝ ﺍﻟﻤﺒﺎﻳﺾ ﺍﻭ ﺍﺣﺪﻫﻤﺎ؟  HR .93 |___|___|
ﻧﻌﻢ       
 ﻻ
ﻫﻞ ﺍﺳﺘﺨﺪﻣﺖ ﻫﺮﻣﻮﻧﺎﺕ ﺃﻧﺜﻮﻳﺔ ﺑﺪﻳﻠﺔ ﻟﻤﺪﺓ ﺷﻬﺮﻳﻦ ﺃﻭ ﺃﻛﺜﺮ ﻟﻌﻼﺝ ﻫﺒﺎﺕ ﺍﻧﻘﻄﺎﻉ ﺍﻟﺪﻭﺭﺓ ﺃﻭ  HR .04
   44؟              ﺍﻹﺟﺎﺑﺔ )ﻻ( ، ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝﻟﺘﺨﻔﻴﻒ ﺃﻋﺮﺍﺿﻬﺎ
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺑﺪﺃﺕ ﺍﺳﺘﺨﺪﺍﻡ ﺍﻟﻬﺮﻣﻮﻧﺎﺕ ﺍﻟﺒﺪﻳﻠﺔ؟  HR .14 |___|___|
 ﻟﻮ ﺟﻤﻌﻨﺎ ﺍﻟﻔﺘﺮﺓ ﺍﻟﺘﻲ ﺍﺳﺘﺨﺪﻣﺖ ﻓﻴﻬﺎ ﺍﻟﻬﺮﻣﻮﻧﺎﺕ ﺍﻟﺒﺪﻳﻠﺔ ﻣﺎ ﻣﺠﻤﻮﻉ ﺍﻟﻔﺘﺮﺓ ؟  HR .24 ﺳﻨﺔ |__|__|
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺗﻮﻗﻔﺖ ﻋﻦ ﺍﺳﺘﻌﻤﺎﻝ ﺍﻟﻬﺮﻣﻮﻧﺎﺕ ﺍﻟﺒﺪﻳﻠﺔ؟  HR .34 |___|___|
 ؟  )ﻣﺘﻌﺪﺩ ﺍﻹﺟﺎﺑﺎﺕ(ﻫﻞ ﺳﺒﻖ ﺃﻥ ﺃﺟﺮﻳﺖ ﺃﻱ ﻣﻦ ﻓﺤﻮﺻﺎﺕ ﺍﻟﺜﺪﻱ ﺍﻟﺘﺎﻟﻴﺔ  SH .44 
 ﻻ  ﻧﻌﻢ 
   94ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝ  –ﻟﻢ ﺃﺟﺮ ﺃﻱ ﻓﺤﺺ  -0
   ﻓﺤﺺ ﺛﺪﻱ ﺷﻌﺎﻋﻲ )ﻣﻤﻮﻏﺮﺍﻓﻲ( -1
   ﺃﻭﻟﺘﺮﺍﺳﺎﻭﻧﺪ -2
    ﻓﺤﺺ ﺫﺍﺗﻲ -3
 ء ﺍﻟﻔﺤﺺ؟ )ﻣﻔﺘﻮﺡ(ﻣﺎ ﻫﻮ ﺳﺒﺐ ﺇﺟﺮﺍ SH .54 |___|
 ------------------------------------------------------------------------------
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻓﻲ ﺃﻭﻝ ﻣﺮﺓ ﺃﺟﺮﻳﺖ ﻓﻴﻬﺎ ﻓﺤﺺ ﺍﻟﺜﺪﻱ؟  SH .64 |___|___|
 ﻛﻢ ﻋﺪﺩ ﻣﺮﺍﺕ ﻓﺤﺺ ﺍﻟﺜﺪﻱ ﺍﻟﺘﻲ ﻗﻤﺖ ﺑﻬﺎ ﺧﻼﻝ ﺍﻟﺨﻤﺲ ﺳﻨﻮﺍﺕ ﺍﻟﻤﺎﺿﻴﺔ؟  SH .74 |___|___|
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺃﺟﺮﻳﺖ ﺁﺧﺮ ﻓﺤﺺ ﻟﻠﺜﺪﻱ؟  SH .84 |___|___|
 )ﻣﺘﻌﺪﺩ ﺍﻹﺟﺎﺑﺎﺕ(ﻫﻞ ﺧﻀﻌﺖ ﻷﻱ ﻣﻦ ﺍﻟﻌﻤﻠﻴﺎﺕ ﺍﻟﺘﺎﻟﻴﺔ:  SH .94 |___|
 ﻻ  ﻧﻌﻢ  
   ﻟﻢ ﺃﺗﻌﺮﺽ -0
   ﺧﺰﻋﺔ ﻣﻦ ﺍﻟﺼﺪﺭ -1
   ﺇﺯﺍﻟﺔ ﻛﺘﻠﺔ ﻣﻦ ﺍﻟﺼﺪﺭ -2
    ﺇﺯﺍﻟﺔ ﻛﺎﻣﻠﺔ ﻟﻠﺜﺪﻱ -3
 ﻣﺎ ﻫﻮ ﻁﻮﻟﻚ؟ )ﺑﺎﻟﻤﺘﺮ( SH .05 |__,__|
 ﻛﻢ ﻭﺯﻧﻚ ﺣﺎﻟﻴﺎ؟ )ﻛﻐﻢ(  SH .15 |___|___|
 ﺃﺷﻬﺮ ﻓﺄﻛﺌﺮ؟  6ﻫﻞ ﺗﻨﺎﻭﻟﺖ ﺃﻳﺎ ﻣﻦ ﺍﻟﺤﺒﻮﺏ ﺍﻟﺘﺎﻟﻴﺔ ﻟﻤﺪﺓ  SH .25 
 ﻻ ﻧﻌﻢ  
   ﻻ ﺷﻲء  -0
    -1  niripsA
   nixogiD -2
    nimrofteM-3
ﻧﻌﻢ       
 ﻻ
ﺍﻹﺟﺎﺑﺔ )ﻻ( ﺍﻧﺘﻘﻞ ﻫﻞ ﺃﺻﻴﺒﺖ ﺇﺣﺪﻯ ﻗﺮﻳﺒﺎﺗﻚ ﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ ﺃﻭ ﻫﻲ ﻣﺼﺎﺑﺔ ﺑﻪ ﺣﺎﻟﻴﺎ؟  HF .35
   55ﻟﻠﺴﺆﺍﻝ
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 ﻣﻦ ﻣﻦ ﻗﺮﻳﺒﺎﺗﻚ ﻣﺼﺎﺑﺔ ﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ ﺃﻭ ﺃﺻﻴﺒﺖ؟ HF .45 
 
 4ﻣﺮﻳﻀﺔ  3ﻣﺮﻳﻀﺔ  2ﻣﺮﻳﻀﺔ  1ﻣﺮﻳﻀﺔ  
     ﺃ. ﺻﻠﺔ ﺍﻟﻘﺮﺍﺑﺔ 
     ﻴﺺﺨﺸﺘﺍﻟﻌﻤﺮﻋﻨﺪ ﺍﻟ.ﺏ
 
ﻧﻌﻢ       
 ﻻ
؟   ﺍﻹﺟﺎﺑﺔ )ﻻ( ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝ ﺃﻗﺮﺑﺎﺋﻚ ﻣﻦ ﻧﻮﻉ ﺁﺧﺮ ﻣﻦ ﺍﻟﺴﺮﻁﺎﻥﻫﻞ ﻋﺎﻧﻰ ﺃﻭ ﻳﻌﺎﻧﻲ ﺃﺣﺪ  HF .55
 75
 ﻣﻦ ﻣﻦ ﺃﻗﺮﺑﺎﺋﻚ ﻋﺎﻧﻰ ﺍﻭ ﻳﻌﺎﻧﻲ ﻧﻮﻋﺎ ﺁﺧﺮ ﻣﻦ ﺍﻟﺴﺮﻁﺎﻥ؟  HF .65 
 4ﻳﺾ ﺮﻣ 3ﻣﺮﻳﺾ  2ﻣﺮﻳﺾ   1ﻣﺮﻳﺾ 
     ﺃ. ﺻﻠﺔ ﺍﻟﻘﺮﺍﺑﺔ
     ﺏ.ﻧﻮﻉ ﺍﻟﺴﺮﻁﺎﻥ
     ﺝ.ﺍﻟﻌﻤﺮ ﻋﻨﺪ ﺍﻟﺘﺸﺨﻴﺺ
 
 ﻫﻞ ﻋﺎﻧﻴﺖ ﺃﻭ ﺗﻌﺎﻧﻴﻦ ﻣﻦ ﺍﻟﺘﺎﻟﻴﺔ؟   HF .75 
 2ﺍﻟﺪﻭﺍء  1ﺍﻟﺪﻭﺍء  )ﻻ( )ﻧﻌﻢ(  
     ﻻ ﺃﻋﺎﻧﻲ  - 0      
     ﺍﺭﺗﻔﺎﻉ ﺿﻐﻂ ﺍﻟﺪﻡ .1
     ﺍﻣﺮﺍﺽ ﺍﻟﻘﻠﺐ ﻭ ﺍﻻﻭﻋﻴﺔ  .2
     ﺍﻣﺮﺍﺽ ﺍﻟﺤﺴﺎﺳﻴﺔ .3
     ﺍﻣﺮﺍﺽ ﺍﻟﻐﺪﺩ .4
     ﺍﻟﻌﻈﺎﻡ ﻫﺸﺎﺷﺔ .5
     ﺃﻣﺮﺍﺽ ﻣﻔﺎﺻﻞ .6
     ﺩﻫﻨﻴﺎﺕ ﺍﻟﺪﻡ .7
     ﺃﻣﺮﺍﺽ ﻣﻨﺎﻋﻴﺔ .8
     ﺳﻜﺮﻱ ﺍ .9
       ﺃﺧﺮ .01
 
ﻧﻌﻢ       
 ﻻ
 46 ؟     ﺍﻹﺟﺎﺑﺔ )ﻻ( ، ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝﻫﻞ ﺃﻧﺖ ﻣﺸﺨﺼﺔ ﻛﻤﺮﻳﻀﺔ ﺳﻜﺮﻱ MD .85
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺷﺨﺼﺖ ﻛﻤﺮﻳﺾ ﺳﻜﺮﻱ ﻷﻭﻝ ﻣﺮﺓ ؟  MD .95 |___|___|
 ﺁﺧﺮ ﻣﺮﺓ ﻓﺤﺼﺖ ﻓﻴﻬﺎ ﻧﺴﺒﺔ ﺍﻟﺴﻜﺮ ﻓﻲ ﺍﻟﺪﻡ ، ﻛﻢ ﻛﺎﻧﺖ ﺍﻟﻨﺘﻴﺠﺔ؟  MD .06 |____|
 
 
 ﺑﺎﻟﺴﻨﻮﺍﺕ ؟ ﻣﺎ ﻫﻲ ﺃﺩﻭﻳﺔ ﺍﻟﺴﻜﺮﻱ ﺍﻟﺘﻲ ﺗﺘﻨﺎﻭﻟﻴﻨﻬﺎ ﺃﻭ ﺗﻨﺎﻭﻟﺘﻬﺎ؟ ﻭ ﻣﺎ ﻫﻲ ﺍﻟﻤﺪﺓ MD .16
 
ﻛﻢ ﻣﺮﺓ  ﻻ  ﻧﻌﻢ  ﻧﻮﻉ ﺍﻟﺪﻭﺍء 
 ﻳﻮﻣﻴﺎ
ﻣﺘﻰ 
 ﺑﺪﺃﺕ؟ 
 ﺳﻨﺔ
ﻣﺘﻰ 
ﺗﻮﻗﻔﺖ؟ 
 ﺳﻨﺔ
      ﻭﻝ ﺣﺎﻟﻴﺎﺎﻻ ﺃﺗﻨ .0
      nimrofteM .1
      )edimalcnebilG( nebulG .2
      )ediripimilG( lyramA .3
      )edinilgapeR( mronovoN .4
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 + nitpilgatiS( tneunaJ .5
 )nimrofteM
     
 + nitpilgadliV( saercuE .6
 )nimrofteM
     
      )enozatilgoiP( sotcA .7
      )nitpilgadliV( suvlaG .8
      )edizipilG( etiR-oculG .9
      )enigralg nilusni( sutnaL .01
      )trapsa nilusni( dipaRovoN .11
      )namuh nilusni(  dratxiM .21
      )trapsa nilusni( xiMovoN .31
      )editulgaril( azotciV .41
      ﺩﻭﺍء ﺁﺧﺮ )ﺣﺪﺩﻱ(  .51
ﻛﻢ ﻣﺮﺓ  ﻻ  ﻧﻌﻢ  ﻧﻮﻉ ﺍﻟﺪﻭﺍء 
 ﻳﻮﻣﻴﺎ
ﻣﺘﻰ 
 ﺑﺪﺃﺕ
ﻣﺘﻰ 
 ﺗﻮﻗﻔﺖ
  
ﻧﻌﻢ       
 ﻻ
ﻫﻞ ﻁﺒﻴﻌﺔ ﻋﻤﻠﻚ ﺗﺘﻄﻠﺐ ﻣﻨﻚ ﺍﻟﻘﻴﺎﻡ ﺑﻨﺸﺎﻁ ﺑﺪﻧﻲ ﺷﺎﻕ ﻣﺜﻞ : ) ﺍﻟﺤﻤﻞ ﺍﻟﺜﻘﻴﻞ ﻭﺍﻟﺤﻔﺮ ﻭﺭﺷﺔ  SL .26
   01ﺍﻟﺘﻲ ﺗﺴﺒﺐ ﺗﻌﺮﻕ ﺷﺪﻳﺪ ﻭﺯﻳﺎﺩﺓ ﻓﻲ ﺿﺮﻳﺎﺕ ﺍﻟﻘﻠﺐ ﻭﺍﻟﺘﻨﻔﺲ ﻟﻤﺪﺓ ﻻ ﺗﻘﻞ ﻋﻦ  -ﺑﻨﺎء 
 ﺩﻗﺎﺋﻖ ﻓﻲ ﺍﻟﻴﻮﻡ؟ 
 56 ﺍﻹﺟﺎﺑﺔ )ﻻ( ، ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝ  
ﺜﻞ ﻫﺬﺍ ﺍﻟﻨﺸﺎﻁ  ) ﺍﻟﺒﺪﻧﻲ ﺍﻟﺸﺎﻕ( ﻛﺠﺰء ﻣﻦ ﻛﻢ ﻳﻮﻣﺎ ﻣﻦ ﺃﻳﺎﻡ ﺍﻷﺳﺒﻮﻉ ﺍﻟﻌﺎﺩﻱ ﺗﻘﻮﻣﻴﻦ ﺑﻤ SL .36 |___|
 ﻋﻤﻠﻚ؟
ﻛﻢ ﻣﻦ ﺍﻟﻮﻗﺖ)ﺳﺎﻋﺔ(  ﺗﻘﻀﻴﻨﻪ ﻓﻲ ﺍﻟﻘﻴﺎﻡ ﺑﻬﺬﺍ ﺍﻟﻨﺸﺎﻁ  ﺍﻟﺒﺪﻧﻲ ﺍﻟﺸﺎﻕ ﻓﻲ ﺍﻟﻴﻮﻡ ﺍﻟﻮﺍﺣﺪ  SL .46 |___| ﺳﺎﻋﺔ
 ﻛﺠﺰء ﻣﻦ ﻋﻤﻠﻚ 
ﻧﻌﻢ       
 ﻻ
ﻫﻞ ﻁﺒﻴﻌﺔ ﻋﻤﻠﻚ ﻳﺘﻄﻠﺐ ﻣﻨﻚ ﺍﻟﻘﻴﺎﻡ ﺑﻨﺸﺎﻁ ﺑﺪﻧﻲ ﻣﺘﻮﺳﻂ ﻣﺜﻞ )ﺍﻟﻤﺸﻲ ﺍﻟﺴﺮﻳﻊ ﺃﻭ ﺣﻤﻞ   SL .56
 01ﺍﻟﺘﻲ ﺗﺴﺒﺐ ﺗﻌﺮﻕ ﺑﺴﻴﻂ ﻭﺯﻳﺎﺩﺓ ﻗﻠﻴﻠﺔ ﻓﻲ ﺿﺮﺑﺎﺕ ﺍﻟﻘﻠﺐ ﻭﺍﻟﺘﻨﻔﺲ( ﻟﻤﺪﺓ  -ﺃﺷﻴﺎء ﺧﻔﻴﻔﺔ 
 ﺩﻗﺎﺋﻖ ﻋﻠﻰ ﺍﻷﻗﻞ ﻓﻲ ﺍﻟﻴﻮﻡ ؟  
 86ﺍﻹﺟﺎﺑﺔ )ﻻ( ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝ 
ﺗﻘﻮﻣﻴﻦ ﺑﻤﺜﻞ ﻫﺬﺍ ﺍﻟﻨﺸﺎﻁ ) ﺍﻟﺒﺪﻧﻲ ﺍﻟﻤﺘﻮﺳﻂ(  ﻛﺠﺰء ﻣﻦ ﻛﻢ ﻳﻮﻣﺎ ﻣﻦ ﺃﻳﺎﻡ ﺍﻷﺳﺒﻮﻉ ﺍﻟﻌﺎﺩﻱ  SL .66 |___|
 ؟ﻋﻤﻠﻚ
ﻛﻢ ﻣﻦ ﺍﻟﻮﻗﺖ )ﺳﺎﻋﺔ( ﺗﻘﻀﻴﻨﻪ ﻓﻲ ﺍﻟﻘﻴﺎﻡ ﺑﻬﺬﺍ ﺍﻟﻨﺸﺎﻁ ﺍﻟﺒﺪﻧﻲ ﺍﻟﻤﺘﻮﺳﻂ  ﻓﻲ ﺍﻟﻴﻮﻡ ﺍﻟﻮﺍﺣﺪ  SL .76 |___| ﺳﺎﻋﺔ
 ﻛﺠﺰء ﻣﻦ ﻋﻤﻠﻚ
ﻧﻌﻢ       
 ﻻ
ﻫﻞ ﺗﺬﻫﺒﻴﻦ ﻣﺸﻴﺎ ﻋﻠﻰ ﺍﻷﻗﺪﺍﻡ ﻟﻠﺘﻨﻘﻞ ﻣﻦ ﻭﺍﻟﻰ ﺍﻷﻣﺎﻛﻦ )ﺍﻟﺰﻳﺎﺭﺍﺕ ، ﺍﻟﺘﺴﻮﻕ ، ﺍﻟﻌﻤﻞ (.  SL .86
؟             ﺍﻹﺟﺎﺑﺔ )ﻻ( ﺍﻧﺘﻘﻞ ﺩﻗﺎﺋﻖ ﻣﺘﻮﺍﺻﻠﺔ ﻋﻠﻰ ﺍﻷﻗﻞ ﻓﻲ ﻛﻞ ﻣﺮﺓ 01ﻟﻤﺪﺓ ﻻ ﺗﻘﻞ ﻋﻦ 
 17 ﻟﻠﺴﺆﺍﻝ
ﺩﻗﺎﺋﻖ ﻓﻲ ﻛﻞ ﻣﺮﺓ  ﻟﻠﺘﻨﻘﻞ ﻣﻦ  01ﻓﻲ ﺍﻷﺳﺒﻮﻉ ﺍﻟﻌﺎﺩﻱ ﻛﻢ ﻳﻮﻣﺎ ﺗﻤﺸﻴﻦ ﻟﻤﺪﺓ  ﻻ ﺗﻘﻞ ﻋﻦ  SL .96 |___|
 ﻭﺍﻟﻰ ﻫﺬﺓ ﺍﻷﻣﺎﻛﻦ ؟
 ﺑﺎﻟﻤﺘﻮﺳﻂ ﻛﻢ ﻣﻦ ﺍﻟﻮﻗﺖ )ﺩﻗﻴﻘﺔ(   ﺗﻤﺸﻴﻦ ﻓﻲ ﻛﻞ ﻣﺮﺓ ﻟﻠﺘﻨﻘﻞ ﻣﻦ ﻭﺍﻟﻰ ﻫﺬﻩ ﺍﻷﻣﺎﻛﻦ   SL .07 |___| ﺩﻗﻴﻘﺔ
ﻧﻌﻢ       
 ﻻ
ﻫﻞ ﺗﻘﻮﻡ ﻓﻲ ﻭﻗﺖ ﻓﺮﺍﻏﻚ  ﺑﻨﺸﺎﻁ ﺑﺪﻧﻲ ﺷﺪﻳﺪ ﺷﺎﻕ ﻛﺎﻟﺮﻳﺎﺿﺔ ﻣﺜﻞ: ﺍﻟﺠﺮﻱ ﺑﺴﺮﻋﺔ ﺃﻭ  SL .17
ﺩﻗﺎﺋﻖ ﻣﺴﺘﻤﺮﺓ  01ﺣﻤﻞ ﺍﺷﻴﺎء ﺛﻘﻴﻠﺔ ، ﺍﻟﺤﻔﺮ ، ﺍﻟﻌﻤﻞ ﻓﻲ  ﺍﻟﻤﺰﺭﻋﺔ ﺃﻭ ﻭﺭﺷﺔ ﺑﻨﺎء ( ﻟﻤﺪﺓ 
 47 ﺍﻹﺟﺎﺑﺔ )ﻻ( ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝﻋﻠﻰ ﺍﻷﻗﻞ؟      
 ﻄﺔ ﺍﻟﺒﺪﻧﻴﺔ ﺍﻟﺸﺪﻳﺪﺓ ؟ﻓﻲ ﺍﻷﺳﺒﻮﻉ ﺍﻟﻌﺎﺩﻱ ﻛﻢ ﻳﻮﻣﺎ ﺗﻘﻮﻣﻴﻦ ﺑﻤﻤﺎﺭﺳﺔ ﻫﺬﻩ ﺍﻷﻧﺸ SL .27 |___|
 ﻓﻲ ﺍﻟﻴﻮﻡ ﺍﻟﻌﺎﺩﻱ: ﻛﻢ ﻣﻦ ﺍﻟﻮﻗﺖ )ﺳﺎﻋﺔ(   ﺗﻘﻮﻣﻴﻦ ﺑﻤﻤﺎﺭﺳﺔ ﺍﻷﻧﺸﻄﺔ ﺍﻟﺒﺪﻧﻴﺔ ﺍﻟﺸﺪﻳﺪﺓ ؟ SL .37 |___| ﺳﺎﻋﺔ
ﻧﻌﻢ       
 ﻻ
ﻫﻞ ﺗﻘﻮﻣﻴﻦ ﻓﻲ ﻭﻗﺖ ﻓﺮﺍﻏﻚ  ﺑﻨﺸﺎﻁ ﺑﺪﻧﻲ ﻣﺘﻮﺳﻂ ﺍﻟﺸﺪﺓ ﻟﻠﻤﺤﺎﻓﻈﺔ ﻋﻠﻲ ﺍﻟﻠﻴﺎﻗﺔ  ﻟﻤﺪﺓ ﻻ  SL .47
ﺍﻟﺴﺮﻳﻊ ﺍﻭ ﺍﻟﺴﺒﺎﺣﺔ ﺍﻭ ﺭﻛﻮﺏ ﺩﺭﺍﺟﺔ ﺍﻭ ﺩﻗﺎﺋﻖ ﻣﺴﺘﻤﺮﺓ ﻓﻲ ﺍﻟﻴﻮﻡ ؟ )ﺍﻟﻤﺸﻰ  01ﺗﻘﻞ ﻋﻦ 
 ﻟﻌﺐ ﺍﻟﻜﺮﺓ ﺍﻟﻄﺎﺋﺮﺓ(
 77ﺍﻹﺟﺎﺑﺔ )ﻻ( ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝ 
 ﻛﻢ ﻳﻮﻣﺎ ﻓﻲ ﺍﻷﺳﺒﻮﻉ ﺍﻟﻌﺎﺩﻱ ﺗﻘﻮﻣﻴﻦ ﺑﻤﻤﺎﺭﺳﺔ ﻫﺬﻩ ﺍﻷﻧﺸﻄﺔ ﺍﻟﺒﺪﻧﻴﺔ ﺍﻟﻤﺘﻮﺳﻄﺔ؟ SL .57 |___|
 ﺍﻟﻤﺘﻮﺳﻄﺔ.؟ﻓﻲ ﺍﻟﻴﻮﻡ ﺍﻟﻌﺎﺩﻱ:  ﻛﻢ ﻣﻦ ﺍﻟﻮﻗﺖ )ﺳﺎﻋﺔ(  ﺗﻘﻮﻣﻴﻦ ﺑﻤﻤﺎﺭﺳﺔ  ﺍﻷﻧﺸﻄﺔ ﺍﻟﺒﺪﻧﻴﺔ  SL .67 |___| ﺳﺎﻋﺔ
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  )ﺳﺎﻋﺔ( ﺗﻤﻀﻴﻦ ﺟﺎﻟﺴﺔ ﺃﻭ ﻣﺴﺘﻠﻘﻴﺔ )ﻣﺎ ﻋﺪﺍ ﻭﻗﺖ ﺍﻟﻨﻮﻡ (ﻓﻲ ﺍﻟﻴﻮﻡ ﺍﻟﻌﺎﺩﻱ ﻛﻢ ﻣﻦ ﺍﻟﻮﻗﺖ  SL .77 |___| ﺳﺎﻋﺔ
ﺗﺸﻤﻞ ﺍﻟﺠﻠﻮﺱ ﻓﻲ ﺍﻟﻌﻤﻞ ، ﺍﻭ ﺍﻟﻘﺮﺍءﺓ ، ﺍﻭ ﻣﺸﺎﻫﺪ ﺓ ﺍﻟﺘﻠﻔﺰﻳﻮﻥ  ﺃﻭ ﺍﻟﺘﻄﺮﻳﺰ ﺃﻭ ﺍﻋﻤﺎﻝ 
 ﻳﺪﻭﻳﺔ ، ﺃﻭ ﺍﻟﻜﻮﻣﺒﻴﻮﺗﺮ ..ﺍﻟﺦ
ﻧﻌﻢ       
 ﻻ
 ﻫﻞ ﺳﺒﻖ ﻭﺍﻥ ﺗﻨﺎﻭﻟﺖ ﻣﺸﺮﻭﺑﺎ ًﻛﺤﻮﻟﻴﺎً؟ ) ﻣﺜﻞ ﺍﻟﺒﻴﺮﺓ ، ﺍﻟﻨﺒﻴﺬ ، ﺍﻟﻮﻳﺴﻜﻲ(   SL .87
 ﺧﻼﻝ ﺍﻻﺛﻨﻰ ﻋﺸﺮ ﺷﻬﺮﺍ ًﺍﻟﻤﺎﺿﻴﺔ ؟
 28ﺍﻹﺟﺎﺑﺔ )ﻻ( ، ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝ  
 ﻓﻲ ﺍﻟﻤﺘﻮﺳﻂ: ﻛﻢ ﻳﻮﻣﺎ  ﺗﺸﺮﺑﻴﻦ ﺍﻟﻤﺸﺮﻭﺑﺎﺕ ﺍﻟﻜﺤﻮﻟﻴﺔ  ﻓﻲ ﺍﻷﺳﺒﻮﻉ ؟ SL .97 |___|
 ﻋﻨﺪﻣﺎ ﺗﺸﺮﺑﻴﻦ ﺍﻟﻜﺤﻮﻝ:  ﻓﻲ ﺍﻟﻤﺘﻮﺳﻂ ﻛﻢ ﻛﺄﺳﺎ ﺗﺸﺮﺑﻴﻦ ﻓﻲ ﺍﻟﻤﺮﺓ ﺍﻟﻮﺍﺣﺪﺓ؟  SL .08 |___|
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺗﻨﺎﻭﻟﺖ ﺍﻟﻜﺤﻮﻝ ﻟﻠﻤﺮﺓ ﺍﻷﻭﻟﻰ ؟  SL .18 |___|___|
ﻧﻌﻢ       
 ﻻ
ﻫﻞ ﺗﺪﺧﻨﻴﻦ ﺣﺎﻟﻴﺎ  ﺃﻱ ﻧﻮﻉ ﻣﻦ ﺃﻧﻮﺍﻉ ﺍﻟﺘﺒﻎ ﺍﻟﺘﺎﻟﻴﺔ ﻣﺜﻞ ﺍﻟﺴﺠﺎﺋﺮ ﺃﻭ ﺍﻟﺴﻴﺠﺎﺭ ﺃﻭ   SL .28
 ﺍﻹﺟﺎﺑﺔ ﻻ ، ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝﺍﻟﻐﻠﻴﻮﻥ......ﺍﻟﺦ ﻣﺎ ﻋﺪﺍ ﺍﻷﺭﺟﻴﻠﺔ ﺳﺄﺳﺄﻟﻚ ﻻﺣﻘﺎ ﻋﻠﻴﻬﺎ            
  78
ﻧﻌﻢ       
 ﻻ
 ﻳﻮﻣﻴﺎ؟ ﻫﻞ ﺗﺪﺧﻨﻴﻦ ﺃﻳﺎ ﻣﻦ ﻫﺬﻩ ﺍﻷﻧﻮﺍﻉ ﺍﻟﺴﺎﺑﻘﺔ )ﺍﻟﺴﺠﺎﺋﺮ ﺃﻭ ﺍﻟﺴﻴﺠﺎﺭ ﺍﻭ ﺍﻟﻐﻠﻴﻮﻥ...( SL .38
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺑﺪﺃﺕ ﺍﻟﺘﺪﺧﻴﻦ؟  SL .48 |___|___|
 ﻛﻢ ﻣﻦ ﺍﻟﻮﻗﺖ ﻣﻀﻰ ﻋﻠﻴﻚ ﻭﺃﻧﺖ ﺗﺪﺧﻨﻴﻦ؟   SL .58 |___| ﺳﻨﺔ
 ﻓﻲ ﺍﻟﻤﺘﻮﺳﻂ ﻛﻢ ﻣﻦ ﻣﻨﺘﺠﺎﺕ ﺍﻟﺘﺒﻎ ﺍﻟﺘﺎﻟﻴﺔ ﺗﺪﺧﻨﻴﻦ ﻳﻮﻣﻴﺎ ﺧﻼﻝ ﺍﻟﺜﻼﺛﻴﻦ ﻳﻮﻣﺎ ﺍﻟﻤﺎﺿﻴﺔ ؟ SL .68 
ﺍﻭ ﺻﻔﺮ ﻛﺘﺎﺑﺔ  ﺍﺫﺍ ﻛﺎﻧﺖ ﺍﻻﺟﺎﺑﺔ ﺍﻧﻪ ﻻ ﻳﺪﺧﻦ ﻧﻮﻉ ﻣﻌﻴﻦ ﻣﻦ ﺍﻟﺘﺎﻟﻲ ﻧﻜﺘﺐ ﻛﻠﻤﺔ )ﻻ ﺷﻲء(
 ﺎﻭﻟﻴﺲ ﺍﺭﻗﺎﻣ
 ﺍﻟﻌﺪﺩ ﻳﻮﻣﻴﺎ 
  ﺍﻟﺴﺠﺎﺋﺮ -ﺃ
  ﺍﻟﺴﺠﺎﺋﺮ ﺍﻟﻠﻒ ﺍﻟﻤﺼﻨﻌﺔ ﻳﺪﻭﻳﺎ -ﺏ
 
 ﻋﺪﺩ ﺍﻟﻤﺮﺍﺕ 
 ﻓﻲ ﺍﻟﺸﻬﺮ ﻓﻲ ﺍﻻﺳﺒﻮﻉ ﻓﻲ ﺍﻟﻴﻮﻡ 
    ﻏﻠﻴﻮﻥ -ﺝ
     ﺳﻴﺠﺎﺭ -ﺩ
ﻧﻌﻢ       
 ﻻ
 ﻫﻞ ﻳﺪﺧﻦ  ﺃﺣﺪ ﻭﺍﻟﺪﻳﻚ )ﺣﺎﻟﻴﺎ ﺃﻭ ﻓﻲ ﺍﻟﺴﺎﺑﻖ( SL .78
ﻧﻌﻢ       
 ﻻ
 09 ؟   ﺍﻹﺟﺎﺑﺔ ﻻ ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝﺍﻟﺘﺪﺧﻴﻦ ﻳﻮﻣﻴﺎﻓﻲ ﺍﻟﻤﺎﺿﻲ ﻫﻞ ﺳﺒﻖ ﻟﻚ  SL .88
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺗﻮﻗﻔﺖ ﻋﻦ ﺍﻟﺘﺪﺧﻴﻦ ؟ SL .98 |___|
ﻧﻌﻢ       
 ﻻ
 49 ﺍﻹﺟﺎﺑﺔ ﻻ ، ﺍﻧﺘﻘﻞ ﻟﻠﺴﺆﺍﻝﻫﻞ ﺗﺪﺧﻨﻴﻦ  ﺍﻻﺭﺟﻴﻠﺔ ﺣﺎﻟﻴﺎ  ؟   SL .09
 ؟   ﺇﺟﺎﺑﺔ ﻭﺍﺣﺪﺓ ﻓﻘﻂﻛﻢ ﻣﺮﺓ ﺗﺪﺧﻦ  ﺍﻻﺭﺟﻴﻠﺔ  SL .19 
 ﺍﻟﺸﻬﺮ ﺍﻻﺳﺒﻮﻉ ﺍﻟﻴﻮﻡ 
     ﻋﺪﺩ ﺍﻟﻤﺮﺍﺕ
 ﻛﻢ ﻛﺎﻥ ﻋﻤﺮﻙ ﻋﻨﺪﻣﺎ ﺑﺪﺃﺕ ﺗﺪﺧﻴﻦ ﺍﻷﺭﺟﻴﻠﺔ ؟ SL .29 |___|
 ﻛﻢ ﺳﻨﺔ ﺩﺧﻨﺖ ﺍﻷﺭﺟﻴﻠﺔ؟  SL .39 |___|
ﻧﻌﻢ       
 ﻻ
 ﻫﻞ ﺗﻠﺒﺴﻴﻦ ﺣﻤﺎﻟﺔ ﺍﻟﺼﺪﺭ )ﺳﺘﻴﺎﻧﺔ ﺃﻭ ﺻﺪﺭﻳﺔ(  ﺃﺛﻨﺎء ﺍﻟﻨﻮﻡ؟  SL .49
ﻧﻌﻢ       
 ﻻ
 ﻫﻞ ﺍﺳﺘﺨﺪﻣﺖ ﺣﺮﺍﻡ ﺍﻟﻜﻬﺮﺑﺎء ﺑﺸﻜﻞ ﺩﻭﺭﻱ ﺧﻼﻝ ﺣﻴﺎﺗﻚ؟  SL .59
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 ﻫﻞ ﺗﺘﻨﺎﻭﻝ ﺃﻱ ﻣﻦ ﺍﻟﺘﺎﻟﻴﺔ : SL .69 
ﻻ ﻳﺘﻨﺎﻭﻝ  
ﻣﺮﺓ  >ﺃﻭ 
 ﺍﻟﺸﻬﺮ  /
 /3-1
 ﺍﻟﺸﻬﺮ
 /ﻣﺮﺓ 
 ﺃﺳﺒﻮﻉ
 /4-2
 ﺃﺳﺒﻮﻉ
  /6-5
 ﺍﺳﺒﻮﻉ
 /ﻣﺮﺓ 
 ﺍﻟﻴﻮﻡ 
 /3-2
 ﺍﻟﻴﻮﻡ
  /5-4
 ﺍﻟﻴﻮﻡ
 
 
 
          ﺑﻴﺘﺰﺍ
          ﺣﻠﻴﺐ
ﻛﻴﻚ  ﺃﻭ 
 ﻣﻌﺠﻨﺎﺕ
         
          ﺑﺴﻜﻮﻳﺖ 
ﺷﻴﺒﺲ ﺍﻭ 
ﺑﻮﺏ 
 ﻛﻮﺭﻥ 
         
          ﻣﻜﺴﺮﺍﺕ
ﻣﺸﺮﻭﺑﺎﺕ 
ﻏﺎﺯﻳﺔ 
 ﺩﺍﻳﺖ
         
ﻣﺸﺮﻭﺑﺎﺕ 
ﻏﺎﺯﻳﺔ 
 ﻋﺎﺩﻱ
         
ﺑﺮﻏﺮ ﺍﻭ 
 ﻛﺮﺍﺕ ﻟﺤﻢ
         
ﺳﻤﻚ  ﺍﻭ 
 ﺗﻮﻧﺎ
         
          ﺩﺟﺎﺝ 
ﻓﻮﻝ 
 ﺳﻮﺩﺍﻧﻲ
         
          ﺑﻄﺎﻁﺎ
          ﺳﻠﻄﺎﺕ 
          ﺑﻴﺾ
          ﺟﺒﻨﺔ
          ﺧﺒﺰ ﺍﺑﻴﺾ
          ﺧﺒﺰ ﺍﺳﻤﺮ 
           ﺯﺑﺪﺓ 
ﻧﻌﻢ       
 ﻻ
 ﻫﻞ ﻋﻨﺪﻙ ﺃﻱ ﻓﻜﺮﺓ ﻋﻦ ﻣﺴﺒﺒﺎﺕ ﺳﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ؟  SL .79
 ﻣﺎﺫﺍ ﺑﺮﺃﻳﻚ ﻳﺴﺒﺐ ﺳﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ؟ )ﻣﻔﺘﻮﺡ( SL .89 
 -----------------------------------------------------------------------------
 
  ﻣﻦ ﺍﻟﻤﻠﻒ ﺍﻟﻤﺮﺿﻲ -ﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ ﻓﻘﻂ ﻟﻠﻤﺸﺨﺼﺎﺕ 
 _____/__ 99 ﻣﺎ ﺗﺎﺭﻳﺦ ﺍﻟﺘﺸﺨﻴﺺ؟
  001 ﻣﺎ ﻧﻮﻉ ﺍﻟﺴﺮﻁﺎﻥ ؟ 
 ﻛﻴﻒ ﺗﻢ ﺍﻛﺘﺸﺎﻑ ﺍﻹﺻﺎﺑﺔ ﺑﺴﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ؟
 ﻋﻦ ﻁﺮﻳﻖ ﺍﻟﺼﺪﻓﺔ  -3ﺑﻮﺍﺳﻄﺔ ﺇﺟﺮﺍء ﻣﺴﺢ ﻭﻗﺎﺋﻲ          -2ﻅﻬﻮﺭ ﺃﻋﺮﺍﺽ ﺍﻟﻤﺮﺽ        -1
 |___| 101
 |___| 201 ﻓﻲ ﺃﻱ ﻣﺮﺣﻠﺔ ﻣﻦ ﺍﻟﻤﺮﺽ ﺗﻢ ﺍﻟﺘﺸﺨﻴﺺ؟
 ﻣﺎ ﻧﻮﻉ ﺍﻟﻌﻼﺝ ﺍﻟﺬﻱ ﺗﻌﺮﺿﺖ ﻟﻪ ؟ )ﻣﺘﻌﺪﺩ ﺍﻹﺟﺎﺑﺎﺕ(
 ﻏﻴﺮ ﺫﻟﻚ -5ﻛﻴﻤﺎﻭﻱ       -4ﻋﻤﻠﻴﺔ ﺟﺮﺍﺣﻴﺔ       -3ﻫﺮﻣﻮﻧﻲ      -2ﺍﺷﻌﺎﻋﻲ      -1
 |___| 301
 ﻻ 401 ﺍﻥ ﺧﻀﻌﺖ ﻟﻌﻤﻠﻴﺔ ﺍﺳﺘﺌﺼﺎﻝ، ﻫﻞ ﺗﻌﺮﺿﺖ ﻟﻌﻼﺝ ﻛﻴﻤﺎﻭﻱ ﻗﺒﻞ ﻋﻤﻠﻴﺔ ﺍﻷﺳﺘﺌﺼﺎﻝ؟
 ﻧﻌﻢ        
 |___|___| 501 ﻛﻢ ﻛﺎﻥ ﻭﺯﻧﻚ ﻗﺒﻞ ﺍﻟﺘﺸﺨﻴﺺ؟
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 ﺍﻟﻣﻭﺍﻓﻘﺔ ﻋﻥ ﻋﻠﻡ ﻟﻠﻣﺷﺎﺭﻛﺔ ﻓﻲ ﺩﺭﺍﺳﺔ
 ﺳﺭﻁﺎﻥ ﺍﻟﺛﺩﻱ ﻭ ﻋﻼﻗﺗﻪ ﺑﺎﻟﺳﻛﺭﻱ 
 
  
ﺃﺳﺒﺎﺏ ﺳﺮﻁﺎﻥ ﺍﻟﺜﺪﻱ، ﻭ ﻋﻼﻗﺘﻪ ﺑﻤﺮﺽ ﺍﻟﺴﻜﺮﻱ ﻭ ﺃﺩﻭﻳﺘﻪ. ﺣﻴﺚ  ﺳﺄﺷﺎﺭﻙ ﻟﻘﺪ ﻁﻠﺐ ﻣﻨﻲ ﺍﻟﻤﺸﺎﺭﻛﺔ ﻓﻲ ﺩﺭﺍﺳﺔ ﺗﺒﺤﺚ ﻓﻲ 
 ﻛﻤﺠﻤﻮﻋﺔ ﺿﺎﺑﻄﺔ  ﻛﺤﺎﻟﺔ )ﻣﺮﻳﺾ ﺍﻟﺬﻱ ُﺷِﺨَﺺ ﺑﻬﺬﺍ ﺍﻟﻤﺮﺽ( ، ﺃﻭ
. ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﺳﻮﻑ ﺗﻘﺎﺭﻥ ﺍﻟﻤﻌﻄﻴﺎﺕ  ﺍﻟﺸﺨﺼﻴﺔ ، ﻭﺍﻟﺘﺎﺭﻳﺦ ﺍﻟﻄﺒﻲ ، ﻭﺳﺒﻞ ﻻ ﻳﻌﺎﻧﻲ ﻣﻦ ﻫﺬﺍ ﺍﻟﻤﺮﺽ( ) ﺷﺨﺺ ﺳﻠﻴﻢ
ﻴﻦ ﺑﺎﻟﻤﺮﺽ. ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﻟﺪﻳﻬﺎ ﺍﻟﻘﺪﺭﺓ ﻋﻠﻰ ﺍﻛﺘﺸﺎﻑ ﻣﻌﻠﻮﻣﺎﺕ ﻫﺎﻣﺔ ﻋﻦ ﻤﺼﺎﺑﺍﻟ ﻏﻴﺮﺍﻟﺘﻌﺮﺽ. ﻭﺫﻟﻚ ﻟﻠﻨﺎﺱ ﺍﻟﻤﺼﺎﺑﻴﻦ ﻭ
 ﺃﺳﺒﺎﺏ ﻫﺬﺍ ﺍﻟﻤﺮﺽ.
 
ﺳﻮﻑ ﻳﻄﻠﺐ ﻣﻨﻲ ﺍﻹﺟﺎﺑﺔ ﻋﻠﻰ ﺃﺳﺌﻠﺔ ﺗﺘﻌﻠﻖ ﺑﻨﻔﺴﻲ ، ﻭ ﺗﻔﺎﺻﻴﻠﻲ ﺍﻟﻄﺒﻴﺔ ، ﻭﺍﻟﻌﻼﺝ ﻓﻲ ﺍﻟﻤﺴﺘﺸﻔﻰ ﺑﺎﻟﻤﺎﺿﻲ ،ﻭ ﻋﺎﺋﻠﺘﻲ 
ﺑﻄﺎﺑﻊ ﻣﻦ ﺍﻟﺴﺮﻳﺔ. ﺍﻟﻤﻘﺎﺑﻠﺔ ﺳﺘﺪﻭﻡ  ،ﻭﺃﻳﻦ ﻋﺸﺖ ،ﻭﻭﻅﺎﺋﻔﻲ ﺍﻟﺘﻲ ﻋﻤﻠﺖ ﺑﻬﺎ ، ﺟﻤﻴﻊ ﺍﻟﻤﻌﻠﻮﻣﺎﺕ ﻓﻲ ﻫﺬﺍ ﺍﻻﺳﺘﺒﻴﺎﻥ ﺳﺘﺤﺘﻔﻆ
 ﺩﻗﻴﻘﺔ ﺃﻭ ﺃﻗﻞ . 04ﺣﻮﺍﻟﻲ 
 
ﺳﺘﺒﻘﻰ ﺳﺮﻳﺔ  ﻮﺻﺎﺕﺍﻟﻔﺤ ﻩ. ﺍﻟﻤﻌﻠﻮﻣﺎﺕ ﻣﻦ ﻫﺬﺳﻴﺘﻢ ﺍﻻﻁﻼﻉ ﻋﻠﻰ ﻧﺘﻴﺠﺔ ﻓﺤﺺ ﺍﻟﺴﻜﺮ ﻓﻲ ﺍﻟﺪﻡ ﻭ ﻓﺤﺺ ﺍﻟﺜﺪﻱ ﺃﻳﻀﺎ 
 ﺃﻳﻀﺎ. ﻭﻻ ﻳﻮﺟﺪ ﻫﻨﺎﻙ ﺃﻱ ﺁﺛﺎﺭ ﺟﺎﻧﺒﻴﺔ ﺃﺧﺮﻯ ﻣﺘﻮﻗﻌﺔ ﻣﻦ ﺍﻟﻤﺸﺎﺭﻛﺔ ﻓﻲ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ.
 
 
 _____________________ﺍﻻﺳﻢ:__________________
 
 ﺃﻭﺍﻓﻖ ﻋﻠﻰ ﺍﺟﺮﺍء ﺍﻟﻤﻘﺎﺑﻠﺔ ) ﺍﻟﺘﻮﻗﻴﻊ ( ________________
 
 ﺍﻟﺘﺎﺭﻳﺦ : ______________________________________
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Approvals from the  Palestinian Ministry of Health  
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